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ABSTRACT 
 
Huntington‟s disease is a fatal autosomal dominant neurodegenerative 
disease caused by an expansion of CAG repeats in the DNA of the Huntingtin 
gene. The length of the repeat is inversely related to the age of disease onset, 
however it only accounts for 60% of the variability in the age of onset. Therefore, 
other genetic and environmental effects contribute to the remaining 40% in the 
variability in age of onset. Multiple neurodegenerative diseases exhibit alterations 
in metal ion homeostasis. Research in our laboratories has demonstrated a 
disease-toxicant interaction between mutant Huntingtin and manganese 
exposure in vitro. Manganese is an essential trace metal that is necessary for 
many physiological processes, including neurotransmitter synthesis. In high 
levels, manganese can be damaging to the brain. Exposure that leads to this 
damage is typically encountered in an occupational setting such as when 
welding, smelting or mining manganese.  
 The research described in this dissertation is the first to describe the 
complex gene-environment interactions between mutant Huntingtin and 
manganese exposure in vivo. The neurochemical and morphological changes 
identified herein are complex and exhibit both positive and negative effects. My 
research also identified the earliest evidence for striatal dendritic pathology in 
YAC128 mice that occur between 13 and 16 weeks postnatal. Additionally, this is 
the first research to show gender-specific changes in MSN morphology following 
manganese exposure. These alterations in neuron morphology were most 
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prevalent when manganese levels were elevated and were not due to differential 
striatal manganese accumulation. 
 Taken together, these data lay the groundwork for understanding the 
gene-environment interaction between mutant Huntingtin and Mn exposure. 
Future studies will further our understanding of this interaction that may one day 
lead to therapeutic intervention. These studies also reinforce the need to include 
animals of both genders in experimentation to further our understanding of 
disease across both genders. 
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CHAPTER I 
 
INTRODUCTION 
 
Huntington‟s disease 
 
Human Disease 
Huntington‟s disease (HD) is a fatal autosomal dominant 
neurodegenerative disease with onset occurring in mid-life. Prevalence of HD in 
populations of European descent is approximately 4-10 per 100,000 people; 
whereas prevalence in non-European populations is reduced by more than 10-
fold and mutations in genes other than Huntingtin (HTT) are commonly found 
(Harper, 1992; Margolis et al., 2005; Wild et al., 2008; Wild and Tabrizi, 2007). 
Duration of the disease is approximately 15 years from symptom onset to death 
(Harper, 1992; Hayden et al., 1981). Diagnostic criteria include a family history of 
the disease, progressive motor dysfunction with chorea or rigidity not due to 
another cause, and psychiatric disturbances with progressive dementia of no 
other cause (Vonsattel and DiFiglia, 1998). To date, tetrabenazine is the only 
drug that has been FDA approved to treat HD chorea, but is only palliative, not a 
disease modifying drug.  
Genetics 
HD is the most common genetic neurodegenerative disease. It is caused 
by an expansion of CAG codon repeats in exon 1 of the HTT gene located on the 
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short arm of chromosome 4 (4p16.3) (Huntington's Disease Collaborative 
Research, 1993). The function of wild-type (WT) HTT is unknown, although it is 
known to play a role in many cellular processes including cell signaling, gene 
transcription, vesicle transport, apoptosis and clathrin-mediated endocytosis 
(Harjes and Wanker, 2003). HD is autosomal dominant; therefore children of 
affected persons have a 50% chance of inheriting the disease. HD does not 
affect reproduction because typical age of disease onset is 40-50 years of age, 
thus the disease can be propagated across generations. Age of disease onset is 
inversely correlated with the number of CAG repeats (Andrew et al., 1993; 
Brinkman et al., 1997; Duyao et al., 1995; Wexler et al., 2004a). The Huntington 
Disease Collaborative Research Group defined a normal range of CAG repeats 
in the HTT gene to be fewer than 30 repeats (Huntington's Disease Collaborative 
Research, 1993). Full penetrance of the disease occurs when CAG repeat length 
is greater than 39 and incomplete penetrance occurs when CAG repeat length is 
between 35 and 39 (Wexler et al., 2004). Juvenile-onset HD accounts for 5-10% 
of HD cases and occurs when CAG repeats exceeds 60 (Huntington's Disease 
Collaborative Research, 1993).  
Although there is a strong inverse correlation between CAG repeat length 
and age of disease onset, it only accounts for approximately 60% of the variation 
in disease onset (Andrew et al., 1993; Brinkman et al., 1997; Duyao et al., 1995; 
Stine et al., 1993; Wexler et al., 2004a). This allows the possibility of other 
genetic or environmental factors to modify the age of disease onset and 
progression of symptoms. 
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Symptoms 
HD is characterized by cognitive, motor and psychiatric symptoms. 
Cognitive dysfunction includes impaired executive function (required for 
organizational and planning behavior), delayed acquisition of new motor skills 
and language function (Folstein, 1989). Depression is a common symptom and 
risk of suicide is ten times greater than the general population (Paulsen et al., 
2005). Mania and other psychotic symptoms can also manifest. Fine motor skills 
deteriorate early on and are useful in establishing the diagnosis of HD (Walker, 
2007). Chorea is the most common motor symptom of adult onset HD, but 
severity and duration of this symptom is not correlated with length of disease. 
Juvenile-onset HD is characterized by rigidity without chorea (Huntington's 
Disease Collaborative Research, 1993). Gait and postural instability are altered 
later in the course of disease. 
Pathology 
The primary pathology of HD is degeneration and loss of neurons in the 
caudate and putamen. Although HTT is ubiquitously expressed throughout the 
entire body, medium spiny neurons (MSN) in the striatum (caudate and putamen 
in humans) are especially susceptible to degeneration. The striatum is not the 
only brain region affected by HD. Studies have shown degeneration and/or 
dysfunction in other subcortical regions such as the substantia nigra (SN), 
thalamus and hypothalamus (Heinsen et al., 1999; Kassubek et al., 2005; Kipps 
et al., 2005; Kloppel et al., 2009; Petersen and Bjorkqvist, 2006; Politis et al., 
2008; van den Bogaard et al., 2011; Wild et al., 2010) and multiple cortical brain 
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regions (Thu et al., 2010). White matter pathways throughout the brain are also 
altered in HD, thereby affecting connectivity throughout the brain (Dumas et al., 
2011; Hobbs et al., 2010). Evidence of changes in volume of multiple brain 
regions is evident in prodromal HD and accelerates the closer a patient gets to 
estimated age of motor symptom onset (Aylward et al., 2000; Aylward et al., 
2011; Aylward et al., 2004; Hobbs et al., 2010; Majid et al., 2011; Tabrizi et al., 
2011). 
Post-mortem studies of neurons in the striatum revealed that MSN are 
specifically damaged in HD. Graveland et al. (1985a) and Ferrante et al. (1991) 
described MSNs in post-mortem striatum of mid- and late-stage HD subjects as 
having either proliferative or degenerative changes. Proliferative changes 
occurred more frequently in mid-stage HD specimens. These changes were 
characterized by an increase in spine density at the ends of dendritic trees, an 
increase in size of dendritic spines and a re-curving of the dendritic tree toward 
the soma. Degenerative changes were more frequent during later stages of HD. 
MSNs exhibiting degenerative changes showed a decrease in spine density, a 
reduced dendritic arbor and focal swellings along the dendrite. Changes in MSN 
morphology precede gross striatal neuron loss (Ferrante et al., 1991). 
 
Animal Models 
Chemical models 
 Chemical models of HD were used before the HTT gene was identified in 
human HD patients. The first chemical model consisted of injecting glutamatergic 
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excitotoxins into the brain. These included substances such as kainic acid and 
quinolinic acid, which are both agonists at ionotropic Glu receptors (Coyle and 
Schwarcz, 1976; McGeer and McGeer, 1976). Quinolinic acid lesions of the 
striatum have been shown to closely reproduce neuropathology, neurochemistry 
and symptomatology that are characteristic of HD (Beal et al., 1991; Ferrante et 
al., 1993; Sun et al., 2003).  
 A second type of chemical lesion has been used to mimic HD. These 
toxicants impair mitochondrial function and deplete the cell of the energy source 
ATP. The electron transport chain generates the energy to produces the majority 
of ATP in the cell through a series of enzyme complexes that reduce oxygen to 
water. Dysfunction of complex II, III and IV has been associated with HD 
(Brennan et al., 1985; Browne et al., 1997; Browne and Beal, 1994; Mann et al., 
1990). 3-nitropropionic acid (3-NP) is a suicide inhibitor of Complex II. Accidental 
ingestion of 3-NP occurred in China through contaminated sugar cane and 
produced an irreversible non-progressive dystonia. Subsequent brain imaging 
showed that exposure to 3-NP caused bilateral damage to the putamen 
(Ferrante, 2009). 3-NP has been used to study the effects of inhibiting Complex II 
on many aspects of striatal biology. These studies have shown that mitochondrial 
dysfunction of this type causes excitotoxicity, oxidative stress, MSN death and 
motor dysfunction (AC et al., 1992; Beal et al., 1993; Brouillet et al., 1993; Sun et 
al., 2002). Interestingly, decortication of animals prior to 3-NP exposure prevents 
striatal lesions, suggesting that Glu excitotoxicity plays a large role in the 
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mechanism of striatal degeneration by 3-NP and potentially in HD (Beal et al., 
1993). 
Exon 1 fragment mouse models  
 After the discovery of the mutated gene that causes HD, a variety of 
mouse models were developed. The first mouse models of HD were published in 
1996 (Mangiarini et al., 1996). They express exon 1 of the human HTT gene, 
with an expansion of CAG repeats, under the control of the human promoter in 
addition to the endogenous mouse huntingtin gene. The R6/1 mouse line has an 
approximate 120 CAG repeat while the R6/2 mouse line has about 150 CAG 
repeats (Mangiarini et al., 1996). The R6/2 line is the most studied mouse model 
of HD. The R6/2 line has an earlier age of disease symptom onset and shorter 
lifespan than the R6/1 line that is likely due to the longer CAG expansion. The 
R6/2 line has phenotypic symptoms similar to HD patients with motor 
dysfunction, atrophy of the striatum, loss of body weight and inclusions of mutant 
HTT (Mangiarini et al., 1996). A comprehensive behavioral study found 
significant and progressive rotarod deficiencies, climbing activity and hypoactivity 
in R6/2 mice at 4 weeks old. R6/2 mice begin to lose weight around 7 weeks and 
gait abnormalities at 8 weeks. At 12 weeks R6/2 mice exhibit an increase in 
anxiety, a deficit in pre-pulse inhibition and a decrease in grip strength (Menalled 
et al., 2009). However, there are inconsistencies between mutant HTT 
aggregation and inclusions between the R6/2 model and HD. The R6/2 mice 
present with aggregates throughout the brain at postnatal day 1 that increase 
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with age. This is in contrast to HD patients who do not develop aggregates this 
aggressively. 
 The R6/1 mouse model is not as extensively studied as the R6/2 model. 
R6/1 mice develop less severe symptoms at a later age compared to R6/2 mice. 
In contrast to R6/2 mice, they have a normal lifespan aided by the slower 
progression of disease symptoms. Mutant HTT aggregates appear at 2 months 
of age, much later than R6/2 mice. R6/1 mice exhibit no striatal neuron loss; 
however there are abnormalities in MSN morphology consistent with a 
degenerative phenotype (Naver et al., 2003; Spires et al., 2004). Because of the 
prolonged progression of symptoms, the R6/1 mouse model may be more useful 
to study potential disease modifying therapeutics than the R6/2 mouse model. 
Full length mouse models 
 A second type of HD mouse model expresses the full length HTT gene. 
The YAC128 mouse model expresses the full length human HTT gene containing 
128 CAG repeats with the human promoter on a yeast artificial chromosome 
(YAC) in addition to the endogenous murine HTT gene (Slow et al., 2003). The 
first abnormality in YAC128 mice is a procedural learning deficit at 2 months of 
age (Van Raamsdonk et al., 2005b). Motor dysfunction sets in at 3 months with a 
hyperkinetic phenotype, a rotarod deficit at 4 months and a hypokinetic 
phenotype by 6 months (Menalled et al., 2009; Slow et al., 2003; Van 
Raamsdonk et al., 2005b). However, despite these motor symptoms changes in 
striatal volume are not detected until 9 months. Cortical volume is reduced, 
striatal neuron loss and HTT aggregates are present at 12 months (Slow et al., 
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2003). This mouse model has a high fidelity of symptoms and pathology with HD, 
which is why we chose to use it for our experiments (Carroll et al., 2011). 
 A second full length HTT mouse model is the BACHD model. A bacterial 
artificial chromosome (BAC) expresses full length mutant human HTT with 97 
repeats that contain both CAA and CAG repeats (Gray et al., 2008). At two 
months old, BACHD mice exhibit deficits on the rotarod that progressively 
worsen with age. There is no significant gross neuropathology at 6 months, but 
there is significant atrophy throughout the brain at 12 months. Electrophysiology 
studies of MSNs revealed a significant decrease in corticostriatal input to MSNs 
in BACHD mice (Gray et al., 2008). 
Exon 1 fragment versus full length huntingtin 
 The full length and exon 1 mouse models of HD show similar motor and 
pathological phenotypes; however there are distinct differences in the rate, 
severity and presence of symptoms between the different models. In general the 
full length mouse models show milder behavior and motor deficits than the R6/2 
mouse model (Menalled et al., 2009; Menalled and Chesselet, 2002). The R6/2 
mouse model has a significantly faster progression than the full length models. 
The R6/2 mice show gait abnormalities, anxiety and a significant decrease in 
survival that is unique to this model. The BACHD mouse model shows some 
behavioral phenotypes that only occur in the R6/2 model, but not other models of 
HD. These include a decrease in grip strength, climbing and a pre-pulse 
inhibition deficit. All models show deficits on the rotarod and open field behavior, 
but to different extents and at different ages.  
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 The neuropathology of HD mouse models does not fully recapitulate the 
disease in humans. R6/2 mice show ubiquitinated mutant HTT aggregates in the 
nucleus and cytoplasm of neurons. However, the extent and distribution of these 
aggregates does not match human pathology. R6/2 mice show an abundance of 
HTT aggregates throughout the entire brain on an overwhelming scale 
(Vonsattel, 2008). BACHD mice, on the other hand, show mutant HTT 
aggregates that are more similar in distribution and number to HD patients 
(Ferrante, 2009). The genetic models are a much more accurate representation 
of HD than the chemical models of HD. 
 
Striatal neurochemistry neuron morphology in HD 
 Post-mortem studies of neuron in the HD striatum showed that MSNs 
exhibit both proliferative and degenerative changes (Ferrante et al., 1991; 
Graveland et al., 1985b). Proliferative changes, characterized by an increase in 
spine density at the ends of dendritic trees, an increase in size of dendritic spines 
and a re-curving of the dendritic tree toward the soma occurred more frequently 
in mid-stage HD. Degenerative changes were more frequent during late stage 
HD and are characterized by a decrease in spine density, a reduced dendritic 
arbor and focal swellings along the dendrite. Neuron morphology studies in 
mouse models of HD consistently show degenerative changes in striatal MSN 
morphology. Morphological studies of striatal MSNs in R6/1(Spires et al., 2004), 
R6/2 (Klapstein et al., 2001), HD48 and HD89 (Guidetti et al., 2001) mice all 
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showed a decrease in spine density across branch order and was only evident in 
symptomatic mice (Klapstein et al., 2001). 
Changes in striatal neurochemistry of HD patients may influence MSN 
morphology and are present in HD mouse models. GABA levels are decreased in 
the putamen, nucleus accumbens, subthalamic nucleus, substantia nigra, 
thalamus, globus pallidus and occipital cortex (Bonilla et al., 1988; Spokes et al., 
1980; Urquhart et al., 1975). Activity of glutamic acid dehydrogenase (GAD), the 
enzyme required to synthetize GABA, is reduced in the putamen, caudate and 
globus pallidus (Urquhart et al., 1975; Wu et al., 1979). Alterations in GABA 
release and GAD expression are also present in mouse models of HD 
(Gourfinkel-An et al., 2003; Nicniocaill et al., 2001). Levels of striatal DA and DA 
receptors are reduced in the striatum and cortex in HD (Andre et al., 2010; 
Augood et al., 1997; Bernheimer et al., 1973; Kish et al., 1987; Pavese et al., 
2010). Reduced striatal DA levels and disturbances in dopaminergic signaling 
have also been observed in the mouse models of HD (Bibb et al., 2000; Cha et 
al., 1998; Johnson et al., 2006). Post-mortem studies of HD and mouse models 
show changes in GABA and DA that may lead to changes in MSN morphology. 
 
Manganese Toxicity 
 
Sources of exposure 
 Manganese (Mn) is an essential trace mental that is present at 0.1% of the 
earth‟s crust and can be found in soil at concentrations from 40 to 900 mg/kg 
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(Cooper, 1984). It can be released into the environment in multitude of ways. Mn 
in the soil can leach into ground water, wells and aquifers thereby contaminating 
drinking water. Mn is also present in a number of common foods including nuts, 
whole grains, tea, leafy vegetables, pineapple, brown rice and beans 
(Pennington and Young, 1991).  The daily intake requirement of Mn is 
approximately 2-5 mg Mn per day (Aschner and Aschner, 2005). Only 1-5% of 
orally ingested Mn is absorbed by the body (Davis et al., 1993). Mn is normally 
excreted in the bile with the exception of the small amount of absorption that 
occurs in the intestine. Neonates absorb a greater percentage of Mn which may 
be due to the fact that their biliary function is not yet fully established. Neonates 
who are critically ill or born prematurely are commonly fed through total 
parenteral nutrition (TPN). Mn concentrations in these solutions are not 
consistent and mineral supplements are commonly added with variable amounts 
of Mn. Neonatal absorption of Mn from milk is approximately 8% whereas 
absorption from TPN is 100% (Aschner and Aschner, 2005). This can pose a 
serious problem to neonates who are exposed to excessive Mn in TPN. Hepatic 
dysfunction and cholestasis are two risk factors for increased Mn accumulation 
(Butterworth, 2010; Butterworth et al., 1995; Krieger et al., 1995). Since at least 
90% of Mn is removed by the liver and excreted in the bile, dysfunction of either 
system could lead to an increase in Mn absorption from the diet. Chronic hepatic 
encephalopathy and biliary atresia in adults can lead to an increase in Mn in the 
globus pallidus (Butterworth et al., 1995; Ikeda et al., 2000). Critically ill neonates 
are also at risk for Mn accumulation in the brain due to TPN containing Mn, 
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underdeveloped biliary function, and frequently develop hepatic dysfunction and 
cholestasis which increases Mn absorption (Aschner and Aschner, 2005). 
Methylcyclopentadienyl manganese tricarbonyl  (MMT) is a gasoline 
additive used as an antiknock agent (Cooper, 1984). This is a controversial 
source of airborne Mn exposure. MMT has been used in Canada for more than 
20 years. In some cases elevated indoor and outdoor Mn levels have been found 
near high traffic urban areas compared to lower traffic rural areas (Bolte et al., 
2004; Boudia et al., 2006; Zayed et al., 2003). However, in other cases airborne 
Mn levels have not exceeded the current reference concentration for inhaled Mn 
set by the United States Environmental Protection Agency and there is little 
evidence for soil contamination in high traffic areas (Dobson et al., 2004; Pfeifer 
et al., 2004). MMT is a controversial source of Mn exposure; however it 
continues to be studied in order to further elucidate the effects of its usage in 
gasoline. 
Mn poisoning can occur though illicit drug use of methcathinone (or 
ephedrone). Methcathinone is a homemade drug that is derived from the 
combination of pseudoephedrine and potassium permanganate (Sikk et al., 
2011; Sikk et al., 2010). Intravenous (i.v.) use of this drug in Eastern Europe and 
Russia was shown to cause symptoms similar to Mn poisoning (manganism) and 
Parkinsonism more than 20 years ago (de Bie et al., 2007; Sanotsky et al., 2007; 
Selikhova et al., 2008; Sikk et al., 2011; Sikk et al., 2010; Sikk et al., 2007; 
Stepens et al., 2008). However, only recently has interest in studying the effects 
of this drug grown. Onset of motor dysfunction associated with methcathinone 
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use can occur as early as months after beginning drug use and up to years later. 
Neuroimaging studies using T1-weighted magnetic resonance imaging (MRI) 
show hyper-intense globus pallidus (GP) and substantia nigra (SN) in current 
methcathinone users, consistent with Mn deposition in these brain regions (Sikk 
et al., 2010; Stepens et al., 2008). Motor symptoms are unresponsive to L-DOPA 
therapy, metal chelation, dopaminergic medications and anticholinergic drugs 
(Sikk et al., 2011). As of yet there is no treatment that improves motor symptoms. 
 The majority of Mn exposure occurs through occupational exposure. Mn is 
commonly used as an agent in welding material. Proper ventilation equipment is 
not always provided or used during welding, therefore exposing welders to Mn 
through inhalation. Not only can Mn be absorbed nasally and transported to the 
brain, it can also accumulate in the lungs and cause respiratory problems 
(Bowler et al., 2006; Bowler et al., 2007a; Bowler et al., 2007b). Ferroalloy 
smelting plants are another means of occupation and environmental Mn 
exposure (Huang et al., 1989; Jiang et al., 2007; Wang et al., 1989). Studies in 
Europe have found Mn contamination and elevated Mn levels in people living 
near ferroalloy plants (Lucchini et al., 2007; Lucchini et al., 2009; Squitti et al., 
2009). Dry cell battery production, manufacturing glass and ceramic glazes are 
other occupational means of Mn exposure (Bader et al., 1999; Srivastava et al., 
1991).  
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Manganism 
 Manganism is a progressive motor dysfunction that was first described in 
Mn ore workers by James Couper in 1837 (Couper, 1837; McMillan, 1999). Early 
stage manganism is characterized by behavioral, emotional and cognitive 
changes. Fine motor skills and speech may also be affected at this stage. At the 
intermediate stage, more severe motor symptoms appear. At this stage patients 
may present with „masque manganique‟ or a loss of facial expression. Psychotic 
symptoms also progress and have been termed „locura manganica‟ or 
manganese madness. The final stage of manganism produces symptoms such 
as limb rigidity, dystonia, tremors, gait abnormalities, a tendency to fall backward 
and a cock-like walk are present (Lucchini et al., 2009; Roth, 2009).  
 The motor symptoms of manganism are similar yet distinct from 
Parkinson‟s disease (PD). Similarities in motor symptoms include rigidity and 
bradykinesia; however, manganism has a distinct cock-walk versus the 
festinating gait observed in PD (Lucchini et al., 2009). Patients with manganism 
rarely show a sustained response to L-3,4-dihydroxyphenylalanine (L-DOPA) or 
other dopamine (DA) replacement therapy and fail to show reduced striatal DA 
uptake (Calne et al., 1994; Huang et al., 2003). Recently, exposure to chronic 
low level Mn exposure has been shown to be a risk factor for PD as is living near 
industrial Mn operations (Gorell et al., 1997; Gorell et al., 1999; Lucchini et al., 
2007; Lucchini et al., 2009; Perl and Olanow, 2007).   
 
 
15 
 
Pathology 
 Mn accumulates preferentially in the basal ganglia, specifically the 
striatum, globus pallidus (GP) and SN (Aschner et al., 2005; Dobson et al., 2004; 
Dodd et al., 2005; Erikson et al., 2002; Erikson et al., 2004b; Fitsanakis et al., 
2008; Olanow et al., 1996; Williams et al., 2010b). Rodent, non-human primate 
and human post-mortem studies have found that the striatum shows damage 
following exposure to Mn (Aschner et al., 2007; Milatovic et al., 2009; Olanow, 
2004; Perl and Olanow, 2007). Moreover, the nigrostriatal DA system is 
negatively impacted by Mn exposure (Guilarte et al., 2008; Guilarte et al., 2006; 
Huang et al., 2003; Kessler et al., 2003; Kim et al., 2002; Stanwood et al., 2009). 
In PD, the pigmented DA neurons of the SN degenerate resulting in damage to 
striatal medium spiny neurons (MSN) (Day et al., 2006; Garcia et al., 2010; 
Wright et al., 2009; Zaja-Milatovic et al., 2005). Therefore, overlapping, but not 
identical brain regions are involved in Mn neurotoxicity and PD, with striatal 
MSNs affected in both conditions (Garcia et al., 2010; Milatovic et al., 2009; Zaja-
Milatovic et al., 2005).   
 
Animal models 
Animal models of Mn toxicity have shown to be reliable representations of 
human Mn poisoning. However, like all animal models of human disease there 
are limitations to disease fidelity. Due to structural differences in brain anatomy, 
rodents accumulate Mn in a slightly different pattern than non-human primates 
and humans. Non-human primates and rats were injected with the same dose of 
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Mn and measured accumulation 2 days later using MRI. Rodents accumulated 
less Mn than the non-human primates of approximately the same size and weight 
(Bock et al., 2008). Olfactory absorption of Mn is observed in animal models of 
inhalational Mn exposure; however it is unlikely to account for the large increase 
in Mn accumulation in the GP, which are thought to be due to systemic exposure 
(Bock et al., 2008; Dorman et al., 2006a; Dorman et al., 2006b).  
Through the use of animal models, we have a better idea of how Mn is 
transported throughout the body and how it accumulates in the brain. Both 
astrocytes and neurons accumulate Mn, however astrocytes can accumulate as 
much as 50x as much Mn as neurons (Wedler et al., 1989). Mn can be taken up 
into cells via the divalent metal transporter 1 (DMT1), transferrin receptor (TfR), 
dopamine transporter (DAT) or other metal cation transporters (Anderson et al., 
2007; Aschner and Gannon, 1994; Erikson and Aschner, 2006; Erikson et al., 
2005). Mn tends to accumulate in non-heme iron (Fe) rich regions of the brain. 
This may be due in part to accumulation though transporters such as DMT1 and 
the TfR that are highly expressed in these brain regions (Dobson et al., 2004). 
Within cells, Mn has been shown to accumulate in the mitochondria and nucleus 
and cause dysfunction of these organelles (Gavin et al., 1999; Kalia et al., 2008).  
Pathology 
Mn toxicity at the molecular level has elucidated potential mechanisms of 
toxicity leading to pathology. Mn has been shown to accumulate in the 
mitochondria through the calcium uniporter (Gavin et al., 1999). This may disrupt 
calcium (Ca) levels in the mitochondria required for normal function (Tjalkens et 
17 
 
al., 2006). Mn can also inhibit Complex I of the mitochondrial electron transport 
chain (Chen et al., 2001). Mn has been shown to cause oxidative stress 
(Milatovic et al., 2007; Milatovic et al., 2009) and oxidize DA (Archibald and 
Tyree, 1987; Benedetto et al., 2010; Florence and Stauber, 1989). 
Animal models of Mn toxicity show similar pathology to manganism, PD 
and animal models of PD. Rodents and non-human primates accumulate high 
levels of Mn in the basal ganglia and show motor deficits (Dodd et al., 2005; 
Golub et al., 2005; Guilarte et al., 2006; Vezer et al., 2007). These motor deficits 
may be due to dysfunction of the nigrostriatal DA pathway and damage to striatal 
MSNs (Burton and Guilarte, 2009; Burton et al., 2009; Guilarte et al., 2008; 
Guilarte et al., 2006; Milatovic et al., 2009; Stanwood et al., 2009). This is similar 
to neuropathology observed in animal models of PD (Day et al., 2006; Garcia et 
al., 2010). 
 
Striatum 
 The striatum is the major input region of the basal ganglia. In humans the 
striatum consists of the caudate and putamen, but it is one structure in rodents. 
The basal ganglia consists of many subcortical nuclei that include the striatum, 
globus pallidus internal and external segments (GPi and GPe, respectively), 
subthalamic nucleus (STN) and substantia nigra pars compacta and pars 
reticulata (SNpc and SNpr, respectively) (Chakravarthy et al., 2010; Stocco et al., 
2010).  
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 The striatum is responsible for integrating information from multiple 
cortical and subcortical areas to regulate motor activity. Control of motor function 
was thought to be the only function of the striatum since movement disorders 
involve pathologies that include striatal dysfunction (Butterworth, 2010; Couper, 
1837; Pfeiffer, 2007; Wilson, 1914). However, recently the striatum has also been 
implicated in cognitive functions such as procedural learning and spatial learning 
(Balleine et al., 2009; Voorn et al., 2004). The striatum receives topographical 
inputs from motor cortex, prefrontal cortex and thalamus, integrates this 
information and sends it back to the cortex through the thalamus. 
 
Medium spiny neuron subtypes 
Striatal MSNs compose approximately 95% of all neurons in the rodent 
striatum and 77% in primates (Graveland et al., 1985c; Rymar et al., 2004; Yelnik 
et al., 1991). In addition to MSNs, the striatum contains a small percentage of 
aspiny GABAergic interneurons and cholinergic interneurons. MSNs are 
GABAergic projection neurons with a medium sized soma and dendrites studded 
with dendritic spines. The striatum is composed of two main populations of MSNs 
defined based on their efferent projection, DA receptor and neuropeptide 
expression (Gerfen et al., 1990; Surmeier et al., 2007). MSNs also make 
inhibitory connections with other MSNs within the striatum through axon 
collaterals (Somogyi et al., 1981).  
DA has opposing effects on the two subtypes of MSNs. There are two 
main categories of DA receptors; both are G-protein coupled receptors (GPCRs), 
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but they each couple to different effector proteins. D1 type DA receptors include 
D1 and D5 receptors (D1R and D5R). When stimulated by DA, these GPCRs 
couple to the Gs effector which stimulates adenylate cyclase (AC) to stimulate 
the neuron. D2 type receptors include D2, D3, and D4 receptors (D2R, D3R and 
D4R). D2Rs couple to the Gi subunit, which inhibits AC and decreases activity 
of these neurons.  
Striatal MSNs receive a DA input from the SNpc and glutamatergic (Glu) 
inputs from the STN, thalamus and cortex. DA neurons form a synapse onto the 
neck of dendritic spines while cortical Glu inputs synapse onto the head of the 
spine. Corticostriatal presynaptic terminals express D2Rs that act to regulate 
corticostriatal Glu release (Bamford et al., 2004). Disruption of this synaptic triad 
has important consequences for motor function (Bamford et al., 2004; Day et al., 
2006; Deutch et al., 2007; Garcia et al., 2010; Joshi et al., 2009). 
 
Direct and indirect extrapyramidal pathways 
There are two large pathways in the basal ganglia, the direct and indirect 
pathways. MSNs that express D1Rs co-express the neuropeptide substance P 
(SP) and project to the GPi/SNpr compose the direct or striatonigral pathway. 
The indirect, or striatopallidal, pathway is comprised of MSNs that express D2Rs 
and the neuropeptide enkephalin that project to the GPe. GABA neurons of the 
GPe project to the STN, where Glu neurons project to the GPi/SNpr. GABAergic 
neurons of the GPi/SNpr then project to the thalamus, and the thalamus projects 
to the cortex. At rest, the indirect pathway predominates to inhibit motor activity. 
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However, prior to onset of motor activity the direct pathway is activated and the 
indirect pathway is inhibited to allow motor activity to occur. This complicated 
integration of motor activity occurs in the striatum and is why its dysfunction plays 
a critical role in motor diseases such as HD, PD and manganism. 
 
Medium spiny neuron morphology 
 Neuron morphology is characteristic of each major type of neuron. The 
dendritic arbor complexity, dendritic spine density and shape of the neuron 
determines how the neuron receives and propagates information that results in 
behavior such as movement or cognition (Alvarez and Sabatini, 2007). Dendritic 
spines and their morphology is importance for synaptic connections. Mature 
spines are mushroom shaped and have a large spine head and thin neck. These 
spines frequently receive glutamatergic inputs onto the head of the spine 
(Nimchinsky et al., 2002). In the case of MSNs, dendritic spines also receive a 
DA input onto the neck of the spine (Gerfen et al., 1990). Neuron morphology is 
labile, especially that of dendritic spines, and is influenced by exposure to 
toxicants, stress, neurochemistry, age, exercise and drugs (Alcantara-Gonzalez 
et al., 2010; Alfarez et al., 2009; Alvarez and Sabatini, 2007; Bindu et al., 2007; 
Eadie et al., 2005; Fischer et al., 2000; Gupta et al., 2007; Irwin et al., 2000; 
Johansson and Belichenko, 2002; Mervis et al., 1991; Milatovic et al., 2010; Solis 
et al., 2009; Stranahan et al., 2007; Yuste and Bonhoeffer, 2001). 
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Gene x Environment Interactions 
 Almost all diseases are the result of a combination of genetics and 
exposure to environment factors (Horowitz and Greenamyre, 2010; Hunter, 2005; 
Nabholz and von Overbeck, 2004). The genetic component can be causal 
(Mendelian) or susceptibility genes. A causal gene is a single gene in which a 
mutation, deletion, insertion or rearrangement directly causes a disease. These 
genes can be autosomal dominant, autosomal recessive or X-linked and follow 
well established inheritance patterns. Susceptibility genes have variations in the 
DNA sequence that occur normally throughout the human population. Each 
susceptibility gene only confers a small increase in risk of developing a specific 
disease. Multiple susceptibility genes or exposure to an environmental agent that 
can interact with such genes can initiate disease onset.  
Exposure to environmental factors can alter gene expression (epigenetics) 
or cell signaling pathways to cause onset of disease or alter disease progression. 
Environmental exposure can occur at any point throughout life to alter 
susceptibility to disease. Prenatal exposure and postnatal exposure in young 
children are critical time periods because the brain is still developing. In utero 
toxicant exposure is an emerging field that will shed light on many factors that 
have the potential to influence disease later in life. Exposure to toxic 
environmental agents is not only a concern during development; it is a growing 
concern in adult populations especially because of an increasing lifespan. 
 Gene-environment interactions play a role in many diseases, from cancer 
to respiratory diseases and autoimmunity diseases to neurodegenerative 
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diseases (Bjorkman et al., 2000; Chia, 2008; Gualtierotti et al., 2010; Horowitz 
and Greenamyre, 2010; Laviola et al., 2008; Nabholz and von Overbeck, 2004; 
Schwartz, 2010; Vance et al., 2010). To illustrate gene-environment interaction 
involvement in disease, I will briefly discuss Parkinson‟s disease. 
 Parkinson‟s disease is a neurodegenerative disease with genetic and 
environmental risk factors. There are a few genes that have a strong link to 
development of familial or heritable PD. These genes include parkin, LRRK2, 
PINK1, -synuclein and DJ-1 (Horowitz and Greenamyre, 2010; Vance et al., 
2010). Familial PD accounts for less than 10% of all PD cases. The majority of 
PD cases are idiopathic (IPD) with links to susceptibility genes such as Tau, 
USP24, ELAVL4 and ApoE (Vance et al., 2010). Environmental factors for the 
disease include aging, male gender, pesticide and Mn exposure. Age is a strong 
risk factor in both monogenetic and sporadic PD. Males are approximately twice 
as likely to develop PD as females. This may be due to sex hormone effects 
and/or occupational exposure to toxicants. Several animal studies suggest that 
estrogen is neuroprotective in multiple models of PD. Specific gene-environment 
interactions have been discovered for PD. Single nucleotide polymorphisms 
(SNP) in the nitric oxide synthase genes in conjunction with pesticide exposure 
and smoking have been shown to increase risk of PD (Hancock et al., 2006; 
Hancock et al., 2008). 
 PD is an illustrative example of a disease that is largely determined by 
gene-environment interactions. Studies have shown that although there is a 
genetic component to PD, penetrance of the disease is variable and incomplete. 
23 
 
An example of this is the discordance rates between monozygotic twins. There is 
variability in disease presentation and age of disease onset (Wirdefeldt et al., 
2011). Exposure to environmental toxicants can produce a form of parkinsonism 
that is indistinguishable from IPD. However, not all people exposed to these 
toxicants develop parkinsonian symptoms, thereby suggesting that there is a 
genetic susceptibility in a small number of people. 
 
Possibility of gene-environment interactions in monogenetic disease 
 Although HD is a monogenetic autosomal dominant disease, the number 
of CAG repeats in the HTT gene only accounts for 60% of the variability in age of 
disease onset (Andrew et al., 1993; Brinkman et al., 1997; Duyao et al., 1995; 
Stine et al., 1993; Wexler et al., 2004b). Environmental exposure and/or other 
genetic factors account for the remaining variability in disease onset and 
therefore may accelerate or slow the age of disease onset and progression 
(Hannan, 2004; van Dellen et al., 2005; van Dellen and Hannan, 2004). 
Monozygotic twin studies have shown discordance in age of onset, symptom 
presentation and disease severity. Some authors ascribe the difference in 
disease to be environmental, while others ascribe it to epigenetic phenomenon 
(Anca et al., 2004; Friedman et al., 2005; Georgiou et al., 1999; Gomez-Esteban 
et al., 2007; Panas et al., 2008). Friedman et al (2005) was the only research 
team that identified potential environmental exposure that could result in 
differential disease phenotypes between monozygotic twins. The birth home of 
the twins was across the street from an industrial factory; the air was polluted 
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and there were numerous chemical spills throughout their childhood. After the 
factory closed, it was designated as a federal toxic site. The twin presenting with 
HD symptoms at the age of 65 had only recently stopped smoking within the 
previous year, while the unaffected twin stopped smoking at the age of 35. The 
unaffected twin also moved out of the birth home long before the affected twin, 
and therefore was not exposed to either cigarettes or industrial toxins as long as 
the affected twin. This is only one example where there is a probable link to 
environmental exposure playing a significant role in onset of HD. Further 
investigation of monozygotic twins and large epidemiological studies may shed 
further light on to how environmental exposure can modify the onset and 
progression of HD. 
  
Evidence for gene-environment interactions in HD animal models 
 Animal models of HD also show gene-environment interactions in disease 
progression. Environmental enrichment (EE) involves placing novel items of 
various texture, shapes and sizes into cages with mice. EE has been shown to 
delay onset of motor symptoms in the R6/1 and R6/2 HD mouse models (Hockly 
et al., 2002; van Dellen et al., 2000). However, EE was not able to slow 
degeneration of striatal MSN (Spires et al., 2004). Dietary restriction through 
fasting was able to improve performance on the rotarod, increased brain derived 
nerve growth factor (BDNF) and increase life span in the HD N171-82Q mouse 
model (Duan et al., 2003). Another modification of the diet to include essential 
fatty acids reduced motor symptoms, but was not able to prevent a reduction in 
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striatal D1R and D2Rs in the R6/1 mouse model (Clifford et al., 2002). 
Supplementation of the YAC128 diet with the essential fatty acid ethyl- 
eicosapentaenoic acid (EPA) beginning at 7 months improved motor function, 
however there was no effect on progression of neurodegeneration (Van 
Raamsdonk et al., 2005a). 
 Interestingly, in human clinical trials, supplementation of the diet with EPA 
improved performance on the Unified Huntington's Disease Rating Scale 
(UHDRS) in two separate clinical trials (Clifford et al., 2002; Puri et al., 2005). A 
third trial failed to find an improvement in performance on the UHDRS, however 
there was no decline in performance observed suggesting that EPA was able to 
at least prevent a decline in performance (Vaddadi et al., 2002). The most recent 
clinical trial (TREND-HD) also failed to detect a difference between EPA and 
placebo in performance on the UHDRS (Investigators, 2008). These trials 
suggest that there is still much to be learned about HD and how environmental 
exposure may or may not have an effect on disease progression. 
 
Gender as a factor in gene-environment interactions 
Gender differences in the toxicokinetics of xenobiotics have been reported 
in the literature (Clewell et al., 2002; Fletcher et al., 1994; Nicolson et al., 2010). 
Multiple factors contribute to the gender differences; from differences in 
cytochrome P450 (CYP450) expression, transporter expression and influences of 
sex hormones on expression of these enzymes and transporters (Bonate, 1991; 
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Harris et al., 1995). Few studies have been conducted to examine the effect of 
gender on Mn exposure and HD. 
Gender and metal toxicity 
  Studies conducted in the general population, unexposed to high levels of 
Mn, have shown conflicting results. Men have been shown to have lower ferritin 
levels, reduced Mn absorption from the gastrointestinal tract and slower Mn 
clearance than women (Finley et al., 1994). Some studies indicate that in a 
healthy unexposed population, serum Mn levels are higher in men than women 
(Davis and Greger, 1992; Greger et al., 1990). However, more recent reports 
indicate that there is no gender difference in baseline serum Mn levels (Diaz et 
al., 2001; Rukgauer et al., 1997). A recent study explored intellectual function of 
children living in a Mexican Mn mining district. Children exposed to Mn had 20x 
the amount of Mn in hair and blood than children unexposed to high Mn levels. 
Young girls exposed to Mn performed worse on the revised Wechsler Intelligence 
Scale for Children than Mn exposed boys (Riojas-Rodriguez et al., 2010). 
Although there were no gender differences in Mn levels of exposed children, this 
suggests that cognitive performance may be differentially affected in boys and 
girls. Gender differences in response to metal exposure are not unique to Mn. 
Human studies have found gender differences in accumulation, storage and 
sensitivity to metals including cadmium (Cd), lead (Pb), Mn, mercury (Hg) and 
nickel (Ni) (Akesson et al., 2002; Akesson et al., 2005; Bjorkman et al., 2000; 
Grandjean et al., 1998; Gulson et al., 1998; Jin et al., 2004; Kobayashi et al., 
2006; Manton et al., 2003; McKeown-Eyssen et al., 1983; Meding et al., 2001; 
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Nielsen et al., 2002; Pounds et al., 1991; Uno et al., 2005; Vahter et al., 2007; 
Vahter et al., 2002). Animal studies also show gender differences in metal 
toxicokinetics and sensitivity. For example, male and female rats accumulated 
Mn differentially across body tissues following Mn exposure by inhalation; 
however, there was no difference in Mn accumulation in the striatum or other 
regions of the basal ganglia (Dorman et al., 2004). Gender differences in 
toxicokinetics following a single oral dose of the gasoline additive 
methylcyclopentadienyl manganese tricarbonyl (MMT) showed that female rats 
accumulated higher MMT levels than male rats due to slower clearance of MMT 
(Zheng et al., 2000). Erikson et al (2004a) exposed juvenile rats to airborne Mn 
for 13 weeks and found gender-specific changes in protein and mRNA 
expression of glutamine synthetase, metallothionein mRNA and glutathione 
levels in multiple regions of the brain. Gender differences in the toxicokinetics of 
Mn are present regardless of route of administration and Mn speciation. As with 
humans, rodents show gender differences upon exposure to other metals such 
as Pb and Hg (Fortoul et al., 2005; Magos et al., 1981; Sager et al., 1984).  
Human studies have found gender differences in accumulation, storage 
and sensitivity to other metals including Cd, Pb, Hg and Ni (Vahter et al., 2007; 
Vahter et al., 2002). Cd accumulates in the renal cortex and exposure to low 
levels of Cd reduced the glomerular filtration rate in women (Akesson et al., 
2005), however, men showed Cd-induced renal tubular effects at lower Cd levels 
than women (Jin et al., 2004; Kobayashi et al., 2006; Uno et al., 2005).  Over 
90% of Pb is stored in skeletal bone and release of Pb from bone parallels 
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increased bone turnover rates in women during pregnancy and lactation (Gulson 
et al., 1998; Manton et al., 2003; Pounds et al., 1991). A recent twin study in 
Sweden found that blood Pb levels have a larger genetic component in women 
than men (Bjorkman et al., 2000). Neurodevelopmental delays in children 
exposed to Hg prenatally are more prominent in boys than girls (Grandjean et al., 
1998; McKeown-Eyssen et al., 1983). Females are more susceptible to topical Ni 
allergy, which may be related to an increase in exposure to Ni containing jewelry 
(Meding et al., 2001; Nielsen et al., 2002).   
Animal studies also show gender differences in metal toxicokinetics and 
sensitivity. Female rats exposed to Pb by inhalation accumulated significantly 
higher levels of Pb than male rats. However, male rats lost more lung nonciliated 
bronchiolar cells and had a higher rate of necrosis (Fortoul et al., 2005). Female 
rats exposed to methylmercury (MeHg) by gastric gavage accumulate higher 
levels of the metal in the brain and have more damage to cerebellar granule 
layers than male rats (Magos et al., 1981). However, Sager et al. (1984) showed 
that male mice exposed to MeHg had fewer cells in the molecular and granule 
layers of the cerebellum than female mice. Male rats had a higher level of Mn in 
the blood, lung and olfactory bulb than female rats following Mn exposure by 
inhalation. Female rats had higher Mn levels in the cerebellum and liver, however 
there was no difference in Mn accumulation in the striatum or other regions of the 
basal ganglia (Dorman et al., 2004). Gender differences in toxicokinetics 
following a single oral dose of the gasoline additive MMT showed that female rats 
had a higher area under the curve (AUC), a longer half-life, a slower clearance 
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(CL) and elimination constant (kel). Overall, the female mice were exposed to 
more MMT than male mice and eliminated MMT from their system more slowly 
(Zheng et al., 2000). Erikson et al., (2004a) exposed juvenile rats to airborne 
manganese sulfate or manganese phosphate for 13 weeks and found gender-
specific and Mn-species specific changes in protein and mRNA expression of 
glutamine synthatase, metallothionen mRNA and glutathione levels in multiple 
regions of the brain. This study suggests that gender-specific differences in 
sensitivity to Mn exposure may also depend on the species of Mn. A recent 
behavioral study suggests that male mice are more susceptible to Mn exposure 
than female mice and that the behavioral deficit may be related to reduced 
striatal DA following Mn exposure (Moreno et al., 2009; Simon et al., 1994).  A 
similar behavioral deficit has been found in a PD mouse model (George et al., 
2008). 
Gender differences in Parkinson‟s disease 
Gender differences in prevalence, age of onset and progression have 
been described for PD (Haaxma et al., 2007; Miller and Cronin-Golomb, 2010; 
Shulman, 2007). Females tend to have a later age of onset and less severe 
symptoms of PD. Gender studies in animal models of PD have also shown that 
estrogen plays a protective role in neuropathology and behavior. Survival of DA 
neurons following exposure to DA neurotoxicants, used in animal models of PD 
is sensitive to gender (Richardson et al., 2008; Tamas et al., 2005). A study 
examining gender effects of 6-hydroxydopamine (6-OHDA) lesions on behavior 
and neuropathology showed that male rats are more sensitive to this toxicant 
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than female rats. Male rats showed a greater loss of DA neurons in the SN and 
had greater deficits in locomotor activity than female rats (Tamas et al., 2005). 
This suggests that the nigrostriatal DA system is more sensitive to toxicants in 
male than female rodents.   
Gender differences in Huntington‟s disease 
Multiple animal models of HD have shown gender differences in 
neuropathology and motor phenotype. Transgenic HD rats carrying a truncated 
HTT fragment with 51 CAG repeats showed gender differences in striatal 
volume, D1 dopamine receptor density and 17--estradiol. Symptomatic male 
rats showed reductions in each of these measures at 14 months (Bode et al., 
2008). Eight weeks of wheel running was shown to increase striatal levels of 
brain derived nerve growth factor (BDNF) in female, but not male, R6/1 mice 
(Zajac et al., 2010). Knock-in HD mice with 140 CAG repeats showed gender 
differences in behavior and striatal neurochemistry. Female knock-in mice 
showed habituation to the running wheel in the cage and spent more time 
running in the dark phase than male knock-in mice. Male knock-in mice showed 
a decrease in ascorbate release in the striatum that was no present in female 
knock-in mice (Dorner et al., 2007). Male N171-82Q HD mice showed a rotarod 
deficit that was not evident in female HD mice. BAG1 is a co-chaperone for HSP-
70 which increases HSP-70 activity. Crossing the HD mice with a neuron specific 
BAG-1 overexpressing line reduced the motor phenotype and reduced 
synaptosomal HTT aggregates in male HD mice (Orr et al., 2008). A 
comprehensive examination of behavior phenotypes, including gender 
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differences, in numerous HD mouse models was reviewed by Menalled et al., 
(2009). These studies show that gender differences in HD animals can be 
detected in motor phenotype, neuropathology and neurochemistry. Furthermore, 
HD mice respond differently to therapeutic interventions based on gender 
(Dorner et al., 2007; Orr et al., 2008; Zajac et al., 2010). 
 
 
Hypothesis and specific aims 
Since the striatum is a common target for both HD pathology and Mn 
accumulation, this provides the opportunity to observe gene-environment 
(heretofore referred to as disease-toxicant) interactions. Data previously 
published by our research groups show that YAC128 mice accumulate less 
striatal Mn relative to wild-type (WT) mice (Williams et al., 2010a; Williams et al., 
2010b). This phenomenon was restricted to the striatum because no significant 
differences in Mn levels between genotypes were observed in other brain 
regions. In vitro experiments by Williams et al. (2010b) and Kwakye et al. (2011), 
showed that a striatal cell line expressing mutant HTT (STHdhQ111/Q111) 
accumulated less Mn and exhibited higher survival rates than striatal cells 
expressing WT HTT (STHdhQ7/Q7). Based on these studies, we hypothesized that 
Mn exposure and mutant HTT would exhibit disease-toxicant interactions at the 
level of neuron morphology and neurochemistry in the striatum of YAC128 mice.  
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Specific Aims 
 This work aims to answer the following questions; (1) is there a disease-
toxicant interaction between mutant HTT and Mn exposure in striatal 
neurochemistry and MSN morphology and (2) does gender play a role in the 
disease-toxicant interaction in MSN morphology? 
Specific Aim 1 
 In this aim we determine if (1) Mn exposure, (2) mutant HTT expression 
and (3) the combination of Mn exposure and mutant HTT expression alters 
striatal neurochemistry and MSN morphology at two time points. In order to 
address the question if a disease-toxicant interaction between HD and Mn 
exposure alters striatal neurochemistry and MSN morphology, we exposed WT 
and YAC128 mice to vehicle (Veh) or Mn and examined striatal neurochemistry 
by HPLC and MSN morphology by Golgi staining.  
Specific Aim 2 
Based on the literature of gender differences in Mn exposure and HD 
animal models, we hypothesized that gender may be a factor in Mn and/or HD 
neuropathology. Therefore, we examined striatal MSN morphology and striatal 
Mn content 24 hours and 3 weeks following Mn exposure in mice of both genders 
and genotypes to determine (1) if gender has an effect on MSN morphology in 
the presence or absence of Mn exposure, (2) if gender is a factor in striatal Mn 
accumulation and (3) if gender differences in MSN morphology are present when 
Mn levels return to baseline.     
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Chemical Reagents 
Osmium tetroxide and glutaraldehyde were obtained from Electron 
Microscopy Sciences (Hatfield, PA), MnCl2 from Alfa Aesar (Ward Hill, MA), 
paraformaldehyde from Fisher Scientific (Pittsburgh, PA), Phosphate Buffered 
Saline (PBS) from Mediatech Inc. (Manassas, VA), isoflurane from Phoenix 
Pharmaceutical Inc., (St. Joseph, MO) and all other chemicals were obtained 
from Sigma Chemical Company (St. Louis, MO). 
 
Animal Housing and Mn Exposure 
The FVB-Tg (YAC128)53Hay/J mouse line (YAC128) was purchased from 
JAX (#004938, Bar Harbor, ME) (Slow et al., 2003). All animal exposure 
protocols were approved by the Vanderbilt University Medical Center Institutional 
Animal Care and Use Committee (IACUC) and strictly adhered to in order to 
minimize the mice‟ pain. All treatment and procedures followed NIH laboratory 
animal care and use guidelines. Genotyping of the mice and confirmation of a 
static CAG-triplet repeat length in mutant animals was carried out by PCR 
according to a previously published protocol (#004938; from JAX) (Slow et al., 
2003). Mice were distributed into exposure groups across multiple litters and the 
gender in each of the groups was balanced. The Mn exposure paradigm was 
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adapted from the previously published protocol (Dodd et al., 2005; Williams et al., 
2010b) that resulted in a significant increase in striatal Mn levels without 
significant motor impairment on experimental day 7, 24 hours following the last 
Mn exposure. Twelve week old mice were subcutaneously (s.c.) injected at the 
hind leg with vehicle (water) or MnCl2-4H2O (50 mg/kg) on experimental day 0, 3, 
and 6. 
 
Quantification of Striatal Manganese Levels 
Mice were decapitated on experimental day 7 (13 weeks, 7 mice per 
group) or 28 (16 weeks, 5 mice per group) and the striatum was rapidly 
dissected. The striatum was then placed in liquid nitrogen and stored at -80oC. 
Samples were dried in glass vials on a heat block at 100o C for 3 days 
underneath a beaker turned upside down and digested with 65-70% nitric acid for 
3 hours at 90o C. To each sample, 10 mL of 1 % nitric acid was added. Next, 
samples were filtered (Arcodisc, 0.45 m HT Tuffryn membrane) and submitted 
for Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) analysis. A Perkin-
Elmer ELAN DRC II ICP-MS was calibrated and verified before reading the blank 
(1% nitric acid). 50 L of In-115 at a concentration of 50 g/L was added to each 
sample as an internal control. Analysis of each sample was read with the 
following settings: nebulizer flow 0.9-1 L/min, radio frequency power 1,250-1,300 
W, plasma gas flow 15 L/min, lens voltage 6.5-7.5 V, auto lens on, 3 replicates 
per reading, 100 ms dwell time per atomic mass unit, 1000 ms integration time 
with peak hopping scan mode. 
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Golgi Silver Impregnation 
Multiple Golgi staining methods have been used in the striatum, so we 
compared two methods to identify one that produced high quality staining of 
striatal MSNs. We first completed a pilot study comparing the FD 
Neurotechnologies Rapid GolgiStain Kit (Ellicott City, MD), published previously 
in our laboratory, with the single section rapid Golgi method that was optimized to 
stain MSNs (Garcia et al., 2010; Kusnoor et al., 2010). In our hands, the FD 
Neurotechnologies Rapid GolgiStain Kit did not fully impregnate a large number 
of neurons in the striatum. For example, there were numerous breaks in staining 
along the dendrite (Figure 23A, white arrow) or non-specific blebbing (Figure 
23A, black arrow). In comparison to the FD Neurotechnologies Rapid GolgiStain 
Kit staining, the single section rapid Golgi method (Figure 23B) produced high 
quality staining without any breaks in staining or blebbing along the dendrites. 
For this reason, we chose to use the single section Golgi method for the full 
studies to analyze how the disease-toxicant interaction between mutant HTT and 
Mn modifies striatal MSN morphology. 
On experimental day 7 (13 weeks) or day 28 (16 weeks) the mice were 
deeply anesthetized with isoflurane, and transcardially perfused with 15 mL 0.1M 
phosphate buffer (PB) followed by 40 ml of 2% paraformaldehyde and 2.5% 
glutaraldehyde in 0.1M PB. The brains were removed from the skulls and post-
fixed for 3 hours at room temperature. Vibratome sections were cut in the coronal 
plane at 150 m. The single-section Golgi silver impregnation method was 
36 
 
previously described (Garcia et al., 2010; Kusnoor et al., 2010). The sections 
were incubated in 1% osmium tetroxide for 20-40 minutes, transferred to 3.5% 
potassium dichromate and incubated overnight. The sections were then 
incubated in silver nitrate between two slides for 4-6 hours. Sections were 
washed in water, mounted on 0.5% gelatin coated slides, dehydrated and 
cleared and coverslipped. There were 4-5 mice per exposure group at 13 weeks 
and five mice in all groups at 16 weeks. The FD Neurotechnologies Rapid 
GolgiStain Kit (Ellicott City, MD) was used according to the manufacturer‟s 
instructions. 
 
Neuron Reconstruction and Analysis 
Golgi-impregnated striatal medium spiny neurons were reconstructed 
under 60x magnification using the NeuroLucida (MicroBrightfield, Inc., Williston, 
VT) system. One researcher, blinded to genotype and exposure conditions, 
selected, traced and analyzed the neurons. Four to six neurons were traced per 
animal and were selected for tracing based on the following strict criteria: location 
in the striatum (Bregma +0.14 mm to +0.86 mm), soma and dendrites must be 
fully impregnated without beading or breaks in staining along the dendrite, and 
must have at least 2 primary dendrites and reach the 3rd branch order. Neurons 
were analyzed using NeuroExplorer (MicroBrightfield, Inc., Williston, VT). 
Morphometric characteristics were either averaged over the entire neuron (total 
neuron measures) or analyzed as a function of distance from the soma. Dendritic 
length and spine number are summed over the entire dendritic tree to give total 
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dendritic length and total spine number, respectively. Total spine density is the 
number of spines per 10 m. The point of each dendrite branching is termed a 
node. Therefore, the total number of nodes is the total number of branch points 
summed across the dendritic tree. The total number of ends refers to the number 
of dendrite endings. Concentric circles of 10 m radiating outward from the 
center of the soma were used to analyze morphometric features as a function of 
distance from the soma. Branching complexity was measured by tallying the 
number of dendrites that cross each of the concentric circles (intersections). The 
space in between each of the concentric circles creates a shell in which 
morphologic features, such as dendrite length, spine number and spine density 
were measured. This information provides a more detailed view of neuron 
morphology (Sholl, 1953). 
 
Amino Acid and Monoamine Neurochemistry Analysis 
Mice were euthanized at week 13 or 16 by decapitation. The striatum was 
rapidly dissected, placed in liquid nitrogen and stored at -80oC. Samples were 
submitted to the Center for Molecular Neuroscience/Kennedy Center 
Neurochemistry Core Lab at Vanderbilt University for measurement of amino 
acids (n=3-8 mice per group) and monoamine neurotransmitters (n = 4-6 mice 
per group) by HPLC.  
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Immunohistochemical Staining 
On either day 7 or day 28 the animals were deeply anesthetized with 
isoflurane, and transcardially perfused with 0.1M PB followed by 4% 
paraformaldehyde in 0.1M PB. The brains were blocked and post-fixed overnight. 
The following day the brains were transferred into 30% sucrose for 
cryoprotection. Coronal sections (40 m) were made using a cryostat to collect 
multiple sets of sections. Immunostaining was done according to previously 
published protocols (Bubser 2000, 1998? Deutch 1991 Cereb Ctx w/mods). 
Briefly, free-floating sections were washed in TBS, incubated in primary antibody 
overnight at room temperature, washed in TBS, incubated in a biotyinylated 
secondary antibody for 90 mins at room temperature, washed with TBS, and 
incubated in HRP-conjugated streptavidin for 1 hr at room temperature. Sections 
were washed in TBS and developed with (0.0005%) DAB in TBS plus 
(0.00009%) H2O2. The reaction was quenched by washing with TBS multiple 
times. Sections were mounted, cleared and coverslipped. 
 
Antibodies 
Sheep polyclonal tyrosine hydroxylase (TH, 1:3000 Millipore, Temecula 
CA, USA) was used to identify dopamine neurons in the substantia nigra. Mouse 
monoclonal glutamic acid decarboxylase 67 (GAD67, Millipore) was used to 
identify medium spiny neurons in the striatum. Biotinylated secondary antibodies 
(1:1600) and horseradish peroxidase (HRP) conjugated streptavidin (1:1000) 
were obtained from Jackson ImmunoResearch (Bar Harbor, MA, USA).  
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Statistical Models 
 Data were generated through various experimental methodologies and 
require different statistical models in order to meet critical assumptions required 
for each model. Grubb‟s outlier test was used prior to statistical analysis to find 
and eliminate outliers in data with the significance of alpha set to p < 0.05. 
Univariate, multivariate and repeated measures analysis of variance (ANOVA) 
followed by post-hoc analysis using Fisher‟s LSD multiple comparison test were 
performed using PASW Statistics 18 (SPSS, Inc, Chicago, IL). Striatal Mn levels, 
total neuron measures, striatal neurochemistry and immunohistochemistry were 
assessed by multivariate ANOVA with age, exposure, gender and genotype 
(when appropriate) as fixed factors. Age, exposure, gender and genotype (when 
appropriate) and radius were assigned as fixed factors in the analysis where 
neuron morphologic characteristics were measured as a function of distance 
from the soma. When ANOVA results were significant, post-hoc analysis of all 
pairwise combinations by Fisher‟s LSD was used to determine statistical 
differences between exposure groups.   
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CHAPTER III 
 
MORPHOMETRIC ANALYSIS IN NEURODEGENERATIVE DISORDERS 
 
Abstract 
The study of dendritic length and spine density has become standard in the 
analysis of neuronal abnormalities, since a considerable number of neurological 
diseases have their foundation in alterations in these structures. One of the best 
ways to study possible alterations in neuronal morphometry is the use of Golgi 
impregnation. Introduced more than a century ago, it is still the standard and 
state-of-the-art technique for visualization of neuronal architecture. We 
successfully applied the Golgi method to mouse, rat, monkey, and human brain 
tissues for studying both the normal and abnormal morphology of neurons. We 
were able to discover subtle morphological alterations in neuronal dendrites and 
dendritic spines in different brain areas. Although Golgi preparations can be 
examined by electronic microscopy, we used light microscopy and reconstruction 
using Neurolucida software to quantitatively explore the relationship between 
total dendritic length and spine density in different types of neurons. This unit 
summarizes the methodology used to quantify neuronal abnormalities and 
discusses the utility of these techniques in different models of 
neurodegeneration. 
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Introduction 
 
Basic protocol: Golgi-Cox Stain with Rapid GolgiStain™ kit 
 In our morphological studies and this unit we use the FD Rapid Golgi 
Staining Kit (FD Neurotechnologies, http://fdneurotech.com/), a commercial Golgi-
Cox staining system that has been proven to produce good results in animal and 
post-mortem human brain tissues. This method results in an adequate number of 
well impregnated neurons with nicely visible spines. Tracing and quantitative 
neuronal morphology is performed with the use of the Neurolucida system (MBF 
Bioscience, http://www.mbfbioscience.com/). Neurolucida is an advanced scientific 
software for performing neuron tracing and morphometry, as well as brain and 
anatomical mapping. Neurolucida can be used with live images from color video 
cameras or with stored image sets from confocal microscopes, electron 
microscopes, and scanning tomographic sources. When used in connection with 
light microscopes, Neurolucida utilizes a computer-controlled motorized XYZ 
stage for integrated navigation through tissue sections. Once the tracing is 
complete, images can be transferred to NeuroExplorer, a three-dimensional 
visualization and morphometric analysis program designed for data analysis, 
permitting determination of total dendritic length and number of spines per 
neuron. A representative neuronal tracing from our previous study with monkey 
brain is presented in Figure 1.   
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Figure 1. Golgi-impregnated Neurolucida-traced Purkinje cell from the 
monkey brain. 
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The following Basic Protocol is a description of the methodology for 
impregnation and staining of neuronal tissue; the Anticipated Results section in 
the Commentary describes concrete examples of quantitative characterization of 
neuronal morphology in studies conducted by our laboratories. For our staining, 
we use the FD NeuroTechnologies Rapid Golgi Staining kit (FD kit); it is based 
on the Golgi-Cox method of Ramon-Moliner (1970) and Glaser and Van der Loos 
(1981). It has been used in multiple animal species, as well as human post-
mortem tissue, to assess neuronal morphometry in a variety of brain regions. The 
kit is simple and easy to use with few technical requirements. NOTE: All protocols 
involving living animals must first be reviewed and approved by an Institutional 
Animal Care and Use Committee (IACUC) and must conform to governmental 
regulations regarding the care and use of laboratory animals.  
 
Materials 
 Experimental animal, e.g., mouse, rat, monkey 
 FD Rapid Golgi Stain Kit (FD NeuroTechnologies, cat. no. PK-401) 
 50%, 70%, 95%, and 100% ethanol 
 Xylenes 
 Paraffin 
 1% (w/v) bovine serum albumin (Sigma A3912) in PBS 
 Tissue-Tek O.C.T. Compound (Sakura Finetek, cat. no. 4583) 
 0.1% cresyl violet 
 Histo-Clear (National Diagnostics; optional) 
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 Cytoseal XYL mounting solution (Thermo Fisher Scientific) 
 Dissecting equipment 
 Razor blade (e.g., surgical carbon steel #12, single edge, VWR 55411-
055) 
 15-ml conical plastic tubes 
 Histology cassettes 
 Automated histology processor, e.g., Thermo Scientific Shandon Excelsior 
 Embedding molds 
 Automated rotary microtome (Leica RM 2235) or manual rotary microtome 
(Leica 
 RM 2125) 
 Superfrost Plus microscope slide (25 × 75 × 1–mm; e.g., VWR, cat. no. 
48311-703) 
 Histology oven 
 Cryostat and chuck 
 Gelatin-coated microscope slides (see recipe) 
 Slide box 
 Plastic staining dishes and rack (e.g., Sakura Finetek 4451) 
 Coverslips (24 × 50–mm, no. 1 1/2; e.g., VWR, cat. no. 48393-241) ) 
 Light microscope, e.g., Olympus BX62 with motorized stage 
 Neurolucida and NeuroExplorer software (MBF Bioscience, 
http://www.mbfbioscience.com) 
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 Additional reagents and equipment for anesthesia (Donovan and Brown, 
1998) and euthanasia (Donovan and Brown, 2006) of animals 
 
NOTE: Keep containers closed tightly at all times. Protect tissues from light 
during and after exposure to Solutions A and B. Perform all procedures at room 
temperature, unless specified. 
 
Tissue preparation 
1. Clean and rinse all containers with distilled water. 
a. Plastic containers are preferred, but glass containers are 
acceptable. Do not use metal implements when Solutions A and B 
from the FD Kit are present. 
2. At least 48 hr prior to experiment, prepare impregnation solution by 
combining equal volumes of Solutions A and B from the FD Rapid Golgi 
stain kit, gently mix (do not stir), and leave in the dark. Transfer 5- to 10-ml 
aliquots into 15-ml tubes. Prepare at least 5 ml of impregnation solution 
per cm3 of tissue. 
a. CAUTION: Solutions A and B contain mercuric chloride, potassium 
dichromate, and potassium chromate, and are toxic to the skin and 
potentially fatal if swallowed. 
3. Deeply anesthetize experimental animals (Donovan and Brown, 1998) 
prior to sacrifice (Donvan and Brown, 2006). 
4. Remove the brain from the skull quickly, but avoid damage to the brain. 
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5. Dissect the brain using a surgical razor blade. 
a. The dissection procedure should depend on the specific brain 
regions of interest. Avoid processing tissue pieces with volume >1 
cm3, which may result in incomplete tissue impregnation. 
6. Briefly rinse tissue with double distilled or Milli-Q water to remove blood 
from the surface. 
 
Silver Impregnation 
7. Place tissue into 15-ml conical tubes containing 10 ml of the impregnation 
solution (see step 2; use ≥5 ml solution/cm3 of tissue) for 2 weeks at room 
temperature in the dark. 
a. Only use the top part of the impregnation solution and avoid the 
precipitate. 
8. Replace the impregnation solution with fresh impregnation solution on the 
next day. 
a. CAUTION: Dispose of the impregnation solution in accordance with 
your institution’s hazardous waste regulations. 
9. Transfer the tissue into Solution C from the kit (in a 15-ml tube) and store 
in the dark at 4◦C for 5 to 7 days. 
10.  Replace Solution C on the next day. 
11.  After 1 week processing in Solution C in the dark at 4◦C, transfer the 
tissue into a new 20-ml scintillation vial and fill with water. Wash the tissue 
under running water overnight at room temperature. 
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12.  Place the very well rinsed tissue in a histology cassette, immerse 
cassette in 70% ethanol, and process in an automated histology processor 
as described in the following steps. 
a. All submitted tissue should be placed in cassettes and properly 
labeled with a unique identification number. 
 
Tissue processing in automated tissue processor 
After fixation (3 weeks: 2 weeks with Solutions A and B and 1 week with 
Solution C; steps 7 to 11) and preparatory procedures, the tissue is ready to go 
through the process of dehydration, clearing, infiltration, and embedding. Tissue 
processing and embedding in wax provide a support matrix for the tissue. Tissue 
must be completely fixed before processing. Processors have many containers of 
reagents into which the samples are transferred sequentially (using a carousel) 
and are pumped in or out. 
13.  Immerse tissues in increasing concentrations of ethanol to remove water 
from the tissue (once in 70% ethanol, three times in 95% ethanol, three 
times in 100% ethanol, each time for 1 hr). Following dehydration, clear 
samples in xylene (twice, each time for 1 hr) and infiltratewith paraffin, 
three times, each time for 1 hr using the automated processor. 
a. Poor dehydration results in poor processing. Too much time in 
alcohol can cause artifacts such as vacuolization and shrinkage. 
Incubation in clearing agents for too long can harden tissue and 
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make sectioning difficult. Tissue processing schedules for 
automated processors are devised according to brain size. 
14.  Using embedding molds, immerse samples in melted paraffin wax, which 
when solidified provides a support matrix. 
 
Paraffin block sectioning 
15. Section paraffin blocks at 50 to 80 μm on a rotary microtome. 
16. Float sections in purified water at 10◦C below the melting point of the wax 
used, then pick them up on BSA-coated charged (Superfrost Plus) slides. 
a. Slides are coated by immersing in 1% BSA in PBS for ≥30 min, 
then rinsing with water. 
b. Two sections may be placed on each slide. 
17. Drain slides upright and dry at 37◦C for a minimum of 20 min. 
18. Leave sections in histology oven at 60◦C for at least 1 hr (preferably 
overnight) to improve adhesion. 
 
Cryostat sectioning 
Following processing with Solution C and washing (step 11), processed tissue 
can be frozen and sectioned with a cryostat (although the authors usually use 
paraffin-embedded tissue since paraffin sections are more stable): 
a. Rapidly freeze tissue block by gently wrapping it in aluminum foil 
and placing in the cryostat chamber for at least 10 min. 
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b. Apply O.C.T. tissue-embedding compound on the chuck and allow 
it to solidify. Set the cryostat thickness to ∼100 μm and cut through 
the embedding compound until a flat surface large enough to 
accommodate the tissue is obtained. 
c. Orient the tissue so that the side of least importance is facing the 
chuck. Place a small amount of O.C.T. tissue-embedding 
compound on the side of the tissue that is least important and 
rapidly freeze tissue on the flat surface of the chuck. Place a small 
amount of tissue-embedding compound around the edge of the 
tissue to secure it to the chuck. Allow tissue embedding compound 
to solidify for ∼5 min. 
d. Cut 50- to 150-μm thick sections quickly on a cryostat at −22◦C. Set 
the chamber temperature to 1◦C colder than the specimen head 
temperature. Set the cryostat temperature the evening before use 
to allow sufficient time for the chamber to reach the desired 
temperature. 
e. Fill the dropper from the FD Golgi Stain kit with Solution C and 
place a drop of Solution C at each position on the gelatin-coated 
microscope slide where each section will be placed. Make sure that 
the sections are not placed too close to the edge of the slide. This 
will cause bubbles to form in the mounting medium and render the 
slides unusable. 
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f. Transfer each section onto a drop of Solution C using the glass 
specimen retriever from the kit to mount on gelatin-coated 
microscope slides. 
g. Absorb excess solution using a strip of filter paper or Kimwipe. 
Absorb excess solution so that sections do not fall off of the slides. 
h. Dry sections flat at room temperature overnight in the dark without 
the use of a heating source or fan. 
i. Dried sections should be processed as soon as possible, but they 
may be stored for up to 1 week in a slide box at room temperature. 
Proceed to step 20. 
 
Deparaffinization and staining procedure 
19. Deparaffinize sections by incubating for 5 min successively in three 
changes of xylene in Sakura Finetek staining dishes. 
20. Hydrate sections by immersing successively twice, each time for 5 min, in 
100%, 95%, 70% and 50% ethanol in Sakura Finetek staining dishes. 
21. Rinse in distilled water. 
22. Rinse sections in double distilled or Milli-Q water twice for 2 min each. 
23. Place sections in a mixture consisting of 1 part Solution D, 1 part Solution 
E (both from the FD Rapid Golgi Stain kit), and 2 parts double-distilled or 
Milli-Q water, for 10 min in a Sakura Finetek staining dish. 
a. Solution D 10 ml 
b. Solution E 10 ml 
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c. Water 20 ml. 
i. Prepare working solution just before use. It may be used for 
up to 200 sections (e.g., mouse brain) per 100 ml, 
depending on the size of sections. Cover the bottle and 
staining jar containing the working solution to prevent 
vaporization of the reagent. 
24. Rinse sections in double distilled or Milli-Q water twice, each time for 4 
min. 
a. The distilled water should be renewed frequently. 
25. Stain sections by immersing in 0.1% cresyl violet for 10 min. Quickly rinse 
in distilled water. 
a. Although the FD Rapid Golgi Staining Kit fully impregnates and 
stains neurons, cresyl violet counterstaining provides better 
visualization of brain and results in images especially desirable for 
publication purposes. Staining in warmed cresyl violet solution 
(preheated in a 37o to 50oC oven) can improve penetration and 
enhance staining. 
 
Tissue dehydration and coverslipping 
26. Dehydrate sections by immersing successively twice, each time for 5 min 
in 95% ethanol. 
27. Continue tissue dehydration by immersing successively in two changes of 
100% ethanol, each time for 5 min. 
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28. Clear by immersing slides in xylenes or Histo-Clear two times, each time 
for 5 min. 
29. Take one slide out of the staining rack at a time and drain off excess 
solution on a paper towel. 
30. Add a sufficient amount of Cytoseal to cover the slide (or area with 
sections) and carefully place coverslip on slide. Place more Cytoseal 
around the edge of the coverslip to ensure that a complete seal is made. 
Make sure no air bubbles form between the coverslip and slide. 
a. Cover either the area with the sections or the entire slide with 
mounting medium. Two drops of Cytoseal solution are sufficient to 
mount the coverslips. 
31. Dry the slides at room temperature for 24 to 48 hr, or until completely dry. 
a. Slides should be protected from light.  
b. Stained slides are now ready to be microscopically evaluated using 
a light microscope (Olympus BX62) and Neurolucida software. 
 
Alternative protocol: Single section rapid Golgi stain 
 The rapid Golgi method has been cited in the literature as staining in a 
finer more detailed manner than the Golgi-Cox method than the kit is derived 
from (Rosoklija et al., 2003). This protocol is based on the Gabbott and Somogyi 
single section rapid Golgi method (Gabbott and Somogyi, 1984). While this 
method is more labor intensive, one clear advantage of this protocol is that the 
turnaround time is much shorter than the kit method. Complete neuron 
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impregnation from this method is superior is some brain regions, but poor or 
nonexistent in others.   
 
Additional Materials 
 Heparin sodium (Sigma H9399)  
 0.1 M Sodium Phosphate Buffer (pH 7.3) 
 2% (w/v) Paraformaldehyde + 2.5% (v/v) glutaraldehyde (Electron 
Microscopy Sciences 16210) in 0.1 M sodium phosphate buffer (pH 7.3-
7.4) 
o Heat 100 ml of water 55°C. Add 4.0 g paraformaldehyde and stir to 
dissolve. Cool solution to room temperature and pass through a 
whatman filter #1. Add 20 ml 25% glutaraldehyde, 20 ml water and 
50 ml 0.1 M sodium phosphate buffer. Make solution fresh before 
use or store at 4oC overnight following filtration of 4% 
paraformaldehyde. Solutions can be stored for up to one week at 
4oC, but it is best to use the solution as fresh as possible. 
 Whatman filter paper, grade 1  
 Funnel 
 Peristaltic pump  
 Vibratome 
 Feather blades (Ted Pella 121-9) 
 1% (v/v) aqueous osmium tetroxide (Electron Microscopy Sciences 19190)  
 Paint brush 
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 12 well plates (BD Biosciences 351143) 
 3.5% (w/v) Potassium dichromate (Sigma P5271) 
 1% (w/v) Silver nitrate (Sigma S6506) 
 Lab tape 
 0.5% gelatin coated slides 
o Heat 100 mL water to 55oC and add 0.5 g porcine gelatin type A 
and stir until completely dissolved. Dip slides 3 times into gelatin 
and dry in a 95oC oven for at least 15 minutes or until dry. Store 
slides in slide box or slide rack at room temperature indefinitely. 
 
Day 1 
Tissue preparation 
1. After opening the chest cavity for perfusion, inject 300 µl of 5.9% heparin 
sodium in 0.9% saline into the heart of the mouse. 
2. Flush with 0.1 M sodium phosphate buffer. 
3. Perfuse with about 40 ml of 2% (w/v) paraformaldehyde plus 2.5% (v/v) 
glutaraldehyde. 
4. Place the brain into a brain block and use razor blades to block the region of 
interest. 
5. Post-fix the brain at room temperature in the fixative solution for 3 hours. 
6. Cut 150 µm sections on the vibratome using a high amplitude and low 
advance speed to minimize tissue damage. 
7. Collect sections in 0.1 M sodium phosphate buffer. 
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Tissue processing 
8. Make a fresh 1% (v/v) osmium tetroxide solution in double distilled or Mili-Q 
water. Put 1 ml of solution in each well of the 12-well plate. Using a paint 
brush, place 1-2 sections per well and incubate for 20-40 minutes or until 
sections are stiff and dark. 
9. Make fresh 3.5% (w/v) potassium dichromate solution in double distilled or 
Milli-Q water. Put 1 ml of solution in each well of a fresh 12-well plate. 
Transfer sections into potassium dichromate with paintbrush and incubate 
overnight, about 17 hours, in the dark. 
 
Day 2 
Tissue processing continued 
10. Make a fresh solution of 1% (w/v) silver nitrate in double distilled or Milli-Q 
water and filter with Whatman chromatography paper. Fill a glass jar and 
plastic incubation chambers about 1/3 full with filtered silver nitrate. 
11. Use a paintbrush to transfer one section to a microscope slide. Orient the 
microscope slide such that the long edge is vertical and place the section 
near the bottom of the slide also oriented vertically. Ensure that the region of 
interest is directly exposed to the sliver nitrate solution by cutting off excess 
brain tissue that may block impregnation.  
12. Place another microscope slide on top to make a sandwich and tape the top 
of the slides together. Carefully dip the sandwich into the glass jar of silver 
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nitrate and make sure there are no bubbles under the section. Place the 
sandwich in a staining container with silver nitrate in it and store in the dark at 
room temperature. Repeat this with all of the remaining sections. 
Developing the silver stain 
13. Check the neuron impregnation with a light microscope after 2 hours and 
every 30 minutes following. Once the neurons are fully impregnated, 
dendrites and spines fully impregnated, begin disassembling the sandwiches. 
14. Wash each section quickly in double distilled or Milli-Q water 2-3 times and 
mount onto gelatin coated slides. Absorb excess water with a kimwipe and 
begin incubation in ethanol (EtOH) solutions. 
15. Incubate slides in 50%, 70%, 90% x 3, 100% x 3 EtOH and Histoclear x 3 for 
3 minutes each. Place DPX on slide and coverslip as directed above. 
 
Neuron reconstruction 
 
Select neurons for reconstruction. 
It is important to be careful about which neurons are chosen to be traced 
for morphometric measurements. Knowledge of typical neuron morphology in the 
brain region of interest is crucial to making accurate measurements of the correct 
neuronal subtype. Roitman et al. (2002) describes criteria that neurons are 
required to meet in order to be considered for morphometric analysis. Selection 
criteria may include complete filling of the cell body, no beading or breaks in 
staining along the dendritic branches, limited crossing of dendrites from other 
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neurons, a minimum number of dendritic branches originating from the soma, 
and a minimum number of subsequent branch points. 
 
Trace neurons meeting selection criteria 
Full reconstruction of the individual neurons is time consuming, but 
provides the most information about the neurons. Information includes 
parameters such as soma size, total dendritic length, total spine number, total 
dendritic spine density, spine density as a function of distance from the soma, 
and spine density as a function of branch order. If prior knowledge exists about 
damage to specific regions of the neuron in a particular disease state or toxicant 
exposure, then full reconstructions may not be necessary and neuronal tracings 
may be restricted to the affected areas. This should only be done in 
circumstances where there are ample and consistent data available to support 
the use of partial reconstructions. 
 
Statistical Analysis 
Collect data from at least five neurons in a number of sections from at least four 
animals. The ultimate animal and neuron number should be determined by the 
use of power calculations. Perform statistics as in standard experimental 
situations. In the case of two experimental groups, a Student t-test should be 
utilized, and if there are more than two experimental groups, ANOVA should be 
used in combination with appropriate post-hoc tests. See Chapter II for specific 
discussion. 
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Commentary 
 
Golgi background information 
In spite of being developed more than 130 years ago by Camillo Golgi 
(Golgi, 1873), the impregnation method that bears his name continues to be used 
as the standard for visualization of dendrites and dendritic spines. Successful 
impregnation of brain tissue with this method allows qualitative and quantitative 
characterization of neuronal morphology. The method‟s uniqueness lies in the 
fact that only a small fraction (fewer than 5%) of the neuronal elements are 
stained (Spacek, 1989). Groups of nerve cells are stained randomly, and many 
times selected parts appear completely stained while neighboring areas are 
devoid of staining. Absence of background staining allows visualization of 
neuronal structures and makes it possible to follow dendritic trees even in thick 
sections. However, since the cell bodies, as well as the processes, are filled with 
silver precipitate, cytoplasmic details cannot be examined. 
One of the fine structures that were first revealed by the Golgi method, 
and which caught the eye of Santiago Ramón y Cajal, were the dendritic spines. 
They were first described as small thorns that projected from the dendrites of 
cerebellar Purkinje cells (Ramon y Cajal, 1888). Although originally thought to be 
an artifact, dendritic spines are today known to represent centers of information 
processing that are able to control their own protein synthesis and degradation 
(Halpain et al., 2005; Melendez-Ferro et al., 2009). As principal sites of synaptic 
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input, spines play a key role in connectivity throughout the brain. Dendritic spine 
distribution and structure is altered in response to subtle variations in their 
extracellular milieu due to a number of different factors, including synaptic 
activity, drugs, toxic exposure, and disease (Fiala et al., 2002). In addition to 
spine pathology, alterations in the total dendritic length, dendritic branching, and 
soma size have been observed in a number of neurodevelopmental, 
neurodegenerative, and psychiatric disorders, such as Fragile X mental 
retardation, Down‟s syndrome, Alzheimer‟s disease, Parkinson‟s disease, 
Huntington‟s disease, and schizophrenia (Blanpied and Ehlers, 2004; Fiala et al., 
2002; Garey et al., 1998; Glantz and Lewis, 2000; Irwin et al., 2000; Kaufmann 
and Moser, 2000; Knobloch and Mansuy, 2008; Stephens et al., 2005; Zaja-
Milatovic et al., 2005). These structural neuronal changes are usually found to 
correlate with the disease symptoms. Exercise, stress, and hormonal alterations 
have also been shown to cause alterations in neuron morphology (Alfarez et al., 
2009; Chen et al., 2009; Eadie et al., 2005; Fuchs et al., 2006; Leggio et al., 
2005; Shansky et al., 2009; Stranahan et al., 2007). Therefore, the optimal 
visualization of neuronal architecture allowed by the Golgi method is of primary 
importance for studies of altered neuronal activity and associated morphology in 
different models of brain disorders. 
Currently, there are many variations of the original Golgi method 
(Millhouse, 1981); most rely on a two-step procedure to impregnate and label cell 
profiles in the central nervous system (CNS) (Angulo et al., 1994). In the first 
step, tissue specimens are exposed to a chromating solution containing 
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potassium chromate and/or potassium dichromate. In the second step, the tissue 
is exposed to a silver nitrate solution, which results in the formation of silver 
chromate crystals (Gabbott and Somogyi, 1984; Izzo et al., 1987; Jones, 1988; 
Spacek, 1992). Other procedures eliminate the silver nitrate step, and instead 
add mercuric chloride directly to the chromating solution; the tissue is then 
exposed to ammonia to darken the resulting mercury-based precipitate (e.g., 
Golgi-Cox). There are three major variants of the Golgi method, each exhibiting 
its advantages and disadvantages, depending upon the condition of the tissue 
and the particular needs of the study. The Rapid Golgi method utilizes osmium, 
which can increase the number of cells stained, stabilize the membranes of cells 
allowing complete impregnation (Spacek, 1992), and promote the rate of crystal 
formation (Millhouse, 1981). This method works well with fresh tissue (Marin-
Padilla, 1995), or tissue that has been fixed in formalin for a very short period of 
time, from a few hours to a few days. The Golgi-Cox method utilizes a mixture of 
potassium dichromate and mercuric chloride and has been shown to be highly 
successful in rats (Gibb and Kolb, 1998; Glaser and Van der Loos, 1981). The 
Golgi–Cox method has been reported to be the optimal method for ensuring the 
staining of entire dendritic trees of cortical neurons, but not for impregnation of 
dendritic spines  (Buell, 1982; Ramón-Moliner, 1970), or for studying subcortical 
structures (Riley, 1979). It reportedly gives reliable, progressive, controlled 
impregnation of neuronal processes, and stains dendrites very darkly (Buell, 
1982). However, this method produces a much lighter background than the rapid 
Golgi technique and is successful in young brains, as well as heavily myelinated 
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adult brain tissue (Millhouse, 1981). The Golgi–Kopsch method uses 
formaldehyde and glutaraldehyde as replacement for osmium tetroxide 
(Colonnier, 1964; Kopsch, 1896). This method is successfully used in numerous 
studies for tissues that were fixed in formalin for many years (D'Amelio, 1983), as 
well as for tissues from perfused animals, immediately taken after brain perfusion 
and extraction (Angulo et al., 1996; Riley, 1979). 
 
Expected results 
The protocol in this unit describes the utility of the FD Rapid Golgi Stain 
Kit for the study of neuronal morphometry in animal and human brain tissue. Our 
studies show that this impregnation technique is suitable for the analysis of 
parameters of neuronal morphology, such as dendritic length and spine density, 
both in fresh brain and archived brains fixed in formalin up to several years. We 
have used the Neurolucida system with NeuroExplorer quantitative analysis, 
exploring alterations in neuronal morphology in several models of 
neurodegeneration including innate immunity activation (Milatovic et al., 2003; 
Milatovic et al., 2004), excitotoxicity generated by kainic acid (KA) (Zaja-Milatovic 
et al., 2008), and neurotoxicities associated with Mn exposure (Milatovic et al., 
2009) and anticholinesterase agents (Gupta et al., 2007; Milatovic et al., 2009). 
In the mouse model of activated innate immunity, we have evaluated the 
integrity of pyramidal neurons from the CA1 hippocampal area. As detailed in the 
previous section, we have used Golgi-impregnated (FD Rapid Golgi Stain Kit) 50-
μm thick hippocampal sections from paraffin-embedded blocks. For glial innate 
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immune response we have used a single intracerebroventricular (ICV) injection 
of lipopolysaccharide (LPS, 5 μg/5 μl), a major component of Gram-negative 
bacterial cell walls. Data from this study revealed that, coinciding with the peak in 
oxidative damage to cerebral neuronal membranes at 24 hr post LPS injection, a 
significant reduction in the spine density and dendritic length of pyramidal 
neurons occurred in the CA1 sector of hippocampus. Since LPS itself has no 
direct toxic effect on neurons, LPS-activated glial innate immune response leads 
to indirect neuronal oxidative damage and synaptodendritic degeneration 
exclusively through a CD14-dependent mechanism (Milatovic et al., 2004; 
Montine et al., 2002). Representative Golgi-impregnated Neurolucida-traced 
pyramidal neurons from theCA1 hippocampal area of control animals and LPS-
treated animals are presented in Figure 2. Interestingly, both the dendritic-spine 
density and dendritic length returned to near basal levels by 72 hr post ICV LPS 
injection, again coinciding with resolution of oxidative damage in neurons 
(Milatovic et al., 2004; Montine et al., 2002). 
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Figure 2. Neurolucida tracings of representative Golgi-impregnated 
dorsal hippocampal CA1 neurons.  
 A. Dorsal hippocampal CA1 neuron from control mice. B. Mice 
subjected to intracerebroventricular injection of LPS induced 
degeneration of the hippocampal dendritic system and decrease in 
total length of dendrite and spine density of hippocampal 
pyramidal neurons. Colors indicate the degree of dendritic 
branching (blue = 1◦; red = 2◦; green = 3◦; yellow = 4◦; brown = 5◦).  
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Dendrites have also been quantified according to the centrifugal method of 
Sholl (Sholl, 1953), where spine density and length of dendrites arising from the 
soma are determined in the first- (50 μm), second- (50 to 100 μm), and third-
order segments (100 μm to 150 μm) from the center of the soma. Results of this 
study demonstrated that LPS exposure caused a significant decrease in total 
dendrite length in the proximal (0 to 50 μm) and intermediate (51 to 100 μm) 
Sholl compartments of CA1 pyramidal neurons (Figure 3A). Results also 
revealed that LPS exposure induced a significant decrease in spine density 
(number of spines per 100 μm dendrites) in all three (proximal, intermediate, and 
distal) Sholl compartments of CA1 pyramidal neurons (Figure 3B). 
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Figure 3. Dendritic length and spine density in each Sholl compartment of 
pyramidal neurons from CA1 hippocampal area of mice following ICV injections 
of LPS. 
Brains from rats exposed to LPS were collected 24 hr post injection (n ≥ 4). A) 
Dendritic length in 50 and 100 micron compartments was significantly reduced 
upon exposure to LPS. B) Spine density was reduced in all compartments 
following exposure to LPS. Asterisk (*) indicates that one-way ANOVA had p 
<0.001 with Bonferroni‟s multiple comparison tests showing significant 
difference for Sholl compartment (p <0.05) from control (SAL) versus LPS 
treatment. 
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The integrity of hippocampal dendritic system was also evaluated in the 
model of anticholinesterase neurotoxicity. We have used 
diisopropylphosphorofluoridate (DFP) as a model compound for 
organophosphorus (OP) insecticides or nerve agents, and investigated if 
oxidative/nitrosative damage induced by anticholinesterase exposure is 
accompanied by dendritic damage in the CA1 sector of hippocampal neurons. 
Rats treated acutely with DFP (1.25 mg/kg, s.c.) developed onset of toxicity, 
including seizures and fasciculations, within 60 min. At this time point, DFP 
caused significant increases in biomarkers of cerebral oxidative damage. 
Furthermore, quantitative neuronal analysis of pyramidal neurons with no breaks 
in staining along the dendrites from the CA1 area revealed significant reductions 
in dendritic lengths and spine density (Zaja-Milatovic et al., 2009). 
Representative images of Golgi-impregnated hippocampal sections with their 
traced pyramidal neurons from control and DFP-exposed animal are presented in 
Figure 4. Additional morphometric analysis with the Sholl method of concentric 
circles confirmed early neuronal damage and showed that anticholinesterase 
induced brain hyperactivity targeted the dendritic system with profound dendrite 
regression of hippocampal neurons (Zaja-Milatovic et al., 2009). 
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Figure 4. Photomicrographs of rat hippocampi (2.5×) with pyramidal neurons 
(10×) from CA1 hippocampal area of rat brains. 
 
 
 
 
 
 
 
 
 
 
  
Hippocampal pyramidal neurons were examined 1 hr after saline (control) and 
diisopropylphosphorofluoridate (DFP; 1.25 mg/kg, s.c) injections. Treatment with 
DFP induced degeneration of the hippocampal dendritic system and decrease in 
total length of dendrite and spine density of hippocampal pyramidal neurons. 
Tracing and counting were done using a Neurolucida system at 100× under oil 
immersion. Colors indicate the degree of dendritic branching (yellow = 1◦; red = 
2◦; purple = 3◦; green = 4◦; turquoise = 5◦; gray = 6◦). 
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Manganism (Mn poisoning) is associated with alterations in integrity of the 
dopaminergic innervation of striatal neurons. The MSNs are the target of the 
dopaminergic innervation of the striatum, comprising more than 90% of striatal 
neurons (Deutch et al., 2007). MSNs have radially projecting dendrites that are 
densely studded with spines, synapsing with dopamine and glutamate axons and 
providing the site of integration of several key inputs and outputs of the striatum 
(Day et al., 2006). Consequently, alterations in dendritic length and dendritic 
spine number may destabilize the structural basis of synaptic communication, 
and thus compromise MSN function. Therefore, we investigated if dendritic 
degeneration of MSNs was present in the striatum of mice exposed to a single 
injection or multiple injections of MnCl2. Representative images of Golgi-
impregnated (FDRapid GolgiStain Kit) striatal section with the traced MSN from 
control animal are presented in Figure 5. NeuroExplorer-assisted neuronal 
morphometry revealed progressive spine degeneration (total number of spines 
per neuron) of MSNs in mice with increase in time and dose of MnCl2 exposure. 
Consistent with these effects, Mn also induced dose- and time-dependent 
progressive dendritic damage (total dendritic length per neuron) of MSNs 
(Milatovic et al., 2009). 
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Figure 5. Photomicrographs of mouse striatal sections with representative 
tracings of medium spiny neurons (MSN) from mice treated with saline. 
 
 
 
 
 
 
 
 
 
 
  
Tracing and counting were done using a Neurolucida system at 60× or 100× 
under oil immersion. Colors indicate the degree of dendritic branching (yellow = 
1◦; red = 2◦; purple = 3◦; green = 4◦; turquoise = 5◦). 
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In these animal models of neuroinflammation, seizures, and metal 
neurotoxicity, we have performed Golgi impregnation (FD Rapid Golgi Stain Kit) 
of fresh brain tissue (immediately after the extraction). However, we have used 
the same impregnation procedure for human brain that has been fixed in formalin 
for several years, and investigated if dendritic degeneration in neostriatal MSN is 
associated with Parkinson‟s disease (PD). We have used brains from patients 
diagnosed with PD and controls matched for age and for time in formalin, 
obtained via autopsies at the University of Washington performed between 1987 
and 2003. The time in fixative for PD cases averaged 9.7 years (median, 12.5 
years) and for controls averaged 9.6 years (median, 12.0 years). Portions of fixed 
putamen (∼0.3 cm3) were taken from three consecutive tissue slabs: 
immediately caudal to the anterior commissure (precommissural), at the anterior 
commissure, and immediately rostral to the anterior commissure 
(postcommissure). Tissue was sectioned by Vibratome in the coronal plane at 80 
μm and Golgi impregnation and morphometric analysis performed by an observer 
blinded to diagnosis. Results from that study showed that spine density in all 
three regions in controls remained essentially constant across regions of 
putamen, but progressively decreased across precommissural to 
postcommissural regions in patients with PD. Morphometric values from three 
different regions of putamen from patients with PD or controls are presented in 
Figure 6. Importantly, morphometric analysis of MSNs from these Golgi 
impregnated formalin-fixed brains showed no correlation of time in fixative with 
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dendritic length or spine density in all three regions in control or patients with PD 
(Zaja-Milatovic et al., 2005). 
The Neurolucida system and morphometric analysis has also been used 
in our in vitro experimental models. Confocal immunofluorescent images of 
neurons previously probed with neuronal markers (MAP2, drebrin, or spinophilin) 
were traced with the Neurolucida system, and dendritic length or spine density 
per neuron or the segment evaluated by NeuroExplorer in control and amyloid 
beta (Aβ)–exposed primary neuronal cultures. Representative confocal images, 
neuronal tracings, and morphometric evaluation (dendritic length) of the neurons 
are presented in Figure 7. 
Additionally, we have employed the Rapid Golgi method and evaluated 
impregnation and visualization of dendrites and dendritic spines from fresh 
mouse brain tissue. Our preliminary results showed successful impregnation of 
brain tissue with this method, allowing quantitative characterization of neuronal 
morphology. A Rapid Golgi–impregnated dendritic segment from a mouse MSN 
is presented in Figure 8. 
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Figure 6. Morphometric values (spine density) from three different regions of 
putamen from patients with PD or controls. 
 
 
 
 
 
 
 
 
  
6 to 8 neurons were evaluated in each section and the average value obtained 
for each region in each individual. These individual averages were then 
combined to yield a grand average (± SEM) for each region in PD patients 
(black) and controls (gray). Two-way ANOVA for spine density (F42, 2, 1) had p 
< 0.001 for control versus PD, p < 0.01 for region, and p < 0.05 for interaction 
between these two terms. Bonferroni-corrected post-tests showed that spine 
density was significantly less in PD patients than controls for commissural and 
post-commissural regions (p < 0.001) but not pre-commissural region (p > 
0.05). Adapted from Zaja-Milatovic et al. (2005) with kind permission from 
Walter Kluwer Health. 
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Figure 7. Representative confocal immunofluorescent images, Neurolucida 
tracings, and NeuroExplorer-assisted morphometric evaluation of neurons from 
control and Aβ-exposed mixed cerebral and hippocampal neuronal culture. 
 
 
 
 
 
 
 
 
 
 
  
A) The neurons were probed for MAP2 with mouse anti MAP-2 monoclonal 
antibody (5 μg/ml). MAP2 was visualized withCy3-donkey anti-mouse 
secondary antibody (1:100). B) Control and Aβ-exposed neurons were traced 
out in the Neurolucida program followed by quantitation of the dendritic length 
in NeuroExplorer. Aβ-treated values were significantly different from control (p 
<0.01). 
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Figure 8. Mouse MSN dendritic segment impregnated by the rapid 
Golgi method. 
This image shows a striatal MSN impregnated by the rapid single-
section Golgi method. Dendritic branching is clearly visualized as 
well as dendritic spines. 
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Altogether, we have showed the validity of the use of Golgi impregnation 
technique (FD Rapid Golgi Stain Kit) for the study of human and animal brain 
tissue, as well as for studies on neuronal cultures in vitro. In addition to minimal 
background precipitation, this technique produced good clarity of dendrites and 
dendritic spines in different brain areas. Our preliminary findings with the Rapid 
Golgi technique also showed good neuronal impregnation and sharpness of 
dendritic spines. Moreover, we have shown that the Neurolucida system is 
effective in evaluating neuronal morphometry both in vivo and in vitro. 
 
Critical parameters and troubleshooting 
Tissue sectioning on the cryostat and vibratome are critical parameters in 
the success of either protocol. Trials should be conducted in order to determine 
the optimal temperature for sectioning on the cryostat and optimal blade advance 
and amplitude speeds are critical for sectioning tissue on the vibratome. Optimal 
section thickness should also be determined in a trial experiment to make sure 
that there are routinely enough neurons with complete dendritic arbors visible. 
The developing stage in the FD Neurotechnologies kit is another critical step, if 
the sections are left in the developing solution (Solutions D and E) for too long, 
the tissue will be over stained. This also holds true for the silver nitrate incubation 
in the rapid Golgi protocol, which is why it is important to check the sections 
periodically to ensure they are not being over stained. 
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Time considerations 
Using the FD kit, it takes about 3 weeks to complete processing of the 
tissue. The process of sectioning and staining is less time consuming, and it 
takes 1 to 2 days to section, dry, and stain already processed sections. 
Alternatively, the single section rapid Golgi method only takes 2 days to 
completely process the tissue. It is easier to do a larger number of animals at one 
time using the FD kit because the rate limiting step is sectioning tissue on the 
cryostat. In contrast, the limit for the single section rapid Golgi method is 6-8 
animals per day. The rate limiting factor for this method is how quickly the 
sandwiches can be made, taken apart and slides coverslipped without the 
sections being over stained or dried out. Trials should be performed for each 
protocol prior to conducting a full experiment to reduce unnecessary animal 
usage and to optimize staining for the brain region of interest. The time 
investment required to reconstruct the Golgi stained neurons should also be 
considered because it is a laborious and time intensive commitment to trace the 
Golgi stained neurons. It takes ~2 hr to reconstruct a well preserved pyramidal 
neuron. It can take even longer to reconstruct a well preserved Purkinje cell. 
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CHAPTER IV 
 
CONFOUNDING FACTORS IN MORPHOMETRY 
 
Introduction 
 Neuron morphometry gives keen insight into the health and function of the 
neuron being studied. Dendritic spines are rapidly changing key players in 
neuron function since they are the primary structure receiving excitatory inputs 
from other neurons. Examination of neuron morphology can reveal whether a 
neuron is healthy or if it is degenerating in a disease state. Although neuron 
morphometry can give insight into health of the neuron, there are caveats that 
one must be aware of prior to initiation of these studies. Like many experiments, 
Golgi impregnation and study of neuron morphology requires controls and proper 
experiment design in order to obtain useful information. This chapter will discuss 
confounding factors that need to be taken into consideration when designing 
neuron morphology experiments.  
 
Results 
 
Method of Golgi impregnation 
 There are many methods of Golgi impregnation that have been developed 
since Camillo Golgi first described silver impregnation of neurons in 1807 (Golgi, 
1873). The two methods of silver impregnation that were described in Chapter III 
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were compared prior to initiation of experiments described in Chaper V and 
Chapter VI to determine which method yielded optimal impregnation for analysis.  
FD Neurotechnologies Rapid GolgiStain Kit 
While the single-section rapid Golgi method was being optimized, a small 
group of animals was used to test the FD NeuroTechnologies Rapid GolgiStain™ 
kit (henceforth referred to as the FD kit method). Wild-type vehicle (WT-Veh) (n = 
2) and Mn exposed (WT-Mn) (n = 3) mice were used in this trial. There was no 
difference in soma size or total spine number (Figure 9A and Figure 9B). Total 
spine density (Figure 9C) on MSNs was significantly decreased in WT-Mn mice 
(p < 0.05). There was only a trend towards an increase in total dendritic length 
(Figure 9D) of WT-Mn MSNs (p = 0.08), which was driving the difference in total 
spine density. Examination of neuron morphology as a function of distance from 
the soma failed to find a significant difference in dendritic branching (Figure 10A) 
or dendrite length (Figure 10B) as a function of distance from the soma between 
Veh and Mn exposed mice. Spine number (Figure 10C) and spine density 
(Figure 10D) as a function of distance from the soma were significantly reduced 
in Mn exposed mice (p < 0.05). Spine density as a function of branch order 
(Figure 11) was reduced in Mn exposed mice across all branches. Spine density 
was only significantly reduced along the 3rd branch order (p< 0.05), however 
there was a strong trend towards a significant reduction along the 2nd branch 
order (p = 0.051). Overall, the FD kit method of Golgi staining found a significant 
difference in neuron morphology between WT-Veh and WT-Mn exposed mice. 
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Figure 9. FD Kit Golgi neuron morphology in WT mice. 
 
 
 
  
A) Soma size is unchanged following Mn exposure in WT mice. B) 
Mn exposure does not significantly affect total spine number. C) 
Mn exposure significantly decreases total spine density (p < 0.05). 
D) There is a trend toward an increase in total dendritic length in 
Mn exposed WT mice (p = 0.08). 
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Figure 10. FD Kit Golgi morphometric measures as a function of distance from 
the soma. 
 
 
 
 
 
 
 
  
A) Dendritic branching as a function of distance from the soma is 
unchanged following Mn exposure in WT mice. B) Mn exposure 
does not significantly affect dendrite length as a function of 
distance from the soma. C) Mn exposure significantly decreases 
spine number as a function of distance from the soma (p < 0.05). 
D) Mn exposure significantly decreases spine density as a 
function of distance from the soma (p < 0.001). 
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Figure 11. Spine density as a function of branch order is reduced in WT-Mn 
MSN. 
 
 
 
 
 
 
 
 
  
Spine density as a function of distance from the soma is 
decreased on branch order 3 (p < 0.05), however there is a strong 
trend toward a significant decrease in spine density on branch 
order 2 (p = 0.051). 
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Comparison of Golgi methods 
 We compared the results of the FD kit method to the single-section rapid 
Golgi method. The first thing that was noticed was the difference in staining 
pattern and quality between the methods (Figure 12). The impregnation of MSNs 
with the FD kit method was inconsistent and not of high quality. There were 
frequent breaks in staining along the dendrite, which renders that neuron 
unusable for inclusion in the experiment. Also common were blebs, or large 
blobs, of precipitate along the dendrite. These neurons are also unable to be 
included in the experiment. The single-section rapid Golgi method produced clear 
staining of neurons without breaks or extraneous staining of the neurons.  
We compared total spine density of WT-Veh animals from each staining 
method with values reported in the literature to ensure that our staining was 
comparable to published data (Figure 13). A literature search of Golgi staining in 
the striatum was conducted and the average total spine density from fully 
reconstructed neurons was determined (Day et al., 2006; Klapstein et al., 2001; 
Lee et al., 2006; Spires et al., 2004). We found that the average total spine 
density of MSNs in the literature was between 6-9 spines/10 m. The average 
total spine density of WT-Veh MSNs from the FD kit method was 4.1 spines/10 
m. MSNs from WT-Veh mice using the single-section rapid Golgi method had 
an average total spine density of 5.8 spines/10 m, which was only slightly below 
the average published density. Based on the fact that the silver impregnation was 
more consistent and total spine density was closer to the average in the 
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literature, we chose to complete our investigation with the single-section Golgi 
method. 
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Figure 12. Comparison of Golgi staining efficacy between FD kit and single-
section Rapid Golgi. 
 
 
 
 
 
 
 
 
 
 
 
 
  
A) Example of a striatal MSN stained using the FD Neurotechnologies Kit. The 
white arrow indicates breaks in dendrite filling which renders that neuron 
unusable for tracing studies. The black arrow indicates nonspecific filling or 
blebbing along the dendrite. B) Typical striatal MSN staining using the Rapid 
Golgi method. No breaks in dendrite filling or blebs along the dendrite were 
found in any neurons with the Rapid Golgi method. 
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Figure 13. Comparison of Total Spine Density from FD Kit and single-section 
Rapid Golgi. 
 
 
 
 
 
 
 
 
 
  
WT-Veh exposed mice were used to compare Golgi impregnation methods. 
Total spine density was assessed from FD Kit and single-section rapid Golgi 
impregnated neurons. The gray lines represent the range of total spine density 
reported in the literature for MSNs. Total spine density in MSNs impregnated 
using the FD Kit method fell below the total spine density reported in the 
literature. The mean total spine density in single section rapid Golgi 
impregnated MSNs was much closer to the range reported in the literature. 
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Golgi processing strategy 
 The time it takes to complete Golgi staining varies greatly between Golgi 
impregnation methods. The kit method takes weeks to complete the staining 
process, while the single-section Golgi method takes only two days. However, 
many more animal tissues can be processed at one time using the kit method. 
The single-section Golgi staining procedure has time critical steps that are the 
rate limiting factor in how many animals can be processed at one time. The limit 
on the number of animals that can be processed at once requires an experiment 
with a large number of subjects to be conducted over a prolonged period of time. 
This in and of itself can result in problems with staining because of the capricious 
nature of Golgi staining.  
 Our experiment was conducted using the single-section Golgi method 
over a period of 8 weeks. Animals from all treatment groups were processed 
during each Golgi experiment to minimize staining bias during each processing 
event (Figure 14). In order to ensure that a systematic error in processing did not 
occur, we analyzed total dendritic length across processing events (Figure 15). 
There was no increase or decrease in dendritic length across processing events 
for all exposure groups. However there was an increase in total dendritic length 
for WT-Veh and WT-Mn groups, but no change in total dendritic length across 
processing events for YAC128-Veh or YAC128-Mn exposure groups. This 
indicates that the changes in dendritic length were due to alterations in neuron 
morphology, not due to a Golgi staining error. 
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Figure 14. Distribution of animals in each exposure group across Golgi 
processing sessions. 
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Figure 15. Total dendritic length across Golgi processing group. 
 
 
 
 
 
 
 
 
 
 
 
  
Golgi processing date did not have an effect on total dendritic length. Animals 
from each exposure group were processed across multiple days and total 
dendritic length did not change due to a systematic error caused by processing 
tissue across multiple sessions. 
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Litter 
 Litter is an important factor to consider when distributing animals across 
exposure groups. The litter-of-origin had a significant effect on rotarod 
performance for the R6/2 HD mouse model, but not on WT littermates (Hockly et 
al., 2003). In this case the R6/2 mice performed more similar to their littermates 
than to other R6/2 mice of the same generation. The ideal distribution of animals 
among exposure groups is to use only one animal per litter. However, this is 
usually not feasible with in-house breeding because of the large number of litters 
that would be required to produce the number of animals needed at the same 
time. For our experiments, we distributed WT and YAC128 mice from each litter 
across exposure groups as evenly as possible (Figure 16). All exposure groups 
contained animals from at least two litters and most litters had animals in more 
than one exposure group. Examining dendrite length across litters (Figure 17), 
there is no significant effect of litter at the early (F(4,89)=1.592, p = 0.138) or late 
(F(4,105)=0.962, p = 0.432) time point. In this case, litter is not a significant factor in 
neuron morphology. 
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Figure 16. Distribution of litters across expsoure groups. 
 
 
 
 
 
 
 
 
  
Mice from each litter were distributed across multiple exposure groups. Each 
exposure group, in turn, was composed on animals from at least two litters. 
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Figure 17. Total dendritic length is not affected by litter. 
 
 
 
 
 
 
 
 
 
 
  
Total dendritic length was compared across litter. Litter was not shown to have 
an effect on total dendritic length. 
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Gender 
 Another important factor in experimental design is gender (Figure 19). 
This factor is often overlooked in multiple ways. First, the vast majority (40-60%) 
of in vivo neuroscience or pharmacology experiments uses only male animals 
(Wald, 2010). Only 10-20% of neuroscience or pharmacology experiments use 
both genders. Approximately 5-20% use animals of unspecified gender and a 
very small percentage, less than 20%, use female animals only (Figure 20). 
Secondly, even when both genders are included in experiments, only two-thirds 
of those manuscripts included gender as a factor in data analysis (Wald and Wu, 
2010). An argument for including both genders in early in vivo experiments is to 
determine if a gender difference is present at early stages of research before 
such it is translated into human treatment. This may improve medical treatments 
for women, who do not necessarily respond to drugs in the same manner as 
men.  Analysis of our neuron morphology data showed a strong influence of 
gender. These data will be discussed further in Chapter VI. 
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Figure 18. Distribution of mice of each gender across exposure groups. 
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Figure 19. Surveying sex bias. 
 
 
 
 
 
 
  
A survey of journal article from 2009 found the strongest bias toward male 
animals in fields most likely to translate to humans. 
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Discussion 
 This chapter focused on factors that are important to take into 
consideration prior to initiating experiments designed for analysis of neuron 
morphology, but the general ideas are applicable to other in vivo 
experimentation. As discussed in here and Chapter III, the method of Golgi 
impregnation is crucial to obtaining optimal neuron staining. One needs to first 
consider which method produces better impregnation of the brain region of 
interest. The second consideration is the number of animals required to complete 
the study and in what timeframe Golgi impregnation experiments will take place. 
The kit method can easily accommodate a large number of animals to be stained 
simultaneously, but the single-section Golgi method can only accommodate a 
limited number of animals per day. If the latter method is chosen, safe guards 
must be put in place to ensure that animals from each experimental group are 
evenly distributed across Golgi impregnation events. One should also consider 
performing analysis of the neuron morphology data to confirm that processing the 
tissue over multiple independent events did not cause a change in impregnation. 
 Distribution of animals into experimental groups is a key factor. Animals 
from multiple litters should be used in each experimental group. Similarly, 
animals from a single litter should be distributed across experimental groups to 
ensure that a single litter does not solely affect one experimental group. The 
contribution of litter to differences in neuron morphology should be statistically 
analyzed to rule out a litter effect. In the same way, male and female animals 
should be equally represented in each experimental group. This ensures that if a 
96 
 
gender effect is present, it is detectible. Inclusion of both genders in disease-
toxicant experiments such as ours, increase knowledge about this specific 
interaction, it allows us to tease out potential disease interventions that may be 
more beneficial to one gender over another.  
 In summary, important factors such as how many independent 
experimental sessions will be required to complete the study, litter and gender 
should be well thought out and planned prior to embarking on an experimental 
plan. Each of these factors introduces a bias into interpreting the experimental 
results. However, with careful planning and post-experimental statistical analysis 
these factors can be eliminated as potential confounding factors in data analysis. 
In fact, including animals from both genders can result in novel and interesting 
results if it does influence the experimental results.     
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CHAPTER V 
 
EARLY CHANGES IN STRIATAL NEUROCHEMISTRY AND MEDIUM SPINY 
NEURON MORPHOLOGY IN HUNTINGTON‟S DISEASE MOUSE MODEL ARE 
MODIFIED BY MANGANESE EXPOSURE 
 
Abstract 
YAC128 Huntington‟s disease (HD) transgenic mice accumulate less manganese 
(Mn) in the striatum relative to wild-type (WT) littermates. We hypothesized that 
Mn and mutant Huntingtin (HTT) would exhibit gene-environment interactions at 
the level of neurochemistry and neuronal morphology. Twelve-week-old WT and 
YAC128 mice were exposed to MnCl2-4H2O (50 mg/kg) on days 0, 3 and 6. 
Striatal medium spiny neuron (MSN) morphology as well as neurotransmitter and 
amino acid content were analyzed at 13 weeks (7 days from initial exposure) and 
16 weeks (28 days from initial exposure). No genotype-dependent differences in 
MSN morphology were apparent at 13 weeks, but an age-dependent genotype-
specific increase in dendrite length and branching complexity in WT mice that 
was absent in YAC128 mice was identified. Mn exposure and genotype exhibited 
both positive and negative interactions and single-factor effects on a subset of 
striatal amino acids. Striatal monoamine levels were unaltered at 13 weeks; 
however at 16 weeks, (a) Mn exposure reduced dopamine (DA) and metabolites 
in WT mice, (b) YAC128 mice had reduced DA and metabolites similar to Mn 
exposed WT mice, and (c) YAC128 mice were protected from further decreases 
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in DA following Mn exposure. YAC128 mice exhibited elevated amino acids at 16 
weeks, and this difference versus WT was fully reversed by exposure to Mn. 
Taken together, these results demonstrate Mn-HD disease-toxicant interactions 
at the onset of striatal dendritic neuropathology in YAC128 mice. Furthermore, 
Mn-exposure of the HD mice ameliorates some mutant HTT-dependent changes 
in striatal neurochemistry while exacerbating phenotypes, including dendritic 
pathology. 
 
Introduction 
Huntington‟s disease (HD) is an autosomal dominant inherited disease 
caused by expansion of a CAG triplet-repeat within the first exon of the 
Huntingtin (HTT) gene (Huntington's Disease Collaborative Research, 1993). The 
primary neuropathology in HD is loss of striatal, followed by cortical neurons (de 
la Monte et al., 1988). HD causes proliferative and/or degenerative changes in 
striatal MSNs (MSNs) as evidenced by post-mortem studies (Ferrante et al., 
1991; Graveland et al., 1985a; Vonsattel et al., 1985). Changes in MSN 
morphology precede gross striatal neuron loss (Ferrante et al. 1991). Analysis of 
MSN morphology can identify early neuropathology prior to death of MSNs and 
further loss of striatal neurons. 
Mn is an essential trace metal that is critical for many physiological 
processes including reproduction, formation of connective tissue and bone and 
normal brain function including neurotransmitter synthesis and metabolism 
(Aschner et al., 2005; Erikson et al., 2005; Golub et al., 2005; Roth and Garrick, 
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2003). Exposure to high Mn levels causes neurotoxicity, especially in brain 
regions where Mn preferentially accumulates including the globus pallidus, 
striatum, substantia nigra and the subthalamic nucleus (Olanow, 2004; Pal et al., 
1999). Rodent studies examining MSN morphology following Mn exposure found 
a decrease in total dendritic length and spine number (Milatovic et al., 2009). 
Various striatal amino acid and monoamine neurotransmitter levels are also 
affected by Mn overexposure, however these studies have predominantly 
focused on just a single amino acid, broad-based assessment of multiple amino 
acids in the same samples have not been reported (Autissier et al., 1982; Burton 
et al., 2009; Gianutsos and Murray, 1982; Gwiazda et al., 2002; Kontur and 
Fechter, 1988; Lipe et al., 1999; Olanow et al., 1996; Reaney et al., 2006; Struve 
et al., 2007; Takeda et al., 2002; Takeda et al., 2003; Vidal et al., 2005).  An 
increase in brain Mn levels is also known to cause motor dysfunction in humans 
(Aschner, 2000; Calne et al., 1994; Olanow, 2004; Pal et al., 1999) and mice 
(Guilarte et al., 2006; Vezer et al., 2005). Since the striatum is a common target 
for both HD and Mn accumulation, this provides the opportunity to observe a 
disease-toxicant interaction. 
Data previously published by our group shows that following Mn exposure 
YAC128 mice exhibit decreased striatal accumulation of Mn relative to wild-type 
(WT) mice (Williams et al., 2010a; Williams et al., 2010b). This phenomenon was 
restricted to the striatum as no significant differences in Mn levels between 
genotypes were observed in other brain regions. In vitro work by Williams et al. 
(2010b) and Kwakye et al. (2011), showed that a striatal cell line expressing 
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mutant HTT (STHdhQ111/Q111) accumulated less Mn upon exposure, exhibit a 
basal Mn deficiency under normal culture conditions and were resistant to Mn 
cytotoxicity relative to wild-type striatal cells (STHdhQ7/Q7). Based on these 
studies, we hypothesized that YAC128 mice would exhibit altered responses to 
Mn exposure in vivo at the level of striatal MSN morphology and striatal 
neurochemistry. We reasoned that a variety of gene-environment interactions 
could be observed given the impaired striatal Mn accumulation we have 
previously reported (Williams et al., 2010a; Williams et al., 2010b). First, 
decreased Mn accumulation in mutant animals could diminish Mn-dependent 
toxic effects.  Second, Mn exposure could suppress striatal phenotypes in the 
YAC128 mice that are caused by a Mn handling deficit in these animals.  Lastly, 
expression of the toxic mutant HTT protein in YAC128 animals could interact with 
striatal Mn neurotoxicity to elicit or enhance changes in dendritic morphology or 
neurochemistry.  Thus, a series of studies were carried out to investigate these 
possibilities by examining MSN architecture and striatal neurotransmitter and 
amino acid content following Mn exposure in WT and YAC128 mice.  
Although CAG repeat length is inversely related to the age of disease 
onset in humans, it only accounts for 60% of the variability in disease onset 
(Andrew et al., 1993; Brinkman et al., 1997; Duyao et al., 1995; Stine et al., 1993; 
Wexler et al., 2004a). Environmental and/or other genetic factors account for the 
remaining variability in disease onset and therefore may accelerate or slow the 
age of disease onset and progression (Anca et al., 2004; Georgiou et al., 1999; 
Hannan, 2004; van Dellen and Hannan, 2004). Disruption in metal homeostasis 
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has been associated with many neurodegenerative diseases including 
Parkinson‟s disease, Huntington‟s disease and Alzheimer‟s disease (Yokel, 
2006). Here we explore the possibility that exposure to manganese (Mn) may 
modulate HD pathophysiology.  
There are many mouse models of HD that express either fragments or the 
full-length mutant HTT gene. We use the full-length YAC128 model because the 
onset of motor symptoms and neuropathology recapitulate many aspects of the 
human disease (Carroll et al., 2011; Slow et al., 2003). Changes in YAC128 
striatal volume are not observed until 9 months of age despite a procedural 
learning deficit at 2 months and motor phenotype onset at 3 months (Menalled et 
al., 2009; Slow et al., 2003; Van Raamsdonk et al., 2005b). At 12 months, 
cortical volume, neuron area and striatal neuron numbers are reduced in 
YAC128 mice (Slow et al., 2003). Degenerative changes in MSN morphology 
have been found in multiple HD models (Guidetti et al., 2001; Klapstein et al., 
2001; Nithianantharajah et al., 2009; Spires et al., 2004), however, striatal MSN 
morphology has been examined in YAC128 mice only at one month of age with 
no alterations identified (Milnerwood et al., 2010; Slow et al., 2003). Therefore, 
we focused our studies on mice at the age of motor dysfunction onset in an 
attempt to characterize the earliest changes in MSN morphology and also to 
match the age at which we found a defect in striatal Mn accumulation in our 
previous study (Williams et al., 2010a; Williams et al., 2010b).  
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Results 
 
YAC128 mice accumulate less Mn in the striatum immediately following exposure 
 The striatum represents a target region for Mn neurotoxicity and also 
degeneration in HD (de la Monte et al., 1988; Ferrante et al., 1991; Graveland et 
al., 1985a; Olanow, 2004; Pal et al., 1999). Accordingly, studies were carried out 
to address the effect of mutant HTT and Mn toxicity on striatal MSN morphology 
and striatal neurotransmitter content in 13 and 16 week old YAC128 and WT 
mice. Twelve-week old mice were exposed to vehicle (Veh, s.c.) or Mn (50 mg/kg 
MnCl2-4H2O, s.c.) on experimental day 0, 3 and 6. Mice were sacrificed on 
experimental day 7 (13 weeks postnatal) or day 28 (16 weeks postnatal) (Figure 
20A). Mice were subsequently used for either measurement of striatal metals by 
ICP-MS, Golgi impregnation for analysis of striatal MSN morphometry or striatal 
neurochemistry analysis. 
Our first objective was to measure striatal Mn concentrations by ICP-MS 
24 hours (experimental day 7, 13 weeks old) and 3 weeks (experimental day 28, 
16 weeks old) following the last Mn injection. At 13 weeks, levels of striatal Mn 
(Figure 20B) were significantly increased in both Mn exposed WT and YAC128 
mice (F(1,23)=783.43, p < 0.0001). There was a significant genotype x exposure 
interaction with YAC128 mice accumulating significantly lower levels of striatal 
Mn compared to WT (F(1,23)=5.33, p < 0.05), corroborating graphite furnace 
atomic absorbance spectroscopy (GFAAS) results in an independent study 
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(Williams et al., 2010b). At 16 weeks, (Figure 20C) this exposure effect persisted 
(F(1,16)=9.19, p < 0.01) and Mn levels in the striatum of WT mice were 
dramatically reduced, but remained significantly elevated compared to vehicle 
injected mice (p < 0.01), but there was no difference in striatal Mn levels between 
WT-Vehicle (WT-Veh), YAC128-Veh and YAC128-Mn groups at 16 weeks.  In 
addition to Mn, other metals were simultaneously analyzed by ICP-MS in the 
striatum of these mice. Striatal levels of copper (Cu) and zinc (Zn) and other 
metals showed no significant differences across the exposure groups at either 
time point (data not shown). These results demonstrate that the sub-acute Mn 
exposure paradigm can significantly and specifically elevate striatal Mn levels 
immediately following exposure. Excess Mn was completely eliminated from 
YAC128 striatum by 3 weeks post exposure, however WT mice still had slightly 
elevated levels of striatal Mn. 
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Figure 20. Striatal Mn levels are significantly elevated in WT-Mn over YAC128-
Mn mice at week 13 but are elevated only above vehicle exposed mice at week 
16. 
 
 
 
 
 
 
 
  
A) Mn exposure paradigm. 12 week-old WT and YAC128 mice were exposed 
to MnCl2-4H2O (50 mg/kg s.c.) or vehicle (filled arrow) on days 0, 3, 6, and 
were sacrificed (open arrow) on experimental day 7 (13 weeks) or day 28 (16 
weeks) for striatal Golgi impregnation or neurochemistry analysis. B) Striatal 
Mn levels, measured by ICP-MS, at week 13 (n = 7) are significantly higher in 
Mn exposed mice compared to their vehicle controls at week 13 
(F(1,23)=783.43, p < 0.0001). There is a genotype x exposure interaction 
whereby significantly less Mn accumulated in the YAC128-Mn exposed group 
compared to WT-Mn exposed mice (F(1,23)=5.33, p < 0.05). C) At week 16 (n = 
5), Mn levels dropped, but a exposure effect still remains (F(1,16)=9.19, p < 
0.001) with Mn levels significantly higher in WT mice. Average striatal Mn 
concentrations +/- SEM. Significant results of post-hoc t-tests: **p < 0.01, ##p < 
0.005 and ***p < 0.001. 
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Figure 21. Representative reconstructions of striatal MSN in week 13 and 16 
mice. 
 
 
 
 
 
 
 
 
 
  
Mice were exposed on day 0, 3, 6 with vehicle or MnCl2-4H2O (50 mg/kg 
s.c.), sacrificed on experimental day 7 (week 13, n = 4-5) or 28 (week 16, n = 
5) and the striatum was processed for Golgi impregnation. Neurons were 
traced and analyzed using Neurolucida and Neuroexplorer, respectively 
(NeuroBrightField, Inc). Representative neurons were within 5% of the mean 
total dendritic length for each exposure group 
106 
 
Genotype influences neuron morphology at 16 weeks 
 Figure 21 depicts representative reconstructions of neurons in each 
exposure group at 13 weeks (experimental day 7) and 16 weeks (experimental 
day 28). We failed to observe any overt differences in neuron morphology based 
on visual inspection of neuronal traces for each group (Figure 21). MSN 
morphology was unaffected by genotype or Mn exposure at week 13 (Figure 22, 
Table 1), however changes in neuron morphology were observed at week 16. 
There was a significant main effect of genotype (F(1,109) = 7.503, p < 0.01) at 16 
weeks on total dendritic length (Figure 22B, Table 2). YAC128 mice in both the 
Veh and Mn exposure groups exhibited shorter total dendritic lengths compared 
to WT-Veh MSNs. Post-hoc tests revealed that total dendritic length of YAC128-
Mn MSNs were significantly shorter than WT-Veh (p = 0.014). There were trends 
towards statistical significance in the differences between WT-Veh and YAC128-
Veh MSNs (p = 0.06) as well as WT-Mn and YAC128-Mn (p = 0.051) MSNs, 
which also contributed to the overall significant main effect of genotype. At 16 
weeks there was a main effect of genotype (F(1,109)= 7.99 p < 0.01) on total spine 
density (Figure 22D, Table 2). YAC128 mice as a group had higher total spine 
densities than WT mice. Post-hoc analysis showed that YAC128-Mn MSNs had a 
significantly higher spine density than WT-Veh and WT-Mn (p < 0.05). The higher 
dendritic spine density in YAC128 mice was strongly driven by the reduction in 
total dendritic length, as we failed to observe a significant difference in total spine 
number or total ends at 13 or 16 weeks (Figure 22 E and Figure 22F, Table 1 
and Table 2). There was a significant main effect of genotype (F(1,109)= 4.06 p < 
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0.05) on the number of dendrite endings at week 16 (Figure 22H). Post-hoc 
analysis revealed a significant reduction in the number of dendrite endings in 
YAC128-Veh compared to WT-Veh mice (p< 0.05). These data consistently show 
that genotype plays a significant role in morphological differences observed in 
MSNs at 16 weeks.  
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Figure 22. Total dendritic length and total number of endings are reduced while 
total spine density is increased in YAC compared to WT mice at 16 weeks. 
 
 
 
 
  
A) Total dendritic length is unchanged in WT and YAC mice at week 13. B) Total 
dendritic length is reduced in YAC vs WT mice revealing a significant main 
genotype effect at 16 weeks (F(1,109) = 7.50, p < 0.01). C) Total spine density is 
unchanged across exposure groups at week 13. D) The increased total spine 
density in YAC vs WT mice reveals a significant main effect of genotype at week 
16 (F(1,109) = 7.99, p < 0.01). E) There is no difference in total number of nodes at 
13 weeks. F) At 16 weeks there is no difference in total number of nodes 
between groups. G) No significant difference in total number of endings was 
observed at 13 weeks. H) Total number of endings were reduced in YAC128-
Veh vs WT-Veh mice revealing a significant genotype effect (F(1,109)= 4.06 p < 
0.05). Week 13: n = 4-5 mice per group, 4-6 neurons/animal. Week 16: n = 5 
mice/group, 4-6 neurons/animal. Error bars indicate SEM. Significant differences 
by post-hoc t-test indicated by *p < 0.05. 
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Table 1. Two-way ANOVA statistics for total dendritic measures at 13 weeks. 
 
 
 
Table 2. Two-way ANOVA statistics for total dendritic measures at 16 weeks. 
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Morphometric measures as a function of distance from the soma are altered by 
genotype and Mn exposure 
 Several measures of neuron morphology as a function of distance from 
the soma were examined in order to gain a detailed understanding of the MSN 
morphology in these mice. Dendritic arborization is an important morphological 
characteristic that determines how the neuron integrates synaptic inputs. Sholl 
analysis measures branching complexity of the neuron by tallying the number of 
dendrites that intersect a series of evenly spaced concentric circles centered at 
the soma (Sholl, 1953). At 13 weeks, there was a significant effect of distance on 
dendritic branching (as expected for Sholl analysis), but no significant 
interactions between distance x genotype, distance x exposure, or three-way 
interaction effects (Figure 23A and Table 3). At 16 weeks (Figure 23B and Table 
4) there was a significant effect of distance x genotype (F(30,3270)=1.71, p = 0.01) 
and as well as a further effect of Mn exposure (distance x genotype x exposure 
interaction effect (F(30,3270)=1.71, p < 0.01)). Post-hoc analysis revealed that the 
basis of the disease-toxicant interaction effect is a significant difference in 
branching complexity between WT-Veh and YAC-Mn mice at 16 weeks (p < 
0.05). There was also a trend towards reduced branching complexity in YAC128-
Mn compared to WT-Mn mice (p = 0.06). These data demonstrate that the 
combined effect of Mn-exposure and the HD mutant genotype caused a 
decrease in dendritic branching complexity greater than either factor alone. 
We examined dendrite length, spine number and spine density as a 
function of distance from the soma as further measures of dendritic arborization 
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and synaptic integration. These morphological characteristics of dendrites were 
measured in each shell made by the concentric circles used for Sholl analysis 
(Figure 23). None of these measures showed significant differences at 13 weeks 
(Table 3). Dendrite length as a function of distance from the soma closely 
resembled the results from Sholl analysis at 16 weeks (Figure 23D, Table 4). 
There was a main effect of distance x genotype (F(30,3270) =2.26, p < 0.0001) and 
a distance x genotype x exposure interaction (F(30,3270) =1.61, p < 0.019). Spine 
number as a function of distance from the soma (Figure 23F) also showed 
distance x genotype (F(30,3270)=1.72, p < 0.01) and distance x genotype x 
exposure (F(30,3270)=3.01, p < 0.0001) effects at 16 weeks (Table 4). There were 
significant distance x genotype (F(17,1853)=1.73, p = 0.032) and distance x 
exposure interactions (F(17,1853)=1.89, p = 0.015) at 16 weeks for spine density as 
a function of distance from the soma (Figure 23H, Table 4). These data 
corroborate the findings by Sholl analysis, and further demonstrate complex 
disease-toxicant interaction effects between HD and Mn exposure that become 
apparent 3 weeks post-exposure. 
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Figure 23. YAC128-Mn exposed mice have decreased branching complexity at 
16 weeks. 
 
 
 
 
 
 
 
 
 
 
 
  
Morphological characteristics of MSNs were assessed using the Sholl method. 
Concentric rings at 10 m intervals were centered at the soma and 
intersections of dendrites at each radius were counted to determine branching 
complexity. A) Dendritic branching complexity is not significantly different 
between groups at 13 weeks. B) Main effects of distance x genotype and 
distance x genotype x exposure for dendritic branching complexity were 
observed only at 16 weeks. C) Dendrite length as a function of distance from 
the soma is unaltered at 13 weeks. D) At 16 weeks, dendrite length as a 
function of distance from the soma is subject to distance x genotype and 
distance x genotype x exposure effects. E) Spine number as a function of 
distance from the soma is unchanged at 13 weeks. F) A distance x genotype 
and distance x genotype x exposure effect were observed at 16 weeks for 
spine number as a function of distance from the soma. G) At 13 weeks spine 
density as a function of distance from the soma was unaffected. H) Spine 
density as a function of distance from the soma was subject to effects of 
distance x genotype and distance x exposure. 
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Table 3. Repeated measures two-way ANOVA statistics for dendritic measures 
as a function of distance from the soma at 13 weeks. 
 
 
 
Table 4. Repeated measures two-way ANOVA statistics for dendritic measures 
as a function of distance from the soma at 16 weeks. 
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Onset of striatal neuropathology occurs by 16 weeks in YAC128 mice 
 Comparing total dendritic length and total spine density across age 
revealed that there was a significant effect of age for both neuron measures and 
an age x genotype interaction for total dendritic length (Table 5). While there was 
a significant increase in total dendritic length in WT (Veh + Mn) MSNs from 13 to 
16 weeks (p = 0.002), there was no significant difference in YAC128 (Veh + Mn) 
MSNs at these time points (Figure 24A). Post-hoc t-tests revealed a significant 
difference in total dendritic length between WT and YAC128 groups at week 16 
(p = 0.007). Based on this novel result, we decided to directly compare WT-Veh 
and YAC128-Veh mice (Figure 24B). There was a significant age x genotype 
interaction for total dendritic length between WT-Veh and YAC128-Veh 
(F(1,100)=4.01, p < 0.05). Total dendritic length increased in WT-Veh mice from 13 
to 16 weeks (p = 0.011), while YAC128-Veh mice showed no significant 
difference in total dendritic length across age. Similarly, total spine density 
(Figure 24C) decreased from week 13 to 16 in both genotypes (p < 0.05). 
However, at 16 weeks total spine density was higher in YAC128 MSNs 
compared to WT MSNs (p = 0.005). Next, we directly compared total spine 
density in WT-Veh and YAC128-Veh mice. Total spine density decreased from 
13 to 16 weeks in WT-Veh MSNs (p = 0.001), but there was not a significant 
decrease in total spine density in YAC128-Veh MSNs across age (Figure 24D). 
The absence of an age-dependent increase in total dendritic length and decrease 
in total spine density of MSNs in YAC128 mice is the earliest sign of 
neuropathology identified to date in this model of HD.  
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Analyses of neuron morphology measures as a function of distance from 
the soma across age revealed significant effects of distance x age for dendritic 
branching, dendrite length and spine density (Figure 24 and Table 6). 
Additionally, distance x age x genotype interactions were detected for dendritic 
branching, dendrite length and spine number (Figure 24 and Table 6). Post-hoc 
analysis confirmed that the genotype effect was driven by a significant increase 
in branching complexity between 13 and 16 weeks in WT mice (Figure 24E) (p < 
0.05). Importantly, there was no significant difference between 13 and 16 week 
branching complexity in YAC128-Veh MSNs (Figure 24I). Therefore, changes in 
dendritic branching that normally occurred in WT-Veh mice did not occur in 
YAC128-Veh mice, indicating an onset of neuropathological changes between 13 
and 16 weeks of age. Similar results were found for dendrite length as a function 
of distance from the soma (Figure 24). WT mice had longer dendrite lengths per 
shell at 16 weeks compared to 13 weeks (p < 0.05), but there was no difference 
in dendrite length per shell between the time points in YAC128-Veh mice (Figure 
24F and Figure 24J). Spine number as a function of distance from the soma was 
not changed between 13 and 16 weeks in either genotype (Figure 24G and 24H). 
Sixteen-week old WT-Veh mice had significantly decreased spine density per 
shell (Figure 24H) compared to 13 week WT-Veh mice (p < 0.05), but there was 
no difference between spine densities in YAC128 mice from week 13 to 16 
(Figure 24L). This parallels the changes observed in total spine density across 
age groups. Together these data corroborate that subtle neuropathological 
changes in MSN morphology commence as early as 16 weeks of age and that 
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the disease-toxicant interaction between Mn and mutant HTT has a subtle effect 
on dendrite length in YAC128 mice. 
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Figure 24. Onset of striatal neuropathology in YAC128 mice. 
 
 
 
 
 
 
 
 
  
A) Total dendritic length of WT mice increased from week 13 to week 16, but 
was unchanged in YAC128 mice. B) Total dendritic length increased in WT-
Veh mice from week 13 to week 16, but was unchanged in YAC128-Veh mice. 
C) Dendritic branching, measured by Sholl analysis, increased from week 13 to 
week 16 in WT-Veh mice. D) Dendrite length as a function of distance from the 
soma also increased from week 13 to week 16 in WT-Veh mice. E) Spine 
number as a function of distance from the soma was unchanged from week 13 
to week 16 in WT-Veh mice, recapitulating the similarity between total spine 
number at 13 and 16 weeks. F) Spine density as a function of distance from the 
soma was decreased from week 13 to week 16 in WT-Veh mice. G) There was 
no change in dendrite branching in YAC128-Veh mice from week 13 to 16. H) 
There was no change in dendrite length as a function of distance from the 
soma from week 13 to 16 in YAC128-Veh mice. I) There was no change in 
spine number as function of distance from the soma in YAC128-Veh mice. J) 
There was only a slight decrease in spine density as a function of distance from 
the soma, which is reflected in total spine density across age. Week 13: n = 4-5 
mice per group, 4-6 neurons/animal. Week 16: n = 5 mice/group, 4-6 
neurons/animal. Average values +/- SEM; p-values from post-hoc t-tests are on 
each graph, significant values indicated in bold. ** p < 0.01. 
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YAC128 mice were more sensitive to Mn-dependent changes in striatal amino 
acids 
In addition to striatal neuron morphology, we examined total levels of 
striatal amino acids and monoamine neurotransmitters to identify neurochemical 
changes that may underlie the alterations in MSN dendritic morphology. Many of 
these amino acids act both as neurotransmitters and in metabolic pathways. 
Striatal amino acids levels have not been previously reported in YAC128 mice or 
following Mn exposure, except as noted in the introduction. Mutant HTT and Mn 
exposure had varied effects on striatal amino acids, though most were 
unchanged by either genotype or exposure. Amino acids that were affected by 
mutant HTT and/or Mn exposure included -amino butyric acid (GABA, Figure 
25A and 25E), citrulline (Cit, Figure 25B and 25F), glycine (Gly, Figure 25C and 
25G), serine (Ser, Figure 25D and 25H) histidine and alanine (data not shown). 
Mutant HTT and Mn-effects were specific, with striatal levels of aspartate, 
glutamate, leucine, lysine, methionine, ornithine, phenylalanine, proline, taurine 
and tyrosine remaining unchanged relative to their respective controls at both 
time points (Figure 26). 
Striatal GABA levels at 13 weeks (Figure 25A) were significantly elevated 
by Mn exposure (F(1,16)=9.53, p < 0.01). WT- and YAC128-Veh exposed animals 
had nearly identical levels of striatal GABA, but Mn exposure resulted in 
significantly higher GABA levels in both genotypes compared to their respective 
Veh exposed counterparts (p < 0.05). YAC128-Mn striatal GABA levels were also 
elevated over WT-Veh (p < 0.05). Striatal GABA levels at 16 weeks (Figure 25E) 
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were significantly affected by a genotype x exposure interaction (F(1,14)=5.14, p < 
0.05). YAC128-Mn animals had significantly lower levels of striatal GABA 
compared to WT-Mn (p = 0.019). Cit levels in the striatum were significantly 
elevated by Mn exposure (F(1,16)=14.87, p < 0.001) at 13 weeks (Figure 25B). Mn 
exposure resulted in an increase in striatal Cit levels for both genotypes 
(F(1,14)=5.14, p < 0.05) above Veh exposed mice of both genotypes (p < 0.05). 
However, by 16 weeks when Mn was no longer elevated, striatal Cit in Mn 
exposed mice (Figure 25F) was equivalent to WT-Veh.  
Gly levels in the striatum at 13 weeks (Figure 25C) were affected by 
genotype (F(1,16)=4.64, p < 0.05). Post-hoc tests revealed that YAC128-Mn mice 
had significantly higher levels of striatal Gly compared to WT-Veh and WT-Mn 
mice (p < 0.05). At 16 weeks there was a significant main effect of genotype 
(F(1,14)=7.43, p = 0.016) and a genotype x exposure interaction (F(1,14)=11.43, p < 
0.005) on striatal Gly levels (Figure 5G). YAC128-Veh mice had an increase in 
striatal Gly levels over WT-Veh (p = 0.002) mice at 16 weeks. Gly levels were 
only transiently elevated in Mn exposed mice at 13 weeks because at 16 weeks 
Gly levels were at the same level as WT-Veh when Mn levels returned to normal. 
Elevated Gly levels in the YAC128-Veh mice were returned to WT-Veh levels in 
Mn exposed YAC128 mice (YAC128-Mn vs YAC128-Veh p = 0.006). At 13 
weeks striatal Ser levels (Figure 25D) were affected by genotype (F(1,16)=4.66, p 
< 0.05) and exposure (F(1,16)=12.38, p < 0.005). Post-hoc tests revealed that 
levels of Ser in YAC128-Mn mice were significantly elevated above WT-Veh (p < 
0.001), WT-Mn (p < 0.05), and YAC128-Veh (p < 0.005). At 16 weeks striatal Ser 
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levels (Figure 25H) were subject to significant main effects of genotype 
(F(1,14)=9.12, p < 0.01) and exposure (F(1,14)=5.75, p < 0.05). Striatal Ser levels 
were normalized to WT-Veh levels in Mn exposed mice following clearance of Mn 
from the striatum. YAC128-Veh mice had an increase in striatal Ser compared to 
WT-Veh that was normalized to WT-Veh levels in Mn exposed YAC128 mice (p < 
0.05).  
In analyzing striatal amino acids across age groups it is possible to gain 
insight into the effects of Mn on the levels of amino acids over time. There was a 
significant age x exposure interaction for striatal Ser (F(1,36)=12.20, p < 0.001), 
Gly (F(1,36)=4.72, p < 0.05), Cit (F(1,36)=19.95, p < 0.001) and GABA (F(1,36)=9.70, 
p < 0.005). The age x exposure interaction is illustrated by the changing effect of 
Mn over time. Immediately after Mn exposure at 13 weeks, striatal Mn levels 
were significantly elevated and at the same time striatal Ser, Gly, Cit and GABA 
levels were elevated in Mn exposed animals. This may be due to an acute 
response to elevated Mn present in the striatum. Mn was almost completely 
eliminated from the striatum 3 weeks following the end of Mn exposure. At this 
time point, the amino acids that were elevated immediately after Mn exposure 
normalized compared to WT-Veh. 
  
125 
 
 
126 
 
 
Figure 25. Striatal amino acids are altered by Mn exposure and genotype at 13 
and 16 weeks. 
 
 
 
 
 
 
 
  
A) There is a main effect of treatment on GABA at week 13 (F(1,16)=9.53, p < 0.01) 
WT-Mn and YAC-Mn are significantly elevated above WT-Veh (p < 0.05) YAC-Mn 
is also elevated above YAC-Veh (p < 0.05). B) Mn treatment (F(1,16)=14.87, p < 
0.001) caused an increase in striatal citrulline (Cit) levels. Mn treated animals of 
both genotypes are elevated above both vehicle treated groups. C) There is a 
main effect of genotype on Gly concentration in the striatum (F(1,16)=4.64, p < 0.05) 
at week 13. Levels of Gly in YAC128-Mn are significantly higher than WT-Veh and 
WT-Mn, but do not reach significance compared to YAC128-Veh (p = 0.052). D) 
There are significant main effects of genotype (F(1,16)=4.66, p < 0.05) and 
exposure (F(1,16)=12.38, p < 0.005) on striatal Ser levels at 13 weeks. E) There is a 
significant genotype x treatment interaction for striatal GABA levels (F(1,14)=5.14, p 
= 0.04). Striatal GABA is much lower in YAC-Mn compared to WT-Mn animals (p < 
0.02). F) There is no significant difference in Cit levels at week 16. G) At week 16 
there is a main effect of genotype (F(1,14)=7.43, p < 0.02) and a genotype x 
exposure interaction (F(1,14)=11.43, p = 0.04) on striatal Gly levels. YAC128-Veh 
Gly levels are elevated over WT-Veh, WT-Mn and YAC128-Veh (p = 0.002, p = 
0.009, p = 0.006, respectively). H) There are significant main effects of genotype 
(F(1,14)=9.12, p < 0.001) and exposure (F(1,14)=5.75, p < 0.05) on striatal Ser at 16 
weeks. Amino acid neurotransmitter means (week 13 n = 5-6 and week 16 n = 4-
8) are plotted +/-SEM. Significant differences established by pos-hoc t-tests *p < 
0.05, **p < 0.01, ##p < 0.005, and ***p < 0.001. 
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Figure 26. Striatal amino acids unaffected by Mn and genotype. 
 
 
 
 
  
Striatal amino acids including aspartate (A, F), glutamate (B,G),  
ornithine (C, H), taurine (D,I) and tyrosine (E, J) are unaffected by Mn 
and mutant HTT at 13 and 16 weeks. Additionally, isoleucine, leucine, 
valine, methionine, and phenylalanine were unaltered by Mn or mutant 
HTT (data not shown). 
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Striatal monoamine neurotransmitters were altered by Mn exposure and mutant 
HTT expression at 16 weeks 
Monoamine neurotransmitters and metabolites, which have not been 
previously reported in the YAC128 mice, were also measured in the striatum at 
13 and 16 weeks by HPLC. At 13 weeks, serotonin (5-HT) and the metabolite 5-
hydroxyindoleacetic acid (5-HIAA, data not shown), dopamine (DA, Figure 27A) 
and its metabolites (Figure 27B), 3,4-dihydroxyphenylacetic acid (DOPAC), 
homovanillic acid (HVA) and, 3-methoxytyramine (3-MT), were not significantly 
different between genotype and exposure groups although the DA turnover rate, 
measured by the DOPAC/DA ratio (Figure 27B), was significantly affected by 
genotype (F(1,18)=6.67, p < 0.05). DA turnover was reduced in YAC128-Mn 
compared to WT-Mn mice (p < 0.05). Overall, at 13 weeks there were no 
changes in striatal monoamine neurotransmitter levels, but the DA turnover rate 
was significantly affected by genotype. 
By 16 weeks there were significant exposure and genotype effects on 
monoamine neurotransmitter levels in the striatum. Significant main effects of 
exposure occur for 5-HIAA (F(1,17)=6.53, p < 0.05, data not shown), DA (Figure 
27C, F(1,17)=6.11, p < 0.05), DOPAC (Figure 27D, F(1,17)=7.65, p < 0.05),  and 
HVA (Figure 27D, F(1,17)=12.91, p < 0.005)  levels in the striatum. There were 
also significant main effects of genotype on DA (F(1,17)=6.32, p < 0.03) and its 
metabolites DOPAC (F(1,17)=6.77, p < 0.02) and HVA (F(1,17)=7.22, p < 0.02). 
Serotonin levels were unaffected by Mn exposure or mutant HTT, but the 5-HT 
metabolite 5-HIAA was significantly reduced by Mn exposure (data not shown). 
129 
 
In Mn-exposed WT mice there was a non-significant reduction in 5-HIAA (p = 
0.087) compared to vehicle, while YAC128 mice had a significant reduction in 5-
HIAA levels in the striatum following Mn exposure (p = 0.016). 
Striatal DA and its metabolites exhibited genotype and exposure effects at 
16 weeks. DA levels (Figure 27C) were reduced by Mn exposure in WT mice (p < 
0.05). YAC128-Veh mice had decreased striatal DA levels (p < 0.05) that were 
indistinguishable from WT-Mn levels. Unlike in WT mice, Mn exposure failed to 
decrease DA levels in YAC128 mice. Striatal DA levels in YAC128-Mn mice were 
similar to YAC128-Veh and WT-Mn levels. DA metabolites DOPAC and HVA 
(Figure 27D) were similarly affected by genotype and Mn exposure. Mn exposure 
reduced DOPAC and HVA levels in WT mice (p < 0.01). Similarly, YAC128-Veh 
mice had DOPAC and HVA levels reduced by approximately the same degree as 
WT-Mn versus WT-Veh (p < 0.05). DA metabolites in YAC128 mice were not 
further affected by Mn exposure with DOPAC and HVA levels were similar 
between YAC128-Mn, YAC128-Veh and WT-Mn mice. The DOPAC and HVA 
metabolite, 3-MT, was not significantly different in any group at 16 weeks (Figure 
27D). The DOPAC/DA ratio was also unaltered at 16 weeks (Figure 27D). 
Analysis of striatal neurochemistry across time points revealed an age x 
exposure interaction for DOPAC (F(1,37)=4.28, p < 0.05) and HVA (F(1,37)=5.12, p 
< 0.05). These data revealed an effect of Mn exposure and genotype on the 
nigrostriatal dopaminergic system that only occurred at the later time point. 
Overall, at 16 weeks, Mn exposure reduced striatal DA and metabolites 
specifically only in WT animals. Mutant HTT reduced striatal DA and metabolites 
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as well, relative to WT-Veh. However, Mn exposure failed to show an effect on 
striatal DA and its metabolites in YAC128 mice. 
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Figure 27. Striatal monoamine neurotransmitters and metabolites are more 
strongly affected at week 16 by Mn exposure and genotype. 
 
 
 
 
 
 
 
 
 
 
 
  
A) There are no significant differences in striatal DA levels at week 13. B) There 
is no difference between striatal levels of DOPAC or HVA at week 13, however 
there is a significant main effect of genotype on ratio DOPAC/DA (F(1,18)=6.67, p 
< 0.02). The turnover rate of DA is significantly lower in YAC128-Mn than WT-
Mn (p < 0.04), and although lower it does not reach statistical significance 
compared to WT-Veh mice (p = 0.053). D) At week 16 there is a significant 
effect of genotype (F(1,17)=6.32, p = 0.022 and treatment (F(1,17)=6.11, p = 0.024) 
on striatal DA levels. WT-Mn, YAC128-Veh and YAC128-Mn have lower levels 
of striatal DA than WT-Veh mice (p = 0.028, p = 0.033 and p =0.007 
respectively). E)  There are also significant genotype and treatment effects on 
DA metabolites DOPAC (genotype: F(1,17)=6.77, p = 0.019; treatment: 
F(1,17)=7.66, p = 0.013) and HVA (genotype: F(1,17)=7.22, p = 0.016; treatment: 
F(1,17)=12.91, p = 0.002) at week 16. Levels of striatal DOPAC and HVA in WT-
Mn, YAC128-Veh and YAC128-Mn are significantly lower than in WT-Veh mice 
(p < 0.01 and p < 0.015 respectively). Monoamine neurotransmitter and 
metabolite averages (week 13 n = 4-6 and week 16 n = 3-8) are graphed +/-
SEM. Significance by post-hoc t-test *p < 0.05, **p < 0.01 and ##p < 0.005.  
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Discussion 
 This study identifies novel in vivo correlates of a recently discovered gene-
environment interaction between the disease-causing allele of HTT and Mn 
exposure revealed by analysis of striatal neurochemistry and MSN dendritic 
architecture. Additionally, we identified the age of onset for striatal dendritic 
neuropathology and neurochemical phenotypes in the YAC128 HD mouse model 
to be between 13 and 16 weeks of postnatal life, approximately corresponding to 
the age of onset for motor phenotypes (Menalled et al., 2009; Slow et al., 2003; 
Van Raamsdonk et al., 2005b). 
 
Onset of YAC128 striatal neuropathology 
 Neuron morphology studies of striatal MSNs in R6/1(Spires et al., 2004), 
R6/2 (Klapstein et al., 2001), HD48 and HD89 (Guidetti et al., 2001) mice 
showed a decrease in spine density across branch order that was only evident in 
symptomatic mice (Klapstein et al., 2001). In the YAC128 mice, hyperkinetic 
activity is present at the initiation of Mn exposure at 12 weeks and motor 
impairment was just beginning at 16 weeks when we observed morphological 
changes in MSNs (Van Raamsdonk et al., 2005b). Milnerwood et al. (2010) 
found no morphological differences in striatal MSNs in YAC128 mice at 4 weeks 
of age. We detected no morphological or neurochemical associated 
abnormalities in YAC128-Veh mice at 13 weeks (Figure 22, Figure 23, Figure 25 
and Figure 27). Our measurements on  total dendritic length and total spine 
density for the 13 week WT-Veh and YAC128-Veh groups are nearly identical to 
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values reported by Milnerwood et al. (2010) (Figure 22). Morphological and 
neurochemical changes in the striatum of the YAC128 mice were observed at 16 
weeks. YAC128 mice failed to show an increase in total dendritic length and 
dendritic branching that was apparent in WT mice from 13 to 16 weeks (Figure 
24) indicating the onset of MSN neuropathology in YAC128 mice. YAC128 mice 
also failed to show a significant decrease in total spine density at 16 weeks 
(Figure 24). These subtle changes in neuron morphology may have large effects 
on synaptic input integration and transmission. 
The morphological changes that we observed in YAC128-Veh mice at 16 
weeks (Figures 22 thru 24) may be related to alterations in striatal 
neurotransmitter content. At 16 weeks YAC128-Veh mice had significantly lower 
levels of DA and its metabolites, DOPAC and HVA, (Figure 27) compared to WT-
Veh mice. Reduced striatal DA levels and disturbances in dopaminergic signaling 
have also been observed in the  R6/1 (Ortiz et al., 2011) and R6/2 mouse models 
of HD (Bibb et al., 2000; Cha et al., 1998; Johnson et al., 2006; Ortiz et al., 
2010); however striatal DA levels were only altered in L-DOPA treated YAC128 
mice (Tang et al., 2007). Not only was the nigrostriatal DA system altered in 16-
week old YAC128-Veh mice, but the amino acids Gly and Ser were also elevated 
in the striatum (Figure 25). Elevated levels of Gly have also been detected in HD 
patient platelets (Reilmann et al., 1997) and CSF (Nicoli et al., 1993). Not only do 
YAC128 animals have an increase in NMDAR co-agonsists Ser and Gly, they 
also have an increase in NR2B expressing extrasynaptic NMDA receptors 
(Milnerwood et al. 2010). YAC128 animals are known to be sensitive to NMDAR 
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excitotoxicity and signaling through extrasynaptic NMDARs that have been 
shown to contribute to apoptosis of MSNs in these animals (Fernandes et al., 
2007; Graham et al., 2009; Graham et al., 2006; Tang et al., 2005; Zeron et al., 
2004; Zeron et al., 2002). Collectively, our data are consistent with N-methyl-D-
aspartate receptor (NMDAR) dependent excitotoxicity in YAC128 mice at the 16-
week time point. First, we found a reduction in striatal DA (Figure 27) that may 
result in less modulation of glutamatergic signaling at dendritic spines (Bamford 
et al., 2004). Secondly, an increase in striatal levels of NMDAR co-agonists Ser 
and Gly (Figure 25), which includes the metabolic pool of amino acids, may 
facilitate signaling through the NMDAR (Johnson and Ascher, 1987; 
Kartvelishvily et al., 2006). The facilitation of NMDAR signaling and dysregulation 
of glutamate release likely contributes to an excitotoxic environment (Milnerwood 
et al., 2010; Okamoto et al., 2009). 
 
Mn exposure caused acute and chronic changes in striatal neurochemistry of WT 
mice 
 Mn exposure in WT mice influenced striatal neurochemistry at both 13 and 
16 weeks (Figure 25 and Figure 27). Acute effects of Mn exposure included an 
increase in GABA and Cit (Figure 25) in WT mice at 13 weeks. These effects are 
likely a temporary response to Mn levels, as by 16 weeks these 
neurotransmitters levels returned to baseline levels. Mn exposure has been 
shown to increase expression of the enzyme nitric oxide synthase (NOS) that 
converts arginine into Cit and nitric oxide (NO) (Moreno et al., 2008). Cit levels 
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were elevated in the striatum only while Mn levels were elevated, suggesting that 
the effect of Mn on NOS expression is readily reversible. There was a significant 
decrease in striatal DA, HVA and DOPAC (Figure 27) at week 16 in WT-Mn 
mice, which was not present at 13 weeks. Previous studies using different Mn 
exposure paradigms have found similar alterations in striatal GABA and DA 
levels (Autissier et al., 1982; Gianutsos and Murray, 1982; Gwiazda et al., 2002; 
Lipe et al., 1999; Reaney et al., 2006; Struve et al., 2007; Vidal et al., 2005), 
although conflicting studies found that Mn exposure did not influence striatal Gly 
or DA levels (Burton et al., 2009; Kontur and Fechter, 1988; Olanow et al., 1996; 
Takeda et al., 2002; Takeda et al., 2003). The alterations in striatal 
neurotransmitter levels at 16 weeks have the potential to cause morphologic 
changes in MSNs. However, we failed to observe any significant effect of Mn 
exposure on MSN morphology at either age in WT mice (Figures 22 thru 24). 
This contrasts with our own previously published data suggesting that sub-acute 
Mn exposure results in morphological changes to striatal MSNs (Milatovic et al., 
2009). One possible explanation for this discrepancy may be that the animals in 
the previous study were younger (6 to 8 weeks vs. 13 to 16 weeks postnatal 
herein) and a different inbred strain (C57Bl/6 vs. FVB). Nevertheless, data 
reported herein are consistent with other reports in the literature of Mn 
neurotoxicity causing damage to the nigrostriatal DA system (Guilarte et al., 
2008; Guilarte et al., 2006; Stanwood et al., 2009).    
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Disease-toxicant interaction caused alteration in striatal neurochemistry  
YAC128 mice showed less striatal Mn accumulation one day after final Mn 
exposure at 13 weeks compared to WT littermates (Figure 21). These data 
replicate findings from a previous study that utilized GFAAS to measure striatal 
Mn levels in similarly exposed YAC128 mice (Williams et al., 2010b). There are 
several potential mechanisms that may influence the differential Mn accumulation 
between genotypes; mutant HTT may interfere with import of Mn into the striatum 
or increase efflux of Mn from the striatum. Additional research is needed to 
determine the exact mechanism for differential striatal Mn accumulation between 
YAC128 and WT mice. 
Mn exposure had significant effects on striatal neurochemistry in YAC128 
mice. Changes in neurochemistry between 13 and 16 weeks in Mn exposed 
YAC128 and WT mice were complex. At 13 weeks, there were no significant 
morphological differences among the exposure groups (Figure 22 and Figure 
23), but there were neurochemical changes in the striatum of YAC128-Mn mice. 
Mn exposure elevated striatal GABA and Cit in both genotypes, but Gly and Ser 
were only elevated in YAC128 mice (Figure 25). Proteomic analysis in the 
striatum of YAC128 mice exposed to Mn using the same exposure paradigm 
revealed an increase in D-3 phosphoglycerate dehydrogenase (PHGDH) levels 
at 13 weeks (unpublished data). The reaction catalyzed by PHGDH is the first 
and rate-limiting step in the synthesis of Ser and its activity regulates synthesis of 
D-Ser (Pizer, 1964; Yang et al., 2010). A direct correlation between levels of Gly 
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and Ser has been demonstrated in PHGDH deficiency (Klomp et al., 2000). 
Elevation of these amino acids at 13 weeks may represent an acute 
compensatory response to Mn exposure because the levels of these amino acids 
were normalized at 16 weeks (Figure 25) once Mn is cleared from the striatum. 
Interestingly, at 16 weeks the increased levels of Gly and Ser seen in YAC128-
Veh mice compared to WT-Veh, were normalized by Mn exposure (Figure 25). 
D-Ser and Gly are co-agonists at the NMDAR and the increased levels of these 
amino acids in the striatum at 13 weeks may facilitate signaling through the 
NMDAR (Johnson and Ascher, 1987; Kartvelishvily et al., 2006). Additionally, Cit 
and therefore NO levels were elevated at 13 weeks in Mn exposed mice of both 
genotypes (Figure 25). NO has been shown to amplify Glu signaling, block Glu 
transporters and increase Glu release, thereby increasing the possibility of 
NMDAR excitotoxicity (Garthwaite, 2008; Guevara-Guzman et al., 1994; Lonart 
and Johnson, 1994; Pogun et al., 1994; Taskiran et al., 2003; West and 
Galloway, 1997). YAC128 mice express high levels of extrasynaptic NMDARs 
which may sensitize them to NMDAR excitotoxicity (Fernandes et al., 2007; 
Graham et al., 2009; Milnerwood et al., 2010; Shehadeh et al., 2006; Zeron et al., 
2004; Zeron et al., 2002). The changes in striatal neurochemistry following Mn 
exposure did not affect every neurotransmitter; for example, 5-HT was unaffected 
by Mn at both 13 and 16 weeks (data not shown) and exposure to Mn did not 
reduce striatal DA levels in YAC128-Mn mice below YAC128-Veh or WT-Mn 
levels at 16 weeks (Figure 27).  
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The gene-environment interaction between mutant HTT and Mn is 
complex. For some phenotypes Mn exposure may suppress pathological 
changes occurring within the striatum of YAC128 HD mice. For example by 
restoring striatal Ser and Gly back to wild-type levels (Figure 25G and 25H). 
Such effects may be due to an amelioration of phenotypes caused by alterations 
in cellular Mn handling. For other phenotypes, YAC128 animals may suppress 
Mn-dependent phenotypes.  For example, Mn exposure of YAC128 mice failed to 
lower striatal DA and metabolite levels further than YAC128-Veh mice (Figure 
27C and 27D). Finally, for other phenotypes YAC128 animals may show 
increased sensitivity to Mn exposure. For example, acute elevations in striatal 
amino acids Gly and Ser at week 13 and morphological changes in striatal MSN 
at 16 weeks were all more severe in the YAC128 animals. Further studies need 
to be carried out to better understand this recently discovered disease-toxicant 
interaction. Nonetheless, our data strongly suggest that Mn exposure has the 
potential to influence HD onset or progression. 
 
Conclusions 
 We set out to determine if Mn, mutant HTT or the combination of the two 
would alter striatal neurochemistry or MSN morphology. Overall, the answer is 
yes – but the direction and degree of the effects and interactions were varied and 
depended upon the specific phenotype being examined.  We found that Mn 
exposure acutely alters striatal amino acid levels, but these acutely influenced 
amino acids return to baseline when Mn is eliminated from the striatum. Mn 
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exposure also has chronic effects on neurochemistry. Striatal DA is significantly 
reduced at 16 weeks in WT-Mn mice. However, we failed to detect morphological 
alterations in MSN dendrites of WT mice exposed to Mn at either time point. We 
identified the onset of alterations in striatal neurochemistry and MSN dendritic 
neuropathology at 16 weeks postnatal in YAC128 mice. The neurochemical 
changes that we identified may promote NMDAR excitotoxicity in the YAC128 
mice. Finally, we identified in vivo correlates of a disease-toxicant interaction as 
anticipated by our previously reported in vitro interactions (Kwakye et al., 2011; 
Williams et al., 2010b). However, the finding of both restorative (Gly, Ser and DA 
neurochemistry) and degenerative effects (dendritic morphology changes) by Mn 
exposure on the early YAC128 mutant phenotypes suggests caution should be 
taken in determining the appropriate nutritional guidelines and environmental 
exposures to Mn for HD patients. Further investigation needs to be completed to 
determine the effect of the HD-Mn interaction on disease progression both at the 
neuroanatomical and behavioral level, as well as to gain insight into targets and 
mechanisms of disease modification. 
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CHAPTER VI 
 
GENDER AND MANGANESE EXPOSURE INTERACTIONS ON MOUSE 
STRIATAL MEDIUM SPINY NEURON MORPHOLOGY  
 
Abstract 
Gender differences in sensitivity and toxicokinetics of multiple metals have 
been identified in humans. A recent study suggested that young girls performed 
worse on intellectual exams than young boys exposed to manganese (Mn) in the 
environment.  Animal studies have shown that Mn exposure causes differential 
effects on behavior in male compared to female mice. We hypothesized that in 
response to Mn exposure striatal Mn accumulation and/or striatal medium spiny 
neuron (MSN) morphology show gender-dependent effects. We evaluated the 
contribution of gender to neuropathology by examining striatal MSN morphology 
in male and female mice exposed to Mn. We found that gender played a 
significant role in alterations of striatal MSN morphology in mice exposed to Mn. 
Gender-dependent changes were strongest when striatal Mn levels were 
elevated 24 hours following the final Mn exposure. Nevertheless, gender-
dependent alterations in neuron morphology were still present 3 weeks after the 
final Mn exposure. Gender differences in neuron morphology were not due to 
differential striatal Mn accumulation between genders. We conclude that 
although gender does not affect striatal Mn accumulation, MSN morphology is 
differentially sensitive to elevated Mn levels. 
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Introduction 
 Gender differences in the toxicokinetics of xenobiotics have been 
previously reported (Clewell et al., 2002; Fletcher et al., 1994; Nicolson et al., 
2010). These differences can be due to multiple factors; from differences in 
cytochrome P450 (CYP450) expression, transporter expression and influences of 
sex hormones on expression of these enzymes and transporters (Bonate, 1991; 
Harris et al., 1995). A limited number of studies have been conducted to examine 
gender differences in Mn toxicokinetics but none have examined morphological 
alterations as a function of gender. 
 Mn exposure typically occurs in occupational settings such as welding, 
smelting, Mn mining and working in a dry-cell battery factory (Bowler et al., 2006; 
Bowler et al., 2007a; Bowler et al., 2007b; Huang et al., 1989; Jiang et al., 2007; 
Ono et al., 2002; Wang et al., 1989; Zayed et al., 2003).  Studies conducted in 
the general population, unexposed to high levels of Mn, have shown conflicting 
results. Men have been shown to have lower ferritin levels, reduced Mn 
absorption from the gastrointestinal tract and slower Mn clearance than women 
(Finley et al., 1994). Some studies indicate that in a healthy unexposed 
population, serum Mn levels are higher in men than women (Davis and Greger, 
1992; Greger et al., 1990). However, more recent reports indicate that there is no 
gender difference in baseline serum Mn levels (Diaz et al., 2001; Rukgauer et al., 
1997). One recent study explored intellectual function of children living in a 
Mexican Mn mining district. Children exposed to Mn had elevated levels (20x) of 
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Mn in hair and blood than children unexposed to high Mn levels. Young girls 
exposed to Mn performed worse on the revised Wechsler Intelligence Scale for 
Children than Mn exposed boys (Riojas-Rodriguez et al., 2010). Although there 
were no gender differences in Mn levels of exposed children, this suggests that 
cognitive performance may be differentially affected in boys and girls. Gender 
differences in response to metal exposure are not unique to Mn. Human studies 
have found gender differences in accumulation, storage and sensitivity to metals 
including cadmium (Cd), lead (Pb), Mn, mercury (Hg) and nickel (Ni) (Akesson et 
al., 2002; Akesson et al., 2005; Bjorkman et al., 2000; Grandjean et al., 1998; 
Gulson et al., 1998; Jin et al., 2004; Kobayashi et al., 2006; Manton et al., 2003; 
McKeown-Eyssen et al., 1983; Meding et al., 2001; Nielsen et al., 2002; Pounds 
et al., 1991; Uno et al., 2005; Vahter et al., 2007; Vahter et al., 2002). Animal 
studies also show gender differences in metal toxicokinetics and sensitivity. For 
example, male and female rats accumulated Mn differentially across body tissues 
following Mn exposure by inhalation; however, there was no difference in Mn 
accumulation in the striatum or other regions of the basal ganglia (Dorman et al., 
2004). Gender differences in toxicokinetics following a single oral dose of the 
gasoline additive methylcyclopentadienyl manganese tricarbonyl (MMT) showed 
that female rats accumulated higher MMT levels than male rats due to slower 
clearance of MMT (Zheng et al., 2000). Erikson et al (2004a) exposed juvenile 
rats to airborne Mn for 13 weeks and found gender-specific changes in protein 
and mRNA expression of glutamine synthetase, metallothionein mRNA and 
glutathione levels in multiple regions of the brain. Gender differences in the 
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toxicokinetics of Mn are present regardless of route of administration and Mn 
speciation. As with humans, rodents show gender differences upon exposure to 
other metals such as Pb and Hg (Fortoul et al., 2005; Magos et al., 1981; Sager 
et al., 1984).  
Mn overexposure results in motor symptoms that closely resemble 
Parkinson‟s disease (PD) (Calne et al., 1994; Lucchini et al., 2009). Acute high-
level Mn exposure results in manganism, symptoms include cognitive, psychiatric 
and motor deficits. Motor symptoms of late-stage manganism are similar but 
distinct from idiopathic PD (Calne et al., 1994). Shared symptoms include rigidity 
and bradykinesia; however, manganism has a distinct cock-walk compared to the 
festinating gait observed in PD (Lucchini et al., 2009). Additionally, patients with 
manganism rarely show a sustained response to dopamine (DA) replacement 
therapy and fail to show reduced striatal DA uptake (Calne et al., 1994; Huang et 
al., 2003). More recently, studies have shown that chronic low level exposure to 
Mn is a risk factor for PD (Gorell et al., 1997; Gorell et al., 1999; Lucchini et al., 
2009; Perl and Olanow, 2007). Mn accumulates preferentially in the basal 
ganglia, specifically the striatum, globus pallidus and substantia nigra (SN) 
(Aschner et al., 2005; Dobson et al., 2004; Dodd et al., 2005; Erikson et al., 
2002; Erikson et al., 2004b; Fitsanakis et al., 2008; Olanow et al., 1996; Williams 
et al., 2010b). Rodent, non-human primate and human post-mortem research 
has found that the striatum shows damage following exposure to Mn (Aschner et 
al., 2007; Milatovic et al., 2009; Olanow, 2004; Perl and Olanow, 2007). 
Furthermore, the nigrostriatal DA system is impacted by Mn exposure (Guilarte et 
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al., 2008; Guilarte et al., 2006; Huang et al., 2003; Kessler et al., 2003; Kim et al., 
2002; Stanwood et al., 2009). In PD, the pigmented DAergic neurons of the SN 
degenerate resulting in damage to striatal medium spiny neurons (MSN) (Day et 
al., 2006; Garcia et al., 2010; Wright et al., 2009; Zaja-Milatovic et al., 2005). 
Thus overlapping, but not identical brain regions are involved in Mn neurotoxicity 
and PD, with the striatal MSNs altered in both conditions.   
Gender differences in prevalence, age of onset and progression have 
been described for PD (Haaxma et al., 2007; Miller and Cronin-Golomb, 2010; 
Shulman, 2007), however the influence of gender on behavior or neuropathology 
in Mn neurotoxicity has not been a major focus in the field of Mn toxicology. 
Females tend to have a later age of onset and less severe symptoms of PD. 
Gender studies in animal models of PD have also shown that estrogen plays a 
protective role in neuropathology and behavior. Survival of DA neurons following 
exposure to DA neurotoxicants, used in animal models of PD, is sensitive to 
gender (Richardson et al., 2008; Tamas et al., 2005). A study examining gender 
effects of 6-hydroxydopamine (6-OHDA) lesions on behavior and neuropathology 
showed that male rats are more sensitive to this toxicant than female rats. Male 
rats showed a greater loss of DA neurons in the SN and had greater deficits in 
locomotor activity than female rats (Tamas et al., 2005). This suggests that the 
nigrostriatal DA system is more sensitive to toxicants in male than female 
rodents. Animal models of manganism and PD share common features of 
neuropathology.  Striatal neurodegeneration and damage to the nigrostriatal DA 
pathway is present in both diseases. A recent behavioral study suggests that 
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male mice are more susceptible to Mn exposure than female mice and that the 
behavioral deficit may be related to reduced striatal DA following Mn exposure 
(Moreno et al., 2009; Simon et al., 1994).  A similar behavioral deficit has been 
found in a PD mouse model (George et al., 2008). Mn is known to cause damage 
to the nigrostriatal DA system and alter striatal MSN morphology (Guilarte et al., 
2008; Guilarte et al., 2006; Milatovic et al., 2009; Stanwood et al., 2009), but 
gender specific changes in neuron morphology following Mn exposure have not 
been previously reported.   
Previous studies carried out in our laboratory on female mice showed that 
their MSNs are vulnerable to Mn toxicity (Milatovic et al., 2009). Based on the 
literature of gender differences in Mn exposure, we hypothesized that gender 
may be a factor in Mn neuropathology. Therefore, we examined striatal MSN 
morphology and striatal Mn content 24 hours and 3 weeks following Mn exposure 
in mice of both genders to determine (1) if gender has an effect on MSN 
morphology in the presence or absence of Mn exposure, (2) if gender is a factor 
in striatal Mn accumulation and (3) if gender differences in MSN morphology are 
present when Mn levels return to baseline. 
 
Results 
Twelve-week-old mice were injected (s.c. hind limb) with Veh (water) or 50 
mg/kg MnCl2 (Mn) on experimental day 0, 3, and 6. MSN morphology was 
examined by Golgi silver impregnation on experimental day 7 (13 weeks old) and 
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day 28 (16 weeks old), which corresponds to 1 day and 3 weeks following the 
final Mn exposure, respectively. 
 
Week 13 
Total Neuron Measures 
One day following the final Mn exposure, neuron morphology studies revealed a 
strong gender difference in neuron morphology. Total spine density was subject 
to a main effect of gender (Figure 28A, Table 7). Gender differences in total 
spine density were only present in Mn exposed mice. Female mice exposed to 
Mn (Mn-F) had MSNs with higher total spine density than Mn exposed male (Mn-
M) mice (p < 0.05). There were no gender differences in total spine density of 
MSNs among Veh exposed mice. Additionally, we failed to detect a significant 
difference in total spine density between Veh and Mn exposed mice. A significant 
main effect of gender (Table 7) was found to affect total dendritic length one day 
post-exposure (Figure 28B). Gender differences in total dendritic length were 
only apparent in mice exposed to Mn. Mn-M mice had MSNs with significantly 
longer total dendritic length than Mn-F mice (p = 0.001). There was no significant 
difference in total dendritic length between genders of Veh exposed mice nor 
was there a significant difference between Veh and Mn exposed mice. Total 
spine number was also affected by gender (Table 7) one day post-exposure 
(Figure 28C). Mn-F mice had fewer total dendritic spines compared to Mn-M. 
This suggests that differences in total spine density were driven by differences in 
both total dendritic length and total spine number. 
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The total number of nodes, or dendritic branch points (Figure 28D), was 
subject to a main effect of gender (Table 7). Again, the only gender difference in 
total number of nodes was in Mn exposed mice. Mn-M mice had MSNs with more 
total nodes than Mn-F mice (p = 0.005). A main effect of gender (Table 7) was 
observed for the total number of dendrite endings (Figure 28E). Gender 
differences in total number of dendrite endings only occurred in Mn exposed 
mice. MSNs from Mn-M animals had more dendrite endings than Mn-F mice (p < 
0.01). No significant difference in total nodes or total endings was found between 
Veh and Mn exposed mice. In general, at the 13 week time point gender 
differences were only present in Mn exposed mice. This held true for all total 
neuron measures. In most cases Mn exposure decreased measures of neuron 
morphology in female mice, except total spine density which was increased in 
female mice.   
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Figure 28. Mn exposed mice exhibit gender-specific changes in MSN morphology 
one day post-Mn exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A) Total spine density was increased in female and decreased in male mice 
exposed to Mn (p = 0.011). B) Mn exposure increased total dendritic length in 
male mice but decreased total dendritic length in female mice (p < 0.001). C) 
Total number of spines were significantly different in male versus female Mn 
exposed mice ( p < 0.05). D) Male mice exposed to Mn had a significantly higher 
number of total ends than Mn exposed female mice (p < 0.011). E) Mn exposed 
male mice had more total nodes than female Mn exposed mice (p < 0.01). Mean 
+/- SEM, * p < 0.05, # p < 0.01, *** p < 0.001. 
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Morphometric measures as a function of radius 
Multiple measures of dendritic morphology were measured by Sholl 
analysis (Sholl, 1953). Briefly, concentric 10 m circles were centered at the 
soma and dendrite measures were analyzed across these circles to give a more 
detailed view of neuron morphology. Repeated measures ANOVA were used to 
analyze neuron morphology as a function of distance from the soma. There was 
a significant main effect of distance x gender on dendritic branching complexity 
as a function of distance from the soma (Figure 29A, Table 7). Gender 
differences in branching complexity were present only in Mn exposed mice. 
There were no significant differences between Veh exposed MSNs or between 
Veh and Mn exposed MSNs. Branching complexity was significantly reduced in 
Mn-F mice compared to Mn-M mice (p < 0.005). Dendrite length as a function of 
distance from the soma was measured in concentric 10 m shells (Figure 29B). 
There was a significant main effect of distance x gender on dendrite length as a 
function of distance from the soma (Table 7). Gender differences in dendrite 
length as a function of distance from the soma only occurred in Mn exposed 
mice. Mn-F mice had significantly shorter dendrite length per 10 m shell than 
Mn-M mice (p = 0.001). There were no significant differences in dendrite length 
per shell in Veh exposed mice nor were there significant differences between 
Veh and Mn exposed mice. Distance x gender had an effect (Table 7) on spine 
number as a function of distance from the soma (Figure 29C). Post hoc analysis 
revealed that Mn-F mice had fewer dendritic spines per 10m shell than Mn-M 
mice (p < 0.05). Spine density as a function of distance from the soma (Figure 
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29D) was subject to a distance x gender effect (Table 7). Post hoc analysis failed 
to detect a statistically significant difference in spine density as a function of 
distance from the soma at one day post-exposure. In sum, main effects of gender 
were apparent for all measures of dendrite morphology one day post-exposure. 
Significant differences in neuron morphology across genders occurred only in 
mice exposed to Mn.  
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Figure 29. Mn exposure causes gender-dependent changes in neuron 
morphology as function of distance from soma at one day post-Mn exposure. 
 
 
 
 
 
 
 
  
A) Mn exposed mice showed gender differences in dendritic branching as a 
function of distance from the soma (p < 0.005). B) Gender differences in dendrite 
length as a function of distance from the soma were present in Mn exposed mice 
(p < 0.001). C) Mn exposure revealed significant gender differences in spine 
number as a function of distance from the soma (p < 0.05). D) There was no 
significant difference in spine density as a function of distance from the soma 
across groups at one day post-exposure. Mean +/- SEM, * p < 0.05, *** p < 
0.001. 
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Table 7. ANOVA statistics for measures of neuron morphology one day post-
exposure. 
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Week 16 
Total Neuron Morphology 
 Measures of MSN morphology three weeks post-exposure (age 16 weeks) 
were markedly different than at one day post-exposure (age 13 weeks). Only one 
metric of neuron morphology was affected by gender three weeks post-exposure. 
Total spine density (Figure 30A) was subject to a gender x exposure interaction 
(Table 8). The gender effect was only present in Mn exposed mice. Mn-F mice 
had significantly lower total spine density than Mn-M mice (p < 0.05). Mn 
exposure caused an increase in total spine density in male mice compared to 
Veh (p < 0.05); however, Mn exposure caused a decrease in total spine density 
in female mice compared to Veh (p < 0.05). Total dendritic length (Figure 30B), 
total spine number (Figure 30C), total number of nodes (Figure 30D) and total 
number of dendrite ends (Figure 30E) exhibited no significant effects of gender or 
Mn exposure. Most measures of neuron morphology do not show gender 
differences three weeks post-exposure, however Mn exposed mice showed 
gender differences in total spine density. 
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Figure 30. Gender specific changes in neuron morphology are present only in 
total spine density of Mn exposed mice three weeks post-Mn exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
  
A) Total spine density was the only measure of neuron morphology to have a 
significant gender difference three weeks post-exposure. Mn exposed male 
mice had a higher total spine density than Mn exposed female mice (p < 
0.05). B) Total dendritic length, C) total number of spines, D) total nodes and 
E) total ends were not subject to gender effects three weeks after Mn 
exposure. Mean +/- SEM, * p < 0.05. 
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Morphometric measures as a function of radius 
 Dendrite measures as a function of distance from the soma three weeks 
post-exposure showed fewer changes in neuron morphology than one day post-
exposure. Dendritic branching complexity (Figure 31A) and dendrite length 
(Figure 31B), measured by Sholl analysis, were not influenced by gender at three 
weeks post-exposure.  
However, two measures of neuron morphology as a function of distance 
from the soma did show gender differences.  Spine number as a function of 
distance from the soma (Figure 31C) was subject to an effect of distance x 
gender x exposure (Table 8). Post hoc tests did not reveal significant pairwise 
differences in spine number per 10 m shell. Spine density as a function of 
distance from the soma (Figure 31D) was subject to main effects of distance x 
gender (Table 8), distance x exposure (Table 8) and a distance x gender x 
exposure interaction (Table 8). Post hoc analysis revealed that Mn exposure 
increased spine density as a function of distance from the soma in male mice 
compared to Veh exposure (p < 0.05). Veh-M mice had a decrease in spine 
density compared to Veh-F mice (p < 0.05).This is the only instance where a 
gender difference was observed in Veh exposed mice.  
In summary, three weeks following Mn exposure there were few gender 
differences in neuron morphology.  Spine number as a function of distance from 
the soma was subject to a distance x gender x exposure interaction. Spine 
density as a function of distance from the soma was subject to distance x gender, 
distance x exposure and distance x gender x exposure effects; however, this was 
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the only measure of neuron morphology to show gender differences in Veh 
exposed mice. 
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Figure 31. Few gender differences persist three weeks following Mn exposure. 
 
 
 
 
 
 
 
 
  
A) Dendritic branching as a function of distance from the soma and B) dendrite 
length as a function of distance from the soma exhibit no differences in neuron 
morphology across all groups. C) Spine number as a function of distance from 
the soma was subject to a distance x gender x exposure interaction (F(30,2940)= 
2.11, p < 0.001), but post hoc tests failed to find a significant difference. D) Mn 
exposure increased spine density as a function of distance from the soma in 
male mice vs Veh exposure (p < 0.05). A gender difference was present in Veh 
exposed mice (p < 0.05). Mean +/- SEM, * p < 0.05. 
158 
 
 
 
 
 
 
Table 8. ANOVA statistics for measures of neuron morphology three weeks post-
exposure. 
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Effects of gender on sensitivity to Mn across age 
 Mice at three weeks post-exposure did not show the same gender 
sensitivity to Mn exposure as mice one day post-exposure. We examined neuron 
morphology across time from exposure groups to gain a better understanding of 
factors important to this difference in susceptibility. Total spine density (Table 9) 
was subject to a main effect of time from exposure (Table 10) and a time from 
exposure x gender x exposure interaction (Table 10). Mn exposed mice had 
differential changes in total spine density across gender at both time points (p < 
0.05). Time from exposure dependent changes in total spine density were 
observed in Veh exposed male mice and Mn exposed female mice (p < 0.01). Mn 
exposure had opposing effects on total spine density in male and female mice at 
three weeks post-exposure (p < 0.05) but no significant effect one day post-
exposure. Total dendritic length (Table 9) was subject to a main effect of time 
from exposure (Table 10) and a time from exposure x gender interaction (Table 
4). These effects were due to the fact that gender effects only occurred one day 
post-exposure in Mn exposed animals (p < 0.005). Time from exposure had a 
significant effect on total dendritic length in female mice only. Mn and Veh 
exposed female mice had an increase in total dendritic length three weeks post-
exposure compared to one day post-exposure (p < 0.05). 
Total number of nodes (Table 9) was subject to a main effect of gender 
(Table 10), time from exposure (Table 10) and a time from exposure x gender 
interaction (Table 10). A gender difference in total number of nodes was only 
present one day post-exposure in Mn exposed mice (p < 0.01). Total number of 
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nodes changed from one day to three weeks post-exposure in female mice only 
in both Mn and Veh exposed mice (p < 0.05) The total number of ends (Table 9) 
was subject to a main effect of gender (Table 10), time from exposure (Table 10) 
and a time from exposure x gender interaction (Table 10). Gender differences in 
total number of endings only occurred in Mn exposed mice one day post-
exposure (p <0.01). A time from exposure effect was present only in Veh 
exposed female mice (p < 0.05). 
Dendritic branching as a function of distance from the soma was subject to 
a distance x time from exposure effect (Table 10), a distance x gender effect 
(Table 10) and a distance x time from exposure x gender interaction (Table 10). 
Dendritic branching complexity in 13 but not 16 week old Mn exposed mice was 
subject to gender effects (Figure 29 and Figure 31). Gender differences in 
dendritic branching complexity were present in 13 week Mn exposed mice only (p 
< 0.005). The effect of time from exposure was present in both Mn and Veh 
exposed female mice (p < 0.05). Dendrite length as a function of distance from 
the soma (Figure 29 and Figure 31) was subject to a distance x time from 
exposure effect (Table 10), a distance x gender effect (Table 10) and a distance 
x time from exposure x gender interaction (Table 10). Similar to dendritic 
branching complexity, gender differences were only present in Mn exposed mice 
at one day but not three weeks after Mn exposure (p < 0.005). Also, time from 
exposure effects were found in both Mn and Veh exposed female mice (p < 
0.05). Spine number as a function of distance from the soma (Figure 29 and 
Figure 31) was subject to a distance x gender effect (Table 10). However, post 
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hoc analysis failed to detect a significant difference between exposure groups. 
Spine density as a function of distance from the soma (Figure 29 and Figure 31) 
was subject to a distance x time from exposure (Table 10), distance x time from 
exposure x exposure (Table 10), a distance x time from exposure x gender effect 
(Table 10) and a distance x time from exposure x gender x exposure effect 
(Table 10). Mn exposure had an effect at three weeks post-exposure in male 
mice only (p < 0.05). A gender dependent difference in spine density as a 
function of distance from the soma was present only in Veh exposed female mice 
at three weeks (p < 0.05). An effect of time from exposure was present in Mn 
exposed female mice and Veh exposed male mice (p < 0.001). 
 In summary, mice one day post-exposure were more susceptible to 
gender differences in response to Mn exposure than at three weeks post-
exposure. One day following Mn exposure all measures of neuron morphology 
were subject to gender based differences in response to Mn exposure. At three 
weeks post-exposure there were only two measures of neuron morphology that 
changed differently across gender following Mn exposure: total spine density and 
spine number as a function of distance from the soma. Spine density as a 
function of distance from the soma was the only characteristic of neuron 
morphology to show gender differences in Veh exposed mice. The only measure 
of neuron morphology subject to gender effects at both one day and three weeks 
post-exposure was total spine density.  
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Striatal Mn levels are insensitive to gender 
Because there were gender differences in striatal MSN morphology in WT 
mice exposed to Mn, we analyzed striatal Mn levels by ICP-MS (Figure 32) to 
determine if gender plays a role in striatal Mn accumulation or if Mn levels can 
alter neuron morphology.  At 24 hours following the last Mn exposure (Figure 
32A), there was a significant effect of exposure (F(1,10)= 405.89, p < 0.001). No 
significant effects of gender or a gender x exposure interaction were detected. 
Mn exposed mice of both genders had elevated striatal Mn levels compared to all 
Veh exposed mice (p < 0.001). There was no difference in striatal Mn between 
genders (p > 0.7). By three weeks Mn was almost completely cleared from the 
striatum (Figure 32B). There was only a trend towards statistical significance for 
the main effect of exposure (F(1,6)= 4.50, p = 0.078) on striatal Mn levels. Again, 
there was no effect of gender and no gender x exposure interaction for striatal 
Mn at three weeks post-exposure. Our data show that gender plays no role in 
differential Mn accumulation in the striatum. Therefore, differential striatal Mn 
accumulation cannot account for gender differences in neuron morphology in Mn 
exposed mice. 
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Figure 32. No gender difference in striatal Mn accumulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A) Mn exposure significantly elevated striatal Mn above Veh exposed mice (p 
< 0.001), but there was no difference in Mn accumulation between genders (p 
> 0.70). B) Striatal Mn was eliminated from the striatum by three weeks 
following exposure. No gender differences in striatal Mn were present. Mean 
+/- SEM, *** p < 0.001. 
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YAC128 mice show no gender differences 
 YAC128 mice exhibited no gender-dependent differences in neuron 
morphology. Veh exposed mice did not show gender differences in neuron 
morphology at 13 or 16 weeks. Unlike WT mice, Mn exposure of YAC128 mice 
did not result in gender-dependent differences in neuron morphology at either 
time point. 
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Figure 33. YAC128 neuron morphology is not affected by gender.  
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Figure 34. YAC128 MSN morphology as a function of distance from the soma is 
not affected by gender.  
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Figure 35. Mn accumulation in the striatum of YAC128 mice is not affected by 
gender. 
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Discussion 
 In this study we report gender-specific changes in striatal MSN 
morphology in mice exposed to Mn. We demonstrate that these gender-specific 
alterations in MSN morphology are not due to differential accumulation of Mn in 
the striatum of these mice. The gender effects were most pronounced one day 
post-exposure when Mn levels are elevated, but were also present at three 
weeks after Mn levels returned to baseline. To our knowledge, this is the first 
demonstration of gender-dependent differences in neuropathology following Mn 
exposure. 
 
Gender differences parallel striatal Mn levels 
Gender differences in neuron morphology parallel striatal Mn levels. Differences 
in neuron morphology between genders were more prevalent one day post-
exposure when Mn levels were elevated (Figures 1 and 2). We detected no 
difference between genders in Mn accumulation in the striatum (Figure 5). This 
suggests that excess Mn may interact with gender-specific hormones to alter 
neuron morphology. When striatal Mn returns to baseline levels, most gender 
differences in neuron morphology disappear. However, there are long lasting 
gender-dependent changes in neuron morphology that remain, even when Mn 
levels have returned to baseline three weeks post-exposure (Figures 3 and 4). 
This suggests that these changes are not solely dependent on transient 
increases in Mn levels, but that neuron morphology has been altered long-term.  
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The results extend findings from a previous study from our laboratory 
examining MSN morphology in female mice only (Milatovic et al., 2009). The 
previous study used the same exposure schedule as ours; however C57Bl/6 
mice were exposed to a higher dose of Mn (100 mg/kg MnCl2) at a younger age 
(6-8 weeks old) than in our study. Only female mice were used in that experiment 
and were sacrificed 24 hours after the last exposure, which is equivalent in 
duration to our one day post-exposure time point. Milatovic et al. (2009) found a 
decrease in total dendritic length and total spine number in Mn exposed mice. 
Although our results do not show a statistically significant decrease in total 
dendritic length in Mn-F vs Veh-F mice (Figure 1), Mn-F MSNs do have shorter 
total dendritic length compared to Mn-M (p < 0.001). Similarly, we saw a 
significant difference in total spine number, total spine density, total number of 
nodes and total number of endings between Mn-F and Mn-M MSNs (Figure 1). 
Milatovic et al. (2009) showed that female mice experience changes in MSN 
morphology after Mn exposure and our findings add to this by demonstrating that 
these changes in MSN morphology are gender-specific. 
 
Gender differences in neuron morphology in the literature 
 Few accounts of gender differences in environmental modulation of 
neuron morphology, regardless of brain region, have been reported in the 
literature. Two examples are chronic restraint stress and environmental 
enrichment (EE), both of which have been shown to have differential effects on 
neuron morphology depending on gender (Galea et al., 1997; Juraska, 1984; 
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Juraska et al., 1985; Juraska et al., 1989). In the case of chronic restraint, male 
rats had a decrease in CA3 pyramidal cell apical branching and dendritic length 
while the apical branches of female rats were unaffected. However, female rats 
did experience decreased branching complexity in the basilar dendritic arbor 
(Galea et al., 1997). EE affected pyramidal neurons in visual cortex differently 
than in the dentate gyrus and CA3 region of the hippocampus. In the visual 
cortex, EE caused an increase in dendrite length of layer III and layer IV 
pyramidal cells from male rats (Juraska, 1984). In the dentate gyrus, female rats 
with EE showed an increase in branching complexity compared to males 
(Juraska et al., 1985). EE caused differential changes in the apical arbor of CA3 
pyramidal cells across gender and radius from the soma. Proximal to the soma, 
CA3 pyramidal cells from female rats with EE had a higher branching complexity 
than males with EE. Distal to the soma, male rats had CA3 pyramidal cells with a 
higher branching complexity than female rats with EE (Juraska et al., 1989). In 
each of these examples, the exposure had a different effect on neurons from 
each gender. There were differential effects on neurons in different brain regions 
from the same exposure. These studies provide evidence that neurons can 
respond differently to an environment based on the gender of the animal.  
Interestingly, in our study several parameters of neuron morphology 
(Figure 1 and Figure 3) showed gender-specific changes in opposite directions 
upon exposure to Mn. Compared to females, male mice exposed to Mn showed 
larger changes in neuron morphology (Figure 1 and 2). Gender differences in 
MSN morphology in control animals have not been previously reported in the 
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literature. We found only one instance in which there was a gender difference in 
neuron morphology in Veh exposed mice (Figure 4D). However the majority of 
our data suggest that gender differences in MSN morphology are only revealed 
upon exposure to an insult (Figure 1-4). If gender is ignored, Mn exposure was 
not sufficient to cause significant changes in neuron morphology from control, 
one day following our 1-week exposure paradigm; however, Mn exposure did 
cause differential responses of MSNs between genders. Estrogen may be 
responsible for the gender specific changes in neuron morphology upon 
exposure to Mn (Lee et al., 2009a; Lee et al., 2009b). 
 
Estrogen may be neuroprotective 
Mn neuropathology shares similarities to PD neuropathology (Garcia et al., 2010; 
Milatovic et al., 2009; Stanwood et al., 2009; Zaja-Milatovic et al., 2005). Gender 
differences in PD have been frequently documented (Miller and Cronin-Golomb, 
2010; Shulman, 2007). Men have a higher risk of PD (2:1), an earlier age of 
onset, and present with bradykinesia or rigidity. Females have an average age of 
onset 2 years later than males and present with resting tremor as their first sign 
of disease. Nigrostriatal dopamine (DA) uptake binding sites were quantified by 
single photon emission computed tomography (SPECT) using the radioligand 
[123I]FP-CIT and women were found to have more binding sites for DA uptake 
than men (Haaxma et al., 2007). The later onset in PD, milder initial symptoms 
and a nigrostriatal DA system that is more intact in females has been 
hypothesized to be due to estrogen. Estrogen has been shown to play a role in 
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maintaining nigrostriatal DA neurons and in striatal MSN maturation (Leranth et 
al., 2000; Stroppolo et al., 2004). Female rodents are less sensitive to 
nigrostriatal damage due to DA toxicants (Richardson et al., 2008; Tamas et al., 
2005). Estrogen has been shown to be protective in multiple neurotoxicant 
models of PD (Baraka et al., 2011; Miller et al., 1998; Morale et al., 2008; 
Ookubo et al., 2008; Smith et al., 2007). Similarly, primary cortical neurons and 
astrocytes are protected from Mn-induced toxicity by pre-treatment with estrogen 
or tamoxifen (Lee et al., 2009a; Lee et al., 2009b). Moreno et al. (2011) recently 
demonstrated that young male mice supplemented with estrogen do not exhibit 
decreased striatal DA levels. Additionally, protein nitrosylation in the SN and glial 
inflammatory signaling in the striatum and SN are decreased in estrogen 
supplemented male mice exposed to Mn. These data suggest that changes in 
MSN morphology in female mice exposed to Mn (Figure 1 and 2) may be less 
pronounced as a result of higher estrogen levels (compared to males).  
Changes in total spine density similar to what we observed in our mouse 
model, may lead to parkinsonian-like symptoms in Mn-exposed humans. This is 
because MSN dendritic spines are the primary recipients of glutamatergic and 
DA input to the striatum. This input is critical to normal motor function. If the input 
to the striatum is altered, the ability of the striatum to integrate and relay 
information through the extrapyramidal motor system, and therefore motor 
function, may be impaired (Deutch et al., 2007). Alterations in total spine density 
are evident in MSNs from post-mortem human PD patients and animal models of 
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PD both of which show motor dysfunction similar to manganism associated motor 
symptoms (Garcia et al., 2010; Zaja-Milatovic et al., 2005). 
 
YAC128 mice do not show gender difference 
 YAC128 mice did not show gender differences in neuron morphology 
following Veh or Mn exposure. This suggests that mHTT can interact with sex 
hormones or Mn in a way that blocks the gender specific differences in neuron 
morphology from occurring. Gender differences in YAC128 mice have been 
observed for various motor and behavior phenotypes (Bode et al., 2008; Dorner 
et al., 2007; Orr et al., 2008; Zajac et al., 2010). Male YAC128 mice had a 
reduced total distance traveled in an open field test compared to female mice at 
16 weeks (Menalled 2009). The gender differences in total distance traveled are 
not due to gender specific differences in MSN morphology at this age since we 
detected no significant gender differences in YAC128 mice. However, the 
genotype effect of reduced motor activity may be related to changes in neuron 
morphology that we previously reported (Madison et al., 2011). Other gender 
differences in weight, rearing activity and light-dark preference occurred at older 
ages not relevant to this study (Menalled 2009). 
 
Conclusions 
In summary, we report gender differences in striatal MSN morphology in 
response to elevated Mn levels in WT but not YAC128 mice. These gender 
dependent changes in neuron morphology correlated with elevated Mn in the 
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striatum, however this was not due to differential Mn accumulation between 
genders. Although the gender effects were more prevalent at 13 weeks when Mn 
levels were elevated, we also observed gender effects at 16 weeks when Mn 
levels were back to baseline. These data raise three important points to consider 
in future studies of Mn toxicity. First, gender may play an important role in 
neuropathology following exposure to Mn. Second, gender-dependent changes 
may be transient and occur only when Mn levels are elevated. Finally, not all 
readouts of Mn toxicity may be dependent on gender. However, that does not 
mean that gender differences are meaningless, rather that gender should always 
be considered as an important factor in Mn toxicity.     
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CHAPTER VIII 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Discussion 
The novel findings of these studies include (1) identification of the onset of 
striatal dendritic pathology and neurochemical changes in YAC128 HD mice 
between 13 and 16 weeks old, (2) identifying in vivo correlates of diseae-toxicant 
interaction between mutant HTT and Mn, (3) discovering gender specific Mn-
induced changes in striatal MSN morphology that are most pronounced when 
striatal Mn is elevated and (4) determining that gender differences in MSN 
morphology are not present in YAC128 Veh or Mn exposed mice. 
 
NMDAR excitotoxicity 
The morphological changes that we identified in YAC128-Veh MSNs at 16 
weeks may be due to alterations in striatal neurotransmitter content that promote 
glutamatergic excitotoxicity. Disruption of the nigrostriatal DA system, which 
occurs in Parkinson‟s disease (PD), is known to cause morphological alterations 
in MSNs of the striatum. 6-hydroxydopamine (6-OHDA) lesions of the SN, a 
rodent model of PD, have been shown to cause dopaminergic cell death in the 
SN, a decrease in striatal DA and a reduction in dendritic spine density of MSNs 
(Day et al., 2006; Ingham et al., 1989; Ingham et al., 1993; Ingham et al., 1998). 
DA release in the striatum decreases corticostriatal Glu release through 
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stimulation of the D2 autoreceptor on presynaptic glutamatergic terminals 
(Bamford et al., 2004). If DA levels are reduced, as is the case in the YAC128-
Veh mice at 16 weeks, Glu release may become dysregulated and lead to 
excitotoxicity. Presynaptic dysfunction of the corticostriatal glutamatergic 
synapse is detectible before YAC128 mice become symptomatic (Milnerwood 
and Raymond, 2007). Additionally, the response of the glutamatergic 
corticostriatal terminal to DA changes as the YAC128 mice progress from a 
presymptomatic to a symptomatic state (Joshi et al., 2009). The decrease in 
striatal DA levels that we observed in YAC128-Veh mice at 16 weeks may further 
contribute to the dysfunction of the corticostriatal terminal. 
In addition to changes in the nigrostriatal DA system, amino acids Gly and 
Ser were also elevated in the striatum. The amino acid L-Ser is converted into 
the NMDA co-agonist D-Ser by the enzyme serine racemase that is expressed in 
the MSNs of the striatum (Miya et al., 2008; Pollegioni and Sacchi, 2010). 
Elevation of these co-agonists may facilitate signaling through the NMDAR, 
which is consistent with the sensitivity to NMDAR exictotoxicity present in 
YAC128 mice. Increased levels of these neurotransmitters are also present in 
other neurodegenerative diseases. An increase in spinal cord Ser has been 
identified as a key factor in Glu toxicity in animal models of amyotrophic lateral 
sclerosis (ALS) (Sasabe et al., 2007) and PD patients have been shown to have 
an increase in plasma Gly (Iwasaki et al., 1992). Importantly, Gly levels were 
found to be elevated in HD patient platelets and CSF (Nicoli et al., 1993; 
Reilmann et al., 1997). 
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Not only do YAC128 mice have an increase in NMDAR co-agonists Ser 
and Gly, they also have an increase in NR2B expressing extrasynaptic NMDA 
receptors (Milnerwood et al., 2010). YAC128 mice are known to be sensitive to 
NMDAR excitotoxicity and signaling through extrasynaptic NMDARs has been 
shown to increase apoptosis of MSNs in these mice (Fernandes et al., 2007; 
Graham et al., 2009; Graham et al., 2006; Shehadeh et al., 2006; Tang et al., 
2005; Zeron et al., 2004; Zeron et al., 2002). However, two groups have found 
that treatment of YAC128 mice with memantine to reduce signaling through 
extrasynaptic NMDARs is neuroprotective and improve motor function 
(Milnerwood et al., 2010; Okamoto et al., 2009). 
We have found multiple factors that may contribute to NMDAR dependent 
excitotoxicity in YAC128 mice at the 16 week time point. First, we observed an 
increase in striatal MSN dendritic spine density. This increase in spine density 
could lead to excitotoxicity through the glutamatergic inputs that synapse 
primarily onto dendritic spine heads, where NMDARs are localized. Secondly, we 
found a reduction in striatal DA that may result in less modulation of 
glutamatergic signaling at dendritic spines. Finally, an increase in striatal levels of 
NMDAR co-agonists Ser and Gly may facilitate signaling through the NMDAR. 
The facilitation of NMDAR signaling in the context of increased dendritic spine 
density and dysregulation of Glu release likely contributes to an excitotoxic 
environment.  
Reducing NMDAR excitotoxicity may have a positive effect on HD. Two 
recent studies in YAC128 mice support the hypothesis that reducing 
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extrasynaptic NMDAR signaling can reduce Glu excitotoxicity in HD mice 
(Milnerwood et al., 2010; Okamoto et al., 2009). Memantine is an uncompetitive 
open-channel NMDAR antagonist that has been shown to have selectivity for 
extrasynaptic NMDARs at low concentrations (Lipton, 2006; Lipton, 2007). 
YAC128 mice were administered memantine in water at 1 mg/kg/day or 30 
mg/kg/day from the age of 2-12 months. Behavior and gross neuropathology 
were assessed at 12 months and compared to 12 month old untreated YAC128 
at WT mice. Low dose memantine (1 mg/kg/day) improved motor function and 
prevented a loss of striatal volume at 12 months. However, high dose memantine 
(30 mg/kg/day) worsened striatal volume loss and failed to improve motor 
function (Okamoto et al., 2009). Although YAC128 mice show only subtle 
neuropathology at 2-4 months (Madison et al., 2011), they do show a procedural 
learning deficit (Van Raamsdonk et al., 2005b).  A second independent study 
examined if the procedural learning deficit could be rectified by treatment with 
memantine. Two month old YAC128 mice were treated with 1 mg/kg/day 
memantine and tested at four months. Memantine treatment prevented the 
procedural learning deficit in YAC128 mice. These studies support the 
hypothesis that reducing NMDAR excitotoxicity can result in marked 
improvement in HD animal models. 
There have been few clinical studies on the effectiveness of memantine in 
HD. The first published account of memantine clinical trials for HD was a 
multicenter open label prospective trial over two years (Beister et al., 2004). 
Subjects with HD were titrated up to 30 mg/day memantine and assessed prior to 
181 
 
starting treatment, at one year and two years. The authors detected no significant 
improvement or deterioration after treatment with memantine. Importantly, there 
was no significant increase in choreiform movements during the trial. The HD 
Study Group showed a 5.3% decrease in motor function over 6 months in 
untreated HD patients. This trial showed only a 4.3% decrease in motor function 
over 2 years. Data from this trial suggest that memantine appears to be 
promising in slowing the progression of HD. The only other published clinical trial 
of memantine in HD was a single center open label trial at Baylor College of 
Medicine Movement Disorders Center (Ondo et al., 2007). HD subjects were 
titrated to 20 mg/day of memantine over one month and continued at this dose 
for three months. There was no significant change in cognition, behavior, total 
functional capacity or independence; however a significant decrease in chorea 
was detected at the final examination. These clinical trials suggest that 
memantine may be beneficial in HD. A randomized, double-blind crossover study 
was initiated in 2008 (Trial NCT00652457), but there have been no reports on 
this trial since its posting (http://clinicaltrials.gov/ct2/show/NCT00652457). 
 
Oxidative stress 
  Oxidative stress is severely damaging to cellular function and vitality. 
Oxidative damage can occur to DNA, proteins and lipids through reactive oxygen 
species (ROS). Mn exposure (Benedetto et al., 2010; dos Santos et al., 2010; 
Lee et al., 2009b; Li et al., 2011; Milatovic et al., 2007; Milatovic et al., 2009; 
Zhang et al., 2007) and expression of mutant HTT (Bogdanov et al., 2001; 
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Browne et al., 1997; Gu et al., 1996; Mann et al., 1990; Perez-Severiano et al., 
2004; Perluigi et al., 2005; Tabrizi et al., 1999; Tabrizi et al., 2000; Wyttenbach et 
al., 2002; Zourlidou et al., 2007) have both been shown to increase ROS in the 
brain. Glu excitotoxicity is known to cause generation of ROS though stimulation 
of the NMDAR, increase intracellular Ca2+ that overwhelms the mitochondria and 
causes production of ROS (Choi et al., 1987; Rao et al., 2003; Reynolds and 
Hastings, 1995). Rao et al. (2003) showed that ROS generated in neurons could 
pass through the plasma membrane and impair astrocyte Glu transporter 
function, thus perpetuating the cycle of Glu excitotoxicity.  
 
Contribution of astrocytes 
 Although astrocytes were not examined in these studies, they play an 
important role in both Mn exposure and HD. Astrocytes are important regulators 
of neuron function and cerebral blood flow. One of the most important metabolic 
functions of astrocytes is the glutamate-glutamine (Gln) shuttle. Astrocytes take 
up most of the extracellular Glu through the glutamate-aspartate transporter 
(GLAST or excitatory amino acid transporter 1, EAAT1 in humans) or glutamate 
transporter-1 (GLT-1, or EAAT2 in humans) and convert it into Gln through the 
Mn-containing enzyme glutamine synthetase (GS). Gln is then shuttled to 
neurons to serve as precursors to Glu and GABA. Through this amino acid 
shuttle, astrocytes protect neurons from Glu excitotoxicity by rapidly taking up 
excess Glu in the synaptic cleft. GLT-1 knock-out mice show phenotypes 
consistent with excitotoxicity; namely hyperexcitability and lethal spontaneous 
183 
 
seizures (Tanaka et al., 1997). This shows the important role of astrocytes in 
regulating extracellular Glu to prevent excitotoxicity. 
Astrocytes are a reservoir for Mn because as much as 80% of Mn in the 
brain is associated with the astrocytic enzyme GS (Tiffany-Castiglion and Qian, 
2001; Wedler et al., 1989). Exposure of cultured astrocytes to elevated levels of 
Mn causes a decrease in expression of Glu and Gln transporters (Lee et al., 
2009a; Sidoryk-Wegrzynowicz et al., 2009; Sidoryk-Wegrzynowicz et al., 2010). 
Similarly, exposure to CHO cells expressing GLAST and GLT-1 shows a 
significant decrease in Glu uptake following Mn exposure (Mutkus et al., 2005). 
This can result in higher extracellular Glu levels and lead to excitotoxicity, similar 
to the GLT-1 knock-out animals. Mn exposure in rats confirms the decrease in 
striatal GLT-1 and GLAST expression in vivo (Deng et al., 2009). In the studies 
discussed herein, we found no significant effect of Mn exposure on striatal Glu; 
however we measured the amount of Glu in whole tissue and were not able to 
determine extracellular Glu levels. Perhaps if microdialysis studies were 
conducted, one could determine if this Mn exposure paradigm did indeed result 
in increased striatal extracellular Glu. 
As previously mentioned, MSNs in the YAC128 mice are more sensitive to 
NMDAR induced excitotoxicity than WT mice (Fernandes et al., 2007; Graham et 
al., 2009; Milnerwood et al., 2010). Thus, dysfunction in astrocyte function in 
these mice may lead to an inability to correctly regulate Glu levels in the striatum 
and lead to excitotoxicity. Post-mortem studies of HD patients have shown a 
decrease in mRNA and protein expression of GLT-1 that is correlated with 
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disease severity (Arzberger et al., 1997; Faideau et al., 2010). Additionally, 
cortical Glu uptake in severely reduced in HD patients in a grade dependent 
manner (Hassel et al., 2008). Studies in R6/2 mice have also shown a decrease 
in GLT-1 expression in the striatum and cortex at 12 weeks (Behrens et al., 2002; 
Faideau et al., 2010; Lievens et al., 2001). A transgenic mouse model expressing 
mutant HTT in astrocytes only showed symptoms similar to mice that express 
mutant HTT ubiquitously. These mice also show a reduction in GLT-1 expression 
that is due to increased binding of mutant HTT with the transcription factor Sp1 
that decreases binding of Sp1 to the GLT-1 promoter (Bradford et al., 2009). 
Treatment of R6/2 mice with ceftriaxone, a beta-lactam antibiotic that has been 
shown to increase Glu transporter expression, improves motor symptoms, 
decreases extracellular Glu and increases protein expression of GLT-1 (Miller et 
al., 2008; Sari et al., 2010).  
Dysfunction of astrocytes has not been thoroughly studied in YAC128 
mice thus far. The few studies that have examined astrocytes have not found 
significant changes in YAC128 astrocytes (Battaglia et al., 2011; Ellrichmann et 
al., 2011). Our studies are consistent with Glu excitotoxicity in 16 week old 
YAC128 mice. Astrocyte dysfunction may contribute to the Glu excitotoxicity 
through downregulation of Glu transporter expression and function like in the 
R6/2 mouse model and human HD patients. If in fact, there is a reduction in 
GLAST and/or GLT-1 expression or function, this would result in an increase in 
extracellular Glu. This, in combination with elevated striatal Gly and Ser levels 
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would certainly be able to potentiate signaling through extrasynaptic NR2B 
containing NMDARs and initiate apoptosis in MSNs. 
Together, these data also suggest that the gene-environment interaction 
between mutant HTT and Mn may be detrimental to astrocyte and ultimately 
neuron function. In both Mn overexposure and mutant HTT expression, there is a 
reduction in expression and/or function of astrocytic Glu transporters that can 
lead to excitotoxicity. However, it is also possible for an antagonistic relationship 
to occur between Mn and mutant HTT like in the case of striatal DA levels. In 
both WT-Mn and YAC128-Veh mice, DA levels were reduced compared to WT-
Veh. One might expect that the combination of mutant HTT expression and Mn 
exposure might further reduce DA levels. However, we observed an antagonistic 
effect between Mn and mutant HTT, where DA levels were not reduced further 
than the single insults of Mn exposure or mutant HTT expression. It is possible 
that a similar antagonistic relationship may occur for astrocyte function or that the 
disease-toxicant interaction may be additive or synergistic and damage 
astrocytes further that either insult individually. 
 
Direct vs indirect pathway 
The indirect pathway in the basal ganglia has been shown to be more 
affected in human patients with HD. A post-mortem study of DA receptors in the 
striatum of HD subjects showed a decrease in the number of cells expressing D1 
and D2 receptor mRNA. There was a significant reduction in D2R mRNA per cell 
that correlated with disease progression, but no decrease in D1R mRNA per cell 
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(Augood et al., 1997). Positron emission tomography (PET) imaging over time 
shows a progressive loss of D2Rs in the striatum (Brandt et al., 1990; Feigin et 
al., 2007; Ginovart et al., 1997; Pavese et al., 2010). One study carried out over 
more than three years showed a greater loss of D2Rs over time in asymptomatic 
subjects, but a greater loss of D1Rs over time in symptomatic HD subjects 
(Andrews et al., 1999). Animal studies have shown mixed results as to which 
pathway is more affected in HD. Some studies show a greater or earlier 
dysfunction of the D1R, and therefore the direct pathway (Andre et al., 2011; Cha 
et al., 1998; Kung et al., 2007; Tang et al., 2007), while others show a greater 
dysfunction of the D2R, indirect pathway (Cummings et al., 2007; Joshi et al., 
2009; Spektor et al., 2002; Vetter et al., 2003; Xie et al., 2010).  
Andre et al., (2011) crossed YAC128 mice with mice that express 
enhanced green fluorescent protein under the control of either the D1R promoter 
or the D2R promoter to be able to distinguish between these subpopulations of 
MSNs. Electrophysiology studies were carried out on these distinct 
subpopulations of MSNs from 1.5 months to 12 months old. Andre et al. (2011) 
found that D1R expressing MSNs were affected to a greater extent than D2R 
expressing MSNs at pre-symptomatic and symptomatic stages. Andre et al. 
(2011) found that there was an increase in Glu release onto D1R expressing 
MSNs at 1.5 months that may result in the hyperkinetic phenotype. Additionally, 
studies implicating the indirect pathway generally show a decrease in signaling 
through or expression of the D2R. This would result in an increase in motor 
behavior as the indirect pathway is responsible for decreasing motor activity. 
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Together these data show the hyperactivity exhibited by YAC128 mice at 12 
weeks may be due to a decrease in D2R signaling and an increase in D1R 
signaling.  Unfortunately, our studies are not able to shed light onto whether 
there are changes in MSN morphology of one or both subtypes due to the 
limitations of Golgi impregnation. 
 
Gender contribution 
Gender dependent differences in MSN morphology were only observed in 
Mn exposed WT mice and were more prominent when Mn levels were elevated. 
The fact that YAC128 mice showed no gender differences upon exposure to Veh 
or Mn suggests that mutant HTT interacts with sex hormones or Mn to prevent 
their interaction or mutant HTT may act downstream of the interaction between 
Mn and sex hormones to block the gender effect. Unfortunately there is very little 
known about gender differences in neuron morphology under normal conditions, 
let alone following exposure to a toxicant or in a disease state. As previously 
stated, the vast majority (40-60%) of in vivo neuroscience or pharmacology 
experiments use only male animals (Wald and Wu, 2010). Both genders are 
used only 10-20% of the time in neuroscience or pharmacology experiments. 
Animals of unspecified gender are used approximately 5-20% of the time and a 
very small percentage, less than 20%, use female animals only. Furthermore, 
even when both genders are included in experiments, only two-thirds of those 
manuscripts included gender as a factor in data analysis (Wald, 2010). This 
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severely limits the knowledge we have about gender differences in response to 
disease or toxicant exposure. 
 
Implications 
 These studies may provide some insight into whether Mn exposure can 
alter the onset or progression of HD. We show that Mn exposure altered the 
neurochemical environment of the striatum and affected MSN morphology in 
YAC128 mice. Previous work has demonstrated that survival of striatal cells 
expressing mutant HTT was bolstered by low concentrations of Mn (Williams et 
al., 2010b). Several potential scenarios may occur with HD patients exposed to 
Mn. First, HD patients may be protected from Mn toxicity due to reduced 
accumulation of Mn in the neostriatum. A second scenario is that HD patients 
may accumulate less Mn in the striatum, but may be rendered more sensitive to 
fluctuations in Mn levels due to mutant HTT. This is exemplified by the 
morphological changes as a function of distance from the soma observed in 
YAC128-Mn treated mice compared to WT-Mn mice. Although not reaching 
statistical significance, there are trends towards a greater effect of Mn on MSN 
morphology in YAC128 mice (Figures 4 and 5). These HD mutant mice at 3-4 
months old have been shown to be more sensitive to NMDAR induced 
excitotoxicity (Graham et al., 2009) and Mn exposure results in an increase in 
NMDAR co-agonists Ser and Gly. Although, Mn rescues the elevated amino 
acids by 16 weeks in YAC128 mice, the facilitation of NMDAR signaling at 13 
weeks may have initiated events leading to morphological changes in MSNs. In 
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this scenario mutant HTT may interact with Mn transport resulting in less Mn 
accumulation in the striatum. These mice may not have the ability to correctly 
modulate excess Mn following exposure. This means that even though less Mn is 
getting into the striatum of YAC128 mice, they are not able to effectively handle 
this increase of Mn, thus rendering them more sensitive to changes in Mn levels.  
Another scenario that may increase Mn toxicity is development of Fe 
deficiency anemia in HD subjects. Fe-deficient humans and mice have been 
shown to accumulate higher levels of Mn compared to non-Fe deficient subjects 
(Fitsanakis et al., 2008; Kim et al., 2005). We recently reported that defects in the 
Fe transport system are not responsible for the reduced Mn accumulation in 
striatal cells expressing mutant HTT (Williams et al., 2010a). Furthermore, the 
Fe:Mn ratio may be an important consideration in neurotoxicity of these metals 
since an imbalance in their pro-oxidant and anti-oxidant roles may result in 
production of reactive oxygen species (Dobson et al., 2004). Other 
considerations are the duration, route and level of Mn exposure encountered by 
HD patients. Manganism is typically observed after very high levels of Mn 
exposure after a relatively short time whereas Mn-induced parkinsonian 
symptoms are usually present after a continuous exposure to low level Mn 
(Lucchini et al., 2009). Based on this, we would expect radically different effects 
of Mn on the onset and progression of HD depending on the route and duration 
of Mn exposure encountered. 
Although our in vitro and in vivo models of HD have shown a disease-
toxicant interaction between mutant HTT and Mn, it remains to be seen whether 
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human patients share the phenotype. Our research, thus far, is not conclusive as 
to whether Mn exposure has a beneficial or detrimental effect on HD onset and 
progression. In some instances, Mn exposure normalized amino acids that were 
elevated by mutant HTT, such as Gly and Ser, back to WT-Veh levels at week 
16. On the other hand, Mn exposure also causes acute neurochemical changes 
that may result in morphological alterations in MSNs. At this point, we do not 
know precisely how the morphometric changes we observe affect neuron 
function, or how they continue to change with time. 
 The research described in Chapter VI demonstrates that male and female 
MSNs respond differently to Mn exposure. Gender differences in response to Mn 
exposure have rarely been examined. A recent study of cognition in children 
exposed to environmental Mn suggests that although children of both genders 
accumulate similar levels of Mn, it affects their cognitive function differently 
(Riojas-Rodriguez et al., 2010). These studies provide compelling evidence for 
further study of gender differences in response to toxicant exposure and disease. 
The use of both genders in preclinical research may elucidate data early on that 
would allow for targeted therapies that would benefit patients of both genders. 
 
Future Directions 
 Continued efforts must be made to understand the disease-toxicant 
interaction between HD and Mn to determine if this interaction is beneficial or 
detrimental to disease onset and progression. Studies should be carried out to 
examine the contribution of astrocyte dysfunction in the HD-Mn disease-toxicant 
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interaction. As of yet, no studies have been undertaken to examine astrocytes in 
YAC128 mice. Two studies reported no changes in protein expression in 
astrocytes from YAC128 mice, but an in depth examination of astrocytes of these 
animals has not been done (Battaglia et al., 2011; Ellrichmann et al., 2011). 
Future experiments should be carried out to determine astrocyte function in 
YAC128 mice and how Mn exposure alters YAC128 astrocytes. The rate and 
amount of Mn uptake in astrocytes of WT and YAC128 mice should be 
examined. Glu uptake by astrocytes in the absence and presence of Mn should 
also be examined to determine if astrocyte dysfunction adds to the Glu 
excitotoxicity that has been described in the YAC128 mice. Measurement of 
oxidative stress and response to oxidative stress through signaling pathways can 
also give insight into the health and function of YAC128 astrocytes. 
 While it appears that the D1R expressing MSNs in YAC128 mice are 
affected earlier than D2R expressing MSNs, the evidence in humans shows that 
D2R expressing MSNs are more affected (Andre et al., 2011; Augood et al., 
1997; Brandt et al., 1990). Morphological studies should be carried out using the 
mice generated by Andre et al (2011) to determine the time course of changes in 
morphology among D1R and D2R expressing MSNs. Intracellular fills of D1R or 
D2R expressing MSNs throughout the lifespan of YAC128 mice, can allow insight 
into how the direct and indirect pathways are affected at each stage of 
symptomatology. Additionally, the MSNs can be examined following Mn 
exposure to determine how changed in morphology are affected by exposure to 
Mn.  
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Studies should be carried out using mice of both genders to continue to 
elucidate gender differences in HD symptom progression or retardation due to 
Mn exposure. Behavioral studies should be undertaken to determine how the 
disease-toxicant interaction affects symptom onset and progression. The current 
Mn exposure paradigm can be used to examine how the HD-Mn interaction 
affects the procedural learning deficit that appears at 2 months. It would also be 
beneficial to examine how Mn exposure modifies the onset and progression of 
motor symptoms in YAC128 mice. These studies are crucial to understanding if 
the HD-Mn interaction is beneficial or detrimental to disease progression. 
Electrophysiological studies may be able to shed insight into how Mn perturbs 
MSN morphology and function in YAC128 mice.  Understanding how the HD-Mn 
interaction alters MSN function can give more mechanistic insight into the 
behavioral effects of the disease-toxicant interaction. Electrophysiological studies 
and behavioral studies examining motor function should be carried to determine 
how Mn exposure affects the progression of HD associated motor dysfunction in 
these mice to definitively answer whether Mn exposure is beneficial or 
detrimental to motor symptom onset and progression. 
 A time course of behavioral and electrophysiological experiments should 
be performed to determine if the HD-Mn interaction has long lasting effects or is 
only transient while Mn levels are elevated. Other Mn exposure paradigms 
should also be considered. A chronic low dose Mn exposure paradigm may be 
more beneficial than a subchronic high dose exposure. If the HD-Mn interaction 
is truly beneficial to slowing disease progression, then the proper level of Mn 
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exposure must be determined. However, if the HD-Mn interaction is detrimental 
to disease onset and progression, then the molecular mechanism of this 
interaction will be able to give insight into new targets of disease modifying 
therapy. 
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